Trial Outcomes & Findings for A Study of Obinutuzumab in Combination With Idasanutlin and Venetoclax in Participants With Relapsed or Refractory (R/R) Follicular Lymphoma (FL) or Rituximab in Combination With Idasanutlin and Venetoclax in Participants With R/R Diffuse Large B-Cell Lymphoma (DLBCL) (NCT NCT03135262)

NCT ID: NCT03135262

Last Updated: 2021-12-07

Results Overview

It was planned to be identified in escalation and carried over in expansion phases. However the expansion phase did not take place. phases. The study was closed because at escalation doses 100 (in combination with venetoclax 400 mg) and 150 mg (in combination with venetoclax 200 mg) Idasanutlin, the benefit was mild. The study was terminated at the escalation phase with DLTs showing AEs in all cohorts. The subpopulations of DLBCL and FL were showed no difference in their genetic subtype make-up, therefore, Cohorts Safety, 1, 2, 3 contain both populations. The safety cohort had a different venetoclax schedule of 5 days to ensure safety. Remaining cohorts used a 10 days schedule. No RP2D was identified in the Cohorts 1 and 3.

• Recruitment status: TERMINATED
• Study phase: PHASE1/PHASE2
• Target enrollment: 29 participants
• Primary outcome timeframe: Cycle 1 Day 1 up to Cycle 2 Day 28 (each cycle = 28 days)
• Results posted on: 2021-12-07

Participant Flow

29 Participants (ITT population) were enrolled at 13 sites in the USA, Australia, South Korea, New Zealand and Germany during the dose escalation phase. 1 participant was undefined as the diagnosis at study entry was not provided. Due to the study's pre-mature termination, the planned Dose Expansion Phase did not take place for both arms DLBCL and FL.

The study was prematurely terminated because of the overall modest benefit achieved with MTD during the escalation phase. In each DLBCL and FL arm, participants are in Safety Cohort, Cohort 1, Cohort 2, Cohort 3 and Cohort 3- Not defined (DLBCL only). All Adverse Events are reported per Cohort rather than per Arm.

Participant milestones

Measure	Dose Escalation DLBCL and FL Safety Cohort Idasanutlin 100 mg + Venetoclax 200 mg + Obinutuzumab 1000 mg	Dose Escalation DLBCL and FL Cohort 1 Idasanutlin 100 mg + Venetoclax 200 mg + Obinutuzumab 1000 mg	Dose Escalation DLBCL and FL Cohort 2 Idasanutlin 150 mg + Venetoclax 200 mg + Obinutuzumab 1000 mg	Dose Escalation DLBCL and FL Cohort 3 Idasanutlin 100 mg + Venetoclax 400 mg + Obinutuzumab 1000 mg	Not Defined for DLBCL or FL Subgroups Cohort 3 Idasanutlin 100 mg+ Venetoclax 200mg + obinutuzumab 1000 mg
Overall Study STARTED	9	6	7	6	1
Overall Study COMPLETED	0	0	0	0	0
Overall Study NOT COMPLETED	9	6	7	6	1

Reasons for withdrawal

Measure	Dose Escalation DLBCL and FL Safety Cohort Idasanutlin 100 mg + Venetoclax 200 mg + Obinutuzumab 1000 mg	Dose Escalation DLBCL and FL Cohort 1 Idasanutlin 100 mg + Venetoclax 200 mg + Obinutuzumab 1000 mg	Dose Escalation DLBCL and FL Cohort 2 Idasanutlin 150 mg + Venetoclax 200 mg + Obinutuzumab 1000 mg	Dose Escalation DLBCL and FL Cohort 3 Idasanutlin 100 mg + Venetoclax 400 mg + Obinutuzumab 1000 mg	Not Defined for DLBCL or FL Subgroups Cohort 3 Idasanutlin 100 mg+ Venetoclax 200mg + obinutuzumab 1000 mg
Overall Study discontinued due to worsening of pre-existing medical condition	1	0	0	0	0
Overall Study Progression of disease	0	0	0	1	0
Overall Study Death	6	2	2	2	0
Overall Study Withdrawal by Subject	0	0	1	0	1
Overall Study Study terminated by sponsor	2	4	4	3	0

Baseline Characteristics

ITT

Baseline characteristics by cohort

Measure	Dose-Escalation DLBCL and FL Safety Cohort n=9 Participants Idasanutlin 100 mg + venetoclax 200 mg + obinutuzumab 1000 mg	Dose-Escalation DLBCL and FL Cohort 1 n=6 Participants Idasanutlin 100 mg + venetoclax 200 mg + obinutuzumab 1000 mg	Dose Escaltion DLBCL and FL Cohort 2 n=7 Participants Idasanutlin 150 mg + venetoclax 200 mg + obinutuzumab 1000 mg	Dose Escalation DLBCL and FL Cohort 3 n=6 Participants Idasanutlin 100 mg + venetoclax 400 mg + obinutuzumab 1000 mg	Not Defined for DLBCL or FL Subgroups Cohort 3 n=1 Participants Idasanutlin 100 mg+ Venetoclax 200mg + obinutuzumab 1000 mg	Total n=29 Participants Total of all reporting groups
Age, Continuous	58.6 Years STANDARD_DEVIATION 15.5 • n=5 Participants • ITT	68.5 Years STANDARD_DEVIATION 8.7 • n=7 Participants • ITT	72.4 Years STANDARD_DEVIATION 8.6 • n=5 Participants • ITT	74.3 Years STANDARD_DEVIATION 5.5 • n=4 Participants • ITT	25.0 Years STANDARD_DEVIATION 0 • n=21 Participants • ITT	66.1 Years STANDARD_DEVIATION 14.4 • n=10 Participants • ITT
Sex: Female, Male Female	3 Participants n=5 Participants • ITT Population	3 Participants n=7 Participants • ITT Population	3 Participants n=5 Participants • ITT Population	3 Participants n=4 Participants • ITT Population	0 Participants n=21 Participants • ITT Population	12 Participants n=10 Participants • ITT Population
Sex: Female, Male Male	6 Participants n=5 Participants • ITT Population	3 Participants n=7 Participants • ITT Population	4 Participants n=5 Participants • ITT Population	3 Participants n=4 Participants • ITT Population	1 Participants n=21 Participants • ITT Population	17 Participants n=10 Participants • ITT Population
Ethnicity (NIH/OMB) Hispanic or Latino	0 Participants n=5 Participants	0 Participants n=7 Participants	0 Participants n=5 Participants	0 Participants n=4 Participants	0 Participants n=21 Participants	0 Participants n=10 Participants
Ethnicity (NIH/OMB) Not Hispanic or Latino	9 Participants n=5 Participants	6 Participants n=7 Participants	7 Participants n=5 Participants	6 Participants n=4 Participants	1 Participants n=21 Participants	29 Participants n=10 Participants
Ethnicity (NIH/OMB) Unknown or Not Reported	0 Participants n=5 Participants	0 Participants n=7 Participants	0 Participants n=5 Participants	0 Participants n=4 Participants	0 Participants n=21 Participants	0 Participants n=10 Participants
Race (NIH/OMB) American Indian or Alaska Native	0 Participants n=5 Participants	0 Participants n=7 Participants	0 Participants n=5 Participants	0 Participants n=4 Participants	0 Participants n=21 Participants	0 Participants n=10 Participants
Race (NIH/OMB) Asian	2 Participants n=5 Participants	0 Participants n=7 Participants	1 Participants n=5 Participants	2 Participants n=4 Participants	0 Participants n=21 Participants	5 Participants n=10 Participants
Race (NIH/OMB) Native Hawaiian or Other Pacific Islander	0 Participants n=5 Participants	0 Participants n=7 Participants	0 Participants n=5 Participants	0 Participants n=4 Participants	0 Participants n=21 Participants	0 Participants n=10 Participants
Race (NIH/OMB) Black or African American	0 Participants n=5 Participants	0 Participants n=7 Participants	0 Participants n=5 Participants	1 Participants n=4 Participants	0 Participants n=21 Participants	1 Participants n=10 Participants
Race (NIH/OMB) White	7 Participants n=5 Participants	5 Participants n=7 Participants	6 Participants n=5 Participants	2 Participants n=4 Participants	1 Participants n=21 Participants	21 Participants n=10 Participants
Race (NIH/OMB) More than one race	0 Participants n=5 Participants	1 Participants n=7 Participants	0 Participants n=5 Participants	1 Participants n=4 Participants	0 Participants n=21 Participants	2 Participants n=10 Participants
Race (NIH/OMB) Unknown or Not Reported	0 Participants n=5 Participants	0 Participants n=7 Participants	0 Participants n=5 Participants	0 Participants n=4 Participants	0 Participants n=21 Participants	0 Participants n=10 Participants

PRIMARY outcome

Timeframe: Cycle 1 Day 1 up to Cycle 2 Day 28 (each cycle = 28 days)

Population: Safety Population

It was planned to be identified in escalation and carried over in expansion phases. However the expansion phase did not take place. phases.

The study was closed because at escalation doses 100 (in combination with venetoclax 400 mg) and 150 mg (in combination with venetoclax 200 mg) Idasanutlin, the benefit was mild. The study was terminated at the escalation phase with DLTs showing AEs in all cohorts. The subpopulations of DLBCL and FL were showed no difference in their genetic subtype make-up, therefore, Cohorts Safety, 1, 2, 3 contain both populations.

The safety cohort had a different venetoclax schedule of 5 days to ensure safety. Remaining cohorts used a 10 days schedule. No RP2D was identified in the Cohorts 1 and 3.

Outcome measures

Measure	Dose Escalation DLBCL and FL Safety Cohort n=9 Participants Idasanutlin 100 mg + venetoclax 200 mg + obinutuzumab 1000 mg	Dose Escaltion DLBCL and FL Cohort 1 n=6 Participants Idasanutlin 100 mg + venetoclax 200 mg + obinutuzumab 1000 mg	Dose Escaltion DLBCL and FL Cohort 2 n=7 Participants Idasanutlin 150 mg + venetoclax 200 mg + obinutuzumab 1000 mg	Dose Escalation DLBCL and FL Cohort 3 n=6 Participants Idasanutlin 100 mg + venetoclax 400 mg + obinutuzumab 1000 mg	Not Defined for DLBCL or FL Subgroups Cohort 3 n=1 Participants Idasanutlin 100 mg+ Venetoclax 200mg + obinutuzumab 1000 mg
RP2D of Idasanutlin When Given in Combination With Obinutuzumab or Rituximab	NA mg No qualifying value data available	NA mg No qualifying value data available	150 mg	NA mg No qualifying value data available	NA mg No qualifying value data available

PRIMARY outcome

Timeframe: Cycle 1 Day 1 up to Cycle 2 Day 28 (each cycle = 28 days)

Population: Safety Population

It was planned to be identified in escalation and carried over in expansion phases. However the expansion phase did not take place.

The study was closed because at escalation doses 200 (in combination with 150 mg idasanutlin) and 400 (in combination with 100 mg idasanutlin) mg Venetoclax, the benefit was mild. The study was terminated at the escalation phase with DLTs showing AEs in all cohorts.

The safety cohort had a different venetoclax schedule of 5 days to ensure safety. Remaining cohorts used a 10 days schedule. No RP2D was identified in the Cohorts 1 and 3.

Outcome measures

Measure	Dose Escalation DLBCL and FL Safety Cohort n=9 Participants Idasanutlin 100 mg + venetoclax 200 mg + obinutuzumab 1000 mg	Dose Escaltion DLBCL and FL Cohort 1 n=6 Participants Idasanutlin 100 mg + venetoclax 200 mg + obinutuzumab 1000 mg	Dose Escaltion DLBCL and FL Cohort 2 n=7 Participants Idasanutlin 150 mg + venetoclax 200 mg + obinutuzumab 1000 mg	Dose Escalation DLBCL and FL Cohort 3 n=6 Participants Idasanutlin 100 mg + venetoclax 400 mg + obinutuzumab 1000 mg	Not Defined for DLBCL or FL Subgroups Cohort 3 n=1 Participants Idasanutlin 100 mg+ Venetoclax 200mg + obinutuzumab 1000 mg
RP2D of Venetoclax When Given in Combination With Obinutuzumab or Rituximab	NA mg No qualifying value data available	NA mg No qualifying value data available	200 mg	NA mg No qualifying value data available	NA mg No qualifying value data available

PRIMARY outcome

Timeframe: Cycle 1 Day 1 up to Cycle 2 Day 28 (each cycle = 28 days)

Population: Safety-Evaluable Patients

DLT is defined as any one of the following events occurring during first two Cycles of treatment and assessed by the investigator as clearly not related to patient's underlying disease: - Any Grade 5 adverse event (AE) unless unequivocally due to the underlying malignancy or extraneous causes; - AE of any grade that leads to a delay of more than 14 days at the start of next treatment cycle; - Hematologic AEs (neutropenia, thrombocytopenia); - Non-hematologic AE, except IRRs, laboratory TLS without manifestations of clinical TLS, AST or ALT, diarrhea, nausea or vomiting, fatigue, asthenia, anorexia, or constipation, hepatic transaminase.

Outcome measures

Measure	Dose Escalation DLBCL and FL Safety Cohort n=9 Participants Idasanutlin 100 mg + venetoclax 200 mg + obinutuzumab 1000 mg	Dose Escaltion DLBCL and FL Cohort 1 n=6 Participants Idasanutlin 100 mg + venetoclax 200 mg + obinutuzumab 1000 mg	Dose Escaltion DLBCL and FL Cohort 2 n=7 Participants Idasanutlin 150 mg + venetoclax 200 mg + obinutuzumab 1000 mg	Dose Escalation DLBCL and FL Cohort 3 n=6 Participants Idasanutlin 100 mg + venetoclax 400 mg + obinutuzumab 1000 mg	Not Defined for DLBCL or FL Subgroups Cohort 3 n=1 Participants Idasanutlin 100 mg+ Venetoclax 200mg + obinutuzumab 1000 mg
Percentage of Participants With Dose-Limiting Toxicities (DLTs)	0 Percentage of Participants	16.7 Percentage of Participants	28.6 Percentage of Participants	16.7 Percentage of Participants	0 Percentage of Participants

PRIMARY outcome

Timeframe: From Baseline up to approximately 48 months

Population: Safety Population

An adverse event is any untoward medical occurrence in a participant administered a pharmaceutical product and which does not necessarily have to have a casual relationship with the treatment. An adverse event can therefore be any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease temporarily associated with the use of pharmaceutical product, whether or not considered related to the pharmaceutical product. Preexisting conditions which worsen during a study are also considered as adverse events.

Outcome measures

Measure	Dose Escalation DLBCL and FL Safety Cohort n=9 Participants Idasanutlin 100 mg + venetoclax 200 mg + obinutuzumab 1000 mg	Dose Escaltion DLBCL and FL Cohort 1 n=6 Participants Idasanutlin 100 mg + venetoclax 200 mg + obinutuzumab 1000 mg	Dose Escaltion DLBCL and FL Cohort 2 n=7 Participants Idasanutlin 150 mg + venetoclax 200 mg + obinutuzumab 1000 mg	Dose Escalation DLBCL and FL Cohort 3 n=6 Participants Idasanutlin 100 mg + venetoclax 400 mg + obinutuzumab 1000 mg	Not Defined for DLBCL or FL Subgroups Cohort 3 n=1 Participants Idasanutlin 100 mg+ Venetoclax 200mg + obinutuzumab 1000 mg
Percentage of Participants With Adverse Events (AEs)	100 Percentage of Participants	100 Percentage of Participants	100 Percentage of Participants	100 Percentage of Participants	0 Percentage of Participants

PRIMARY outcome

Timeframe: At end of Induction (EOI) (within 6 to 8 weeks after Cycle 6 Day 1 [up to approximately 28 weeks] [each cycle = 28 days])

Population: The study plan was for the IRC to analyze the efficacy results in participants from the expansion phase (Part II), but the expansion phase was not opened (i.e., no enrollment) because the sponsor decided to terminate the study early due to the modest benefit achieved with the maximum tolerated dose during the dose escalation phase (Part I).

The study plan was for the IRC to analyze the efficacy results in participants from the expansion phase (Part II), but the expansion phase was not opened (i.e., no enrollment) because the sponsor decided to terminate the study early due to the modest benefit achieved with the maximum tolerated dose during the dose escalation phase (Part I). Therefore the result data not derived and not reported.

Outcome measures

Outcome data not reported

SECONDARY outcome

Timeframe: At EOI (6 to 8 weeks after Cycle 6 Day 1 [up to approximately 28 weeks] [each cycle = 28 days]

Population: ITT Population; exploratory analysis of the dose escalation phase (Part I). The study plan was for efficacy analyses to be based on responses in participants enrolled during the expansion phase (Part II), but it was not opened (i.e., no enrollment) and at the study was terminated early.

The investigator evaluated responses at the end of induction treatment using Lugano 2014 criteria for malignant lymphoma for a PET-CT based complete response (CR), which required a complete metabolic response with a score of 1, 2 or 3 with or without a residual mass in lymph nodes and extralymphatic sites on the PET 5-point scale for 18-fluorodeoxyglucose (FDG) uptake (1 = no uptake above background; 2 = uptake less than or equal to [<=] mediastinum; 3 = uptake greater than [>] mediastinum and <= liver; 4 = uptake moderately > liver; 5 = uptake markedly > liver and/or new lesions). The CR criteria were slightly modified to require normal bone marrow by morphology (if intermediate, immunohistochemistry negative). PET-CT scans were performed at end of induction only on participants who had received at least 2 cycles of induction treatment; those without a post-baseline tumor assessment were considered non-responders.

Outcome measures

Measure	Dose Escalation DLBCL and FL Safety Cohort n=9 Participants Idasanutlin 100 mg + venetoclax 200 mg + obinutuzumab 1000 mg	Dose Escaltion DLBCL and FL Cohort 1 n=6 Participants Idasanutlin 100 mg + venetoclax 200 mg + obinutuzumab 1000 mg	Dose Escaltion DLBCL and FL Cohort 2 n=7 Participants Idasanutlin 150 mg + venetoclax 200 mg + obinutuzumab 1000 mg	Dose Escalation DLBCL and FL Cohort 3 n=6 Participants Idasanutlin 100 mg + venetoclax 400 mg + obinutuzumab 1000 mg	Not Defined for DLBCL or FL Subgroups Cohort 3 n=1 Participants Idasanutlin 100 mg+ Venetoclax 200mg + obinutuzumab 1000 mg
Percentage of Participants With CR, Determined by the Investigator on the Basis of PET-CT Scans Using Modified Lugano 2014 Criteria	22.2 Percentage of Participants Interval 4.1 to 54.96	16.7 Percentage of Participants Interval 0.85 to 58.18	28.6 Percentage of Participants Interval 5.34 to 65.87	16.7 Percentage of Participants Interval 0.85 to 58.18	0 Percentage of Participants Interval 0.0 to 95.0

SECONDARY outcome

Timeframe: At EOI (6 to 8 weeks after Cycle 6 Day 1 [up to approximately 28 weeks] [each cycle = 28 days]

Population: The study plan was for the IRC to analyze the efficacy results in participants from the expansion phase (Part II), but the expansion phase was not opened (i.e. , no enrollment) because the sponsor decided to terminate the study early due to the modest benefit achieved with the maximum tolerated dose during the dose escalation phase (Part I).

The IRC was to evaluate responses at the end of induction treatment using the Lugano 2014 response criteria for malignant lymphoma for a computed tomography (CT)-based complete response (CR). The CR criteria required to complete radiologic response with all of the following: target nodal masses must regress to less than or equal to 1.5 centimeters in the longest transverse diameter of a lesion [LDi]; no extralymphatic sites of disease; no non-measured or new lesions; enlarged organs regressing to normal size; and bone marrow normal by morphology (if indeterminate, immunochemistry negative). CT scans were performed at end of induction only on participants who had received at least 2 cycles of induction treatment; those without a post-baseline tumor assessment were to be considered non-responders. Therefore the result data not derived and not reported.

Outcome measures

Outcome data not reported

SECONDARY outcome

Timeframe: At EOI (6 to 8 weeks after Cycle 6 Day 1 [up to approximately 28 weeks] [each cycle = 28 days]

Population: ITT Population; exploratory analysis of the dose escalation phase (Part I). The study plan was for efficacy analyses to be based on responses in participants enrolled during expansion phase (Part II), but it was not opened (i.e., no enrollment) and at the study was terminated early.

The investigator evaluated responses at the end of induction treatment using the Lugano 2014 response criteria for malignant lymphoma for a computed tomography (CT)-based complete response (CR). The CR criteria required a complete radiologic response with all of the following: target nodes/nodal masses must regress to less than or equal to 1.5 centimeters in the longest transverse diameter of a lesion (LDi); no extralymphatic sites of disease; no non-measured or new lesions; enlarged organs regressing to normal size; and bone marrow normal by morphology (if indeterminate, immunohistochemistry negative). CT scans were performed at end of induction only on participants who received at least 2 cycles of Induction treatment; those without a post-baseline tumor assessment were to be considered non-responders. This outcome measure therefore not derived and not reported.

Outcome measures

Outcome data not reported

SECONDARY outcome

Timeframe: At EOI (6 to 8 weeks after Cycle 6 Day 1 [up to approximately 28 weeks] [each cycle = 28 days]

Population: The study plan was for the IRC to analyze the efficacy results in participants from the expansion phase (Part II)., but the expansion phase was not opened (i.e., no enrollment) because the sponsor decided to terminate the study early due to the modest benefit achieved with the maximum tolerated dose during the dose escalation phase (Part I).

The IRC was to evaluate responses at the end of induction treatment using Luagno 2014 criteria for malignant lymphoma for a PET-CT based objective response: either a complete (CR) or partial response (PR). A CR required a complete metabolic response with a score of 1, 2 or 3 on the PET 5-point scale (5PS) for 18-fluorodeoxyglucose (FDG) uptake (scores range from 1 [no uptake above background] to 5 [uptake markedly higher than liver and/or new lesions]), with or without a residual mass in lymph nodes and extralymphatic sites; and a PR required a partial metabolic response with a score 4 or 5 on the 5PS with reduced 18-FDG uptake compared with baseline and residual mass(es) of any size. For bone marrow involvement, the CR criteria required no evidence of FDG-avid disease, and the PR criteria required residual uptake higher than in normal marrow but reduced compared with baseline. Therefore the result data not derived and not reported. The study was pre-maturely terminated.

Outcome measures

Outcome data not reported

SECONDARY outcome

Timeframe: At EOI (6 to 8 weeks after Cycle 6 Day 1 [up to approximately 28 weeks] [each cycle = 28 days]

Population: ITT Population

The investigator was to evaluate responses at end of induction treatment using Lugano 2014 criteria for malignant lymphoma for a PET-CT based objective response: either a complete (CR) or partial response (PR). A CR required a complete metabolic response with a score of 1, 2, or 3 on the PET 5-point scale (5PS) for 18-fluorodeoxyglucose (FDG) uptake (scores range from 1 [no uptake above background] to 5 [uptake markedly higher than liver and/or new lesions]), with or without a residual mass in lymph nodes and extralymphatic sites; and a PR required a partial metabolic response with a score of 4 or 5 on the 5PS with reduced 18-FDG uptake compared with baseline and residual mass(es) of any size. For bone marrow involvement, the CR criteria required no evidence of FDG-avid disease, and the PR criteria required residual uptake higher than in normal marrow but reduced compared with baseline. Participants without a post-baseline tumor assessment were to be considered non-responders.

Outcome measures

Measure	Dose Escalation DLBCL and FL Safety Cohort n=9 Participants Idasanutlin 100 mg + venetoclax 200 mg + obinutuzumab 1000 mg	Dose Escaltion DLBCL and FL Cohort 1 n=6 Participants Idasanutlin 100 mg + venetoclax 200 mg + obinutuzumab 1000 mg	Dose Escaltion DLBCL and FL Cohort 2 n=7 Participants Idasanutlin 150 mg + venetoclax 200 mg + obinutuzumab 1000 mg	Dose Escalation DLBCL and FL Cohort 3 n=6 Participants Idasanutlin 100 mg + venetoclax 400 mg + obinutuzumab 1000 mg	Not Defined for DLBCL or FL Subgroups Cohort 3 n=1 Participants Idasanutlin 100 mg+ Venetoclax 200mg + obinutuzumab 1000 mg
Percentage of Participants With Objective Response, Determined by the Investigator on the Basis of PET-CT Scans Using Modified Lugano 2014 Criteria	33.3 Percentage of Participants Interval 9.77 to 65.51	16.7 Percentage of Participants Interval 0.85 to 58.18	28.6 Percentage of Participants Interval 5.34 to 65.87	33.3 Percentage of Participants Interval 6.28 to 72.87	0 Percentage of Participants Interval 0.0 to 95.0

SECONDARY outcome

Timeframe: At EOI (6 to 8 weeks after Cycle 6 Day 1 [up to approximately 28 weeks] [each cycle = 28 days]

Population: The study plan was for the IRC to analyze the efficacy results in participants from the expansion phase (Part II)., but the expansion phase was not opened (i.e., no enrollment) because the sponsor decided to terminate the study early due to the modest benefit achieved with the maximum tolerated dose during the dose escalation phase (Part I).

The IRC was to evaluate responses at the end of induction treatment using the Lugano 2014 response criteria for malignant lymphoma for a CT-based objective response: either a complete (CR) or partial response (PR). The CR criteria required a complete radiologic response with all of the following: target nodes/nodal masses must regress to less than or equal to 1.5 cm in the LDi; no extralymphatic sites of disease; no non-measured or new lesions; enlarged organs regressing to normal size; and bone marrow normal by morphology (if indeterminate, immunohistochemistry negative). The PR criteria required all of the following: a >=50% decrease in sum of the product of perpendicular diameters of up to 6 target measurable nodes and extranodal sites; no new lesions; non-measured lesion that is absent/nomal, regressed, but no increase; and spleen must have regressed by >50% in length. Therefore the result data not derived and not reported. The study was pre-maturely terminated.

Outcome measures

Outcome data not reported

SECONDARY outcome

Timeframe: At EOI (6 to 8 weeks after Cycle 6 Day 1 [up to approximately 28 weeks] [each cycle = 28 days]

Population: The study plan was for the IRC to analyze the efficacy results in participants from the expansion phase (Part II)., but the expansion phase was not opened (i.e., no enrollment) because the sponsor decided to terminate the study early due to the modest benefit achieved with the maximum tolerated dose during the dose escalation phase (Part I).

The investigator was to evaluate responses at the end of induction treatment using Lugano 2014 response criteria for malignant lymphoma for a CT-based objective response: either a complete (CR) or partial response (PR). The CR criteria required a complete radiologic response with all of the following: target nodes/nodal masses must regress to less than or equal to 1.5 cm in LDi; no extralymphatic sites of disease; no non-measured or new lesions; enlarged organs regressing to normal size; and bone marrow normal by morphology (if indeterminate, immunohistochemistry negative). The PR criteria required all of the following: a >=50% decrease in sum of the product of perpendicular diameters up to 6 target measurable nodes and extranodal sites; no new lesions; non-measured lesion that is absent/normal, regressed, but no increase; and spleen must have regressed by >50% in length. The study was pre-maturely terminated at escalation phase.

Outcome measures

Outcome data not reported

SECONDARY outcome

Timeframe: From Day 1 of Cycle 1 (cycle length = 28 days) up to approximately 48 months

Population: The study plan was for the IRC to analyze the efficacy results in participants from the expansion phase (Part II)., but the expansion phase was not opened (i.e., no enrollment) because the sponsor decided to terminate the study early due to the modest benefit achieved with the maximum tolerated dose during the dose escalation phase (Part I).

The investigator was to evaluate responses at the end of induction treatment using Lugano 2014 response criteria for malignant lymphoma for a CT-based objective response: either a complete (CR) or partial response (PR). The CR criteria required a complete radiologic response with all of the following: target nodes/nodal masses must regress to less than or equal to 1.5 cm in LDi; no extralymphatic sites of disease; no non-measured or new lesions; enlarged organs regressing to normal size; and bone marrow normal by morphology (if indeterminate, immunohistochemistry negative). The PR criteria required all of the following: a >=50% decrease in sum of the product of perpendicular diameters up to 6 target measurable nodes and extranodal sites; no new lesions; non-measured lesion that is absent/normal, regressed, but no increase; and spleen must have regressed by >50% in length. The study was pre-maturely terminated at escalation phase.

Outcome measures

Outcome data not reported

SECONDARY outcome

Timeframe: From Day 1 of Cycle 1 (cycle length = 28 days) up to approximately 48 months (detailed timeframe is mentioned in outcome measure description)

Population: ITT Population was planned. Due to the pre-mature study termination, no participants were available for this endpoint and result data were not collected.

Observed Serum Concentration of Obinutuzumab in Participants With FL was planned to be determined as part of the pharmacokinetics analyses during the expansion phase which did not take place.

The study was prematurely terminated because of the overall modest benefit achieved with MTD during the escalation phase (Part 1); Phase II of the study (expansion) was never initiated. No result data was derived, therefore no result was reported.

The result data not derived due to early termination of the study by the sponsor's decision and did not reach the end of study.

Outcome measures

Outcome data not reported

SECONDARY outcome

Timeframe: Induction: Pre-dose (any time prior to dose on same day) and 30 min post-dose on Day 1 of Cycle 1; Pre-dose (within 5 hrs prior to dose) and 30 min post-dose on Day 1 of Cycles 2, 4 and 6 (each cycle = 28 days)

Population: ITT Population was planned. Due to the pre-mature study termination, no participants were available for this endpoint and result data were not collected.

Observed Serum Concentration of Obinutuzumab in Participants With DLBCL was planned to be determined as part of the pharmacokinetics analyses during the expansion phase which did not take place.

The study was prematurely terminated because of the overall modest benefit achieved with MTD during the escalation phase (Part 1); Phase II of the study (expansion) was never initiated. No result data was derived, therefore no result was reported.

Outcome measures

Outcome data not reported

SECONDARY outcome

Timeframe: Induction: Pre-dose (any time prior to dose on same day) on Day 1 of Cycle 1; Pre-dose (within 5 hrs prior to dose) on Day 1 of Cycles 2, 4, 6; 30 min post-dose on Day 1 of Cycles 1 and 6 (each cycle = 28 days)

Population: ITT Population was planned. Due to the pre-mature study termination, no participants were available for this endpoint and result data were not collected.

Observed Serum Concentration of Rituximab in Participants With FL was planned to be determined as part of the pharmacokinetics analyses during the expansion phase which did not take place.

The study was prematurely terminated because of the overall modest benefit achieved with MTD during the escalation phase (Part 1); Phase II of the study (expansion) was never initiated. No result data was derived, therefore no result was reported.

Outcome measures

Outcome data not reported

SECONDARY outcome

Timeframe: From Day 1 of Cycle 1 (cycle length = 28 days) up to approximately 48 months (detailed timeframe is mentioned in outcome measure description)

Population: ITT Population was planned. Due to the pre-mature study termination, no participants were available for this endpoint and result data were not collected.

Observed Serum Concentration of Rituximab in Participants With DLBCL was planned to be determined as part of the pharmacokinetics analyses during the expansion phase which did not take place.

The study was prematurely terminated because of the overall modest benefit achieved with MTD during the escalation phase (Part 1); Phase II of the study (expansion) was never initiated. No result data was derived, therefore no result was reported.

Outcome measures

Outcome data not reported

SECONDARY outcome

Timeframe: From Day 1 of Cycle 1 up to Day 5 of Cycle 4 (each cycle = 28 days) (detailed timeframe is mentioned in outcome measure description)

Population: ITT Population was planned. Due to the pre-mature study termination, no participants were available for this endpoint and result data were not collected.

Observed Plasma Concentration of Idasanutlin in Participants With FL was planned to be determined as part of the pharmacokinetics analyses during the expansion phase which did not take place.

The study was prematurely terminated because of the overall modest benefit achieved with MTD during the escalation phase (Part 1); Phase II of the study (expansion) was never initiated. No result data was derived therefore no result was reported

Outcome measures

Outcome data not reported

SECONDARY outcome

Timeframe: From Day 1 of Cycle 1 up to Day 5 of Cycle 4 (each cycle = 28 days) (detailed timeframe is mentioned in outcome measure description)

Population: ITT Population was planned. Due to the pre-mature study termination, no participants were available for this endpoint and result data were not collected.

Observed Plasma Concentration of Idasanutlin in Participants With DLBCL was planned to be determined as part of the pharmacokinetics analyses during the expansion phase which did not take place.

The study was prematurely terminated because of the overall modest benefit achieved with MTD during the escalation phase (Part 1); Phase II of the study (expansion) was never initiated. No result data was derived therefore no result was reported

Outcome measures

Outcome data not reported

SECONDARY outcome

Timeframe: From Day 1 of Cycle 1 up to Day 5 of Cycle 4 (each cycle = 28 days) (detailed timeframe is mentioned in outcome measure description)

Population: ITT Population was planned. Due to the pre-mature study termination, no participants were available for this endpoint and result data were not collected.

Observed Plasma Concentration of Venetoclax in Participants With FL was planned to be determined as part of the pharmacokinetics analyses during the expansion phase which did not take place.

The study was prematurely terminated because of the overall modest benefit achieved with MTD during the escalation phase (Part 1); Phase II of the study (expansion) was never initiated.

Outcome measures

Outcome data not reported

SECONDARY outcome

Timeframe: From Day 1 of Cycle 1 up to Day 5 of Cycle 4 (each cycle = 28 days) (detailed timeframe is mentioned in outcome measure description)

Population: ITT Population was planned. Due to the pre-mature study termination, no participants were available for this endpoint and result data were not collected.

Observed Plasma Concentration of Venetoclax in Participants With DLBCL was planned to be determined as part of the pharmacokinetics analyses during the expansion phase which did not take place.

The study was prematurely terminated because of the overall modest benefit achieved with MTD during the escalation phase (Part 1); Phase II of the study (expansion) was never initiated.

Outcome measures

Outcome data not reported

Adverse Events

Dose Escalation DLBCL and FL Safety Cohort

Serious events: 3 serious events

Other events: 9 other events

Deaths: 6 deaths

Dose Escalation DLBCL and FL Cohort 1

Serious events: 3 serious events

Other events: 6 other events

Deaths: 2 deaths

Dose Escalation DLBCL and FL Cohort 2

Serious events: 4 serious events

Other events: 7 other events

Deaths: 2 deaths

Dose Escalation DLBCL and FL Cohort 3

Serious events: 4 serious events

Other events: 6 other events

Deaths: 2 deaths

Not Defined for DLBCL or FL Subgroups Cohort 3

Serious events: 0 serious events

Other events: 0 other events

Deaths: 0 deaths

Serious adverse events

Measure	Dose Escalation DLBCL and FL Safety Cohort n=9 participants at risk Idasanutlin 100 mg + Venetoclax 200 mg + Obinutuzumab 1000 mg	Dose Escalation DLBCL and FL Cohort 1 n=6 participants at risk Idasanutlin 100 mg + Venetoclax 200 mg + Obinutuzumab 1000 mg	Dose Escalation DLBCL and FL Cohort 2 n=7 participants at risk Idasanutlin 150 mg + Venetoclax 200 mg + Obinutuzumab 1000 mg	Dose Escalation DLBCL and FL Cohort 3 n=6 participants at risk Idasanutlin 100 mg + Venetoclax 400 mg + Obinutuzumab 1000 mg	Not Defined for DLBCL or FL Subgroups Cohort 3 n=1 participants at risk Idasanutlin 100 mg+ Venetoclax 200mg + obinutuzumab 1000 mg
General disorders PYREXIA	0.00% 0/9 • From Baseline Up to Approximately 3 Years Reported: Safety Population. During the Safety Follow-up Period, non-Serious Adverse Events occurred at the 5% frequency threshold. There was no non-SAEs occurred reported in Dose Escalation DLBCL only Cohort 3 Not Defined arm.	16.7% 1/6 • Number of events 1 • From Baseline Up to Approximately 3 Years Reported: Safety Population. During the Safety Follow-up Period, non-Serious Adverse Events occurred at the 5% frequency threshold. There was no non-SAEs occurred reported in Dose Escalation DLBCL only Cohort 3 Not Defined arm.	0.00% 0/7 • From Baseline Up to Approximately 3 Years Reported: Safety Population. During the Safety Follow-up Period, non-Serious Adverse Events occurred at the 5% frequency threshold. There was no non-SAEs occurred reported in Dose Escalation DLBCL only Cohort 3 Not Defined arm.	0.00% 0/6 • From Baseline Up to Approximately 3 Years Reported: Safety Population. During the Safety Follow-up Period, non-Serious Adverse Events occurred at the 5% frequency threshold. There was no non-SAEs occurred reported in Dose Escalation DLBCL only Cohort 3 Not Defined arm.	0.00% 0/1 • From Baseline Up to Approximately 3 Years Reported: Safety Population. During the Safety Follow-up Period, non-Serious Adverse Events occurred at the 5% frequency threshold. There was no non-SAEs occurred reported in Dose Escalation DLBCL only Cohort 3 Not Defined arm.
Blood and lymphatic system disorders NEUTROPENIA	11.1% 1/9 • Number of events 2 • From Baseline Up to Approximately 3 Years Reported: Safety Population. During the Safety Follow-up Period, non-Serious Adverse Events occurred at the 5% frequency threshold. There was no non-SAEs occurred reported in Dose Escalation DLBCL only Cohort 3 Not Defined arm.	0.00% 0/6 • From Baseline Up to Approximately 3 Years Reported: Safety Population. During the Safety Follow-up Period, non-Serious Adverse Events occurred at the 5% frequency threshold. There was no non-SAEs occurred reported in Dose Escalation DLBCL only Cohort 3 Not Defined arm.	14.3% 1/7 • Number of events 1 • From Baseline Up to Approximately 3 Years Reported: Safety Population. During the Safety Follow-up Period, non-Serious Adverse Events occurred at the 5% frequency threshold. There was no non-SAEs occurred reported in Dose Escalation DLBCL only Cohort 3 Not Defined arm.	16.7% 1/6 • Number of events 1 • From Baseline Up to Approximately 3 Years Reported: Safety Population. During the Safety Follow-up Period, non-Serious Adverse Events occurred at the 5% frequency threshold. There was no non-SAEs occurred reported in Dose Escalation DLBCL only Cohort 3 Not Defined arm.	0.00% 0/1 • From Baseline Up to Approximately 3 Years Reported: Safety Population. During the Safety Follow-up Period, non-Serious Adverse Events occurred at the 5% frequency threshold. There was no non-SAEs occurred reported in Dose Escalation DLBCL only Cohort 3 Not Defined arm.
Blood and lymphatic system disorders THROMBOCYTOPENIA	0.00% 0/9 • From Baseline Up to Approximately 3 Years Reported: Safety Population. During the Safety Follow-up Period, non-Serious Adverse Events occurred at the 5% frequency threshold. There was no non-SAEs occurred reported in Dose Escalation DLBCL only Cohort 3 Not Defined arm.	0.00% 0/6 • From Baseline Up to Approximately 3 Years Reported: Safety Population. During the Safety Follow-up Period, non-Serious Adverse Events occurred at the 5% frequency threshold. There was no non-SAEs occurred reported in Dose Escalation DLBCL only Cohort 3 Not Defined arm.	0.00% 0/7 • From Baseline Up to Approximately 3 Years Reported: Safety Population. During the Safety Follow-up Period, non-Serious Adverse Events occurred at the 5% frequency threshold. There was no non-SAEs occurred reported in Dose Escalation DLBCL only Cohort 3 Not Defined arm.	16.7% 1/6 • Number of events 1 • From Baseline Up to Approximately 3 Years Reported: Safety Population. During the Safety Follow-up Period, non-Serious Adverse Events occurred at the 5% frequency threshold. There was no non-SAEs occurred reported in Dose Escalation DLBCL only Cohort 3 Not Defined arm.	0.00% 0/1 • From Baseline Up to Approximately 3 Years Reported: Safety Population. During the Safety Follow-up Period, non-Serious Adverse Events occurred at the 5% frequency threshold. There was no non-SAEs occurred reported in Dose Escalation DLBCL only Cohort 3 Not Defined arm.
Gastrointestinal disorders ABDOMINAL PAIN	0.00% 0/9 • From Baseline Up to Approximately 3 Years Reported: Safety Population. During the Safety Follow-up Period, non-Serious Adverse Events occurred at the 5% frequency threshold. There was no non-SAEs occurred reported in Dose Escalation DLBCL only Cohort 3 Not Defined arm.	16.7% 1/6 • Number of events 1 • From Baseline Up to Approximately 3 Years Reported: Safety Population. During the Safety Follow-up Period, non-Serious Adverse Events occurred at the 5% frequency threshold. There was no non-SAEs occurred reported in Dose Escalation DLBCL only Cohort 3 Not Defined arm.	0.00% 0/7 • From Baseline Up to Approximately 3 Years Reported: Safety Population. During the Safety Follow-up Period, non-Serious Adverse Events occurred at the 5% frequency threshold. There was no non-SAEs occurred reported in Dose Escalation DLBCL only Cohort 3 Not Defined arm.	0.00% 0/6 • From Baseline Up to Approximately 3 Years Reported: Safety Population. During the Safety Follow-up Period, non-Serious Adverse Events occurred at the 5% frequency threshold. There was no non-SAEs occurred reported in Dose Escalation DLBCL only Cohort 3 Not Defined arm.	0.00% 0/1 • From Baseline Up to Approximately 3 Years Reported: Safety Population. During the Safety Follow-up Period, non-Serious Adverse Events occurred at the 5% frequency threshold. There was no non-SAEs occurred reported in Dose Escalation DLBCL only Cohort 3 Not Defined arm.
Gastrointestinal disorders UPPER GASTROINTESTINAL HAEMORRHAGE	0.00% 0/9 • From Baseline Up to Approximately 3 Years Reported: Safety Population. During the Safety Follow-up Period, non-Serious Adverse Events occurred at the 5% frequency threshold. There was no non-SAEs occurred reported in Dose Escalation DLBCL only Cohort 3 Not Defined arm.	0.00% 0/6 • From Baseline Up to Approximately 3 Years Reported: Safety Population. During the Safety Follow-up Period, non-Serious Adverse Events occurred at the 5% frequency threshold. There was no non-SAEs occurred reported in Dose Escalation DLBCL only Cohort 3 Not Defined arm.	14.3% 1/7 • Number of events 1 • From Baseline Up to Approximately 3 Years Reported: Safety Population. During the Safety Follow-up Period, non-Serious Adverse Events occurred at the 5% frequency threshold. There was no non-SAEs occurred reported in Dose Escalation DLBCL only Cohort 3 Not Defined arm.	0.00% 0/6 • From Baseline Up to Approximately 3 Years Reported: Safety Population. During the Safety Follow-up Period, non-Serious Adverse Events occurred at the 5% frequency threshold. There was no non-SAEs occurred reported in Dose Escalation DLBCL only Cohort 3 Not Defined arm.	0.00% 0/1 • From Baseline Up to Approximately 3 Years Reported: Safety Population. During the Safety Follow-up Period, non-Serious Adverse Events occurred at the 5% frequency threshold. There was no non-SAEs occurred reported in Dose Escalation DLBCL only Cohort 3 Not Defined arm.
General disorders NON-CARDIAC CHEST PAIN	0.00% 0/9 • From Baseline Up to Approximately 3 Years Reported: Safety Population. During the Safety Follow-up Period, non-Serious Adverse Events occurred at the 5% frequency threshold. There was no non-SAEs occurred reported in Dose Escalation DLBCL only Cohort 3 Not Defined arm.	0.00% 0/6 • From Baseline Up to Approximately 3 Years Reported: Safety Population. During the Safety Follow-up Period, non-Serious Adverse Events occurred at the 5% frequency threshold. There was no non-SAEs occurred reported in Dose Escalation DLBCL only Cohort 3 Not Defined arm.	14.3% 1/7 • Number of events 1 • From Baseline Up to Approximately 3 Years Reported: Safety Population. During the Safety Follow-up Period, non-Serious Adverse Events occurred at the 5% frequency threshold. There was no non-SAEs occurred reported in Dose Escalation DLBCL only Cohort 3 Not Defined arm.	0.00% 0/6 • From Baseline Up to Approximately 3 Years Reported: Safety Population. During the Safety Follow-up Period, non-Serious Adverse Events occurred at the 5% frequency threshold. There was no non-SAEs occurred reported in Dose Escalation DLBCL only Cohort 3 Not Defined arm.	0.00% 0/1 • From Baseline Up to Approximately 3 Years Reported: Safety Population. During the Safety Follow-up Period, non-Serious Adverse Events occurred at the 5% frequency threshold. There was no non-SAEs occurred reported in Dose Escalation DLBCL only Cohort 3 Not Defined arm.
Hepatobiliary disorders CHOLECYSTITIS	0.00% 0/9 • From Baseline Up to Approximately 3 Years Reported: Safety Population. During the Safety Follow-up Period, non-Serious Adverse Events occurred at the 5% frequency threshold. There was no non-SAEs occurred reported in Dose Escalation DLBCL only Cohort 3 Not Defined arm.	0.00% 0/6 • From Baseline Up to Approximately 3 Years Reported: Safety Population. During the Safety Follow-up Period, non-Serious Adverse Events occurred at the 5% frequency threshold. There was no non-SAEs occurred reported in Dose Escalation DLBCL only Cohort 3 Not Defined arm.	14.3% 1/7 • Number of events 1 • From Baseline Up to Approximately 3 Years Reported: Safety Population. During the Safety Follow-up Period, non-Serious Adverse Events occurred at the 5% frequency threshold. There was no non-SAEs occurred reported in Dose Escalation DLBCL only Cohort 3 Not Defined arm.	0.00% 0/6 • From Baseline Up to Approximately 3 Years Reported: Safety Population. During the Safety Follow-up Period, non-Serious Adverse Events occurred at the 5% frequency threshold. There was no non-SAEs occurred reported in Dose Escalation DLBCL only Cohort 3 Not Defined arm.	0.00% 0/1 • From Baseline Up to Approximately 3 Years Reported: Safety Population. During the Safety Follow-up Period, non-Serious Adverse Events occurred at the 5% frequency threshold. There was no non-SAEs occurred reported in Dose Escalation DLBCL only Cohort 3 Not Defined arm.
Hepatobiliary disorders HYPERBILIRUBINAEMIA	0.00% 0/9 • From Baseline Up to Approximately 3 Years Reported: Safety Population. During the Safety Follow-up Period, non-Serious Adverse Events occurred at the 5% frequency threshold. There was no non-SAEs occurred reported in Dose Escalation DLBCL only Cohort 3 Not Defined arm.	16.7% 1/6 • Number of events 1 • From Baseline Up to Approximately 3 Years Reported: Safety Population. During the Safety Follow-up Period, non-Serious Adverse Events occurred at the 5% frequency threshold. There was no non-SAEs occurred reported in Dose Escalation DLBCL only Cohort 3 Not Defined arm.	0.00% 0/7 • From Baseline Up to Approximately 3 Years Reported: Safety Population. During the Safety Follow-up Period, non-Serious Adverse Events occurred at the 5% frequency threshold. There was no non-SAEs occurred reported in Dose Escalation DLBCL only Cohort 3 Not Defined arm.	0.00% 0/6 • From Baseline Up to Approximately 3 Years Reported: Safety Population. During the Safety Follow-up Period, non-Serious Adverse Events occurred at the 5% frequency threshold. There was no non-SAEs occurred reported in Dose Escalation DLBCL only Cohort 3 Not Defined arm.	0.00% 0/1 • From Baseline Up to Approximately 3 Years Reported: Safety Population. During the Safety Follow-up Period, non-Serious Adverse Events occurred at the 5% frequency threshold. There was no non-SAEs occurred reported in Dose Escalation DLBCL only Cohort 3 Not Defined arm.
Infections and infestations DEVICE RELATED INFECTION	0.00% 0/9 • From Baseline Up to Approximately 3 Years Reported: Safety Population. During the Safety Follow-up Period, non-Serious Adverse Events occurred at the 5% frequency threshold. There was no non-SAEs occurred reported in Dose Escalation DLBCL only Cohort 3 Not Defined arm.	0.00% 0/6 • From Baseline Up to Approximately 3 Years Reported: Safety Population. During the Safety Follow-up Period, non-Serious Adverse Events occurred at the 5% frequency threshold. There was no non-SAEs occurred reported in Dose Escalation DLBCL only Cohort 3 Not Defined arm.	0.00% 0/7 • From Baseline Up to Approximately 3 Years Reported: Safety Population. During the Safety Follow-up Period, non-Serious Adverse Events occurred at the 5% frequency threshold. There was no non-SAEs occurred reported in Dose Escalation DLBCL only Cohort 3 Not Defined arm.	16.7% 1/6 • Number of events 1 • From Baseline Up to Approximately 3 Years Reported: Safety Population. During the Safety Follow-up Period, non-Serious Adverse Events occurred at the 5% frequency threshold. There was no non-SAEs occurred reported in Dose Escalation DLBCL only Cohort 3 Not Defined arm.	0.00% 0/1 • From Baseline Up to Approximately 3 Years Reported: Safety Population. During the Safety Follow-up Period, non-Serious Adverse Events occurred at the 5% frequency threshold. There was no non-SAEs occurred reported in Dose Escalation DLBCL only Cohort 3 Not Defined arm.
Infections and infestations PNEUMONIA	0.00% 0/9 • From Baseline Up to Approximately 3 Years Reported: Safety Population. During the Safety Follow-up Period, non-Serious Adverse Events occurred at the 5% frequency threshold. There was no non-SAEs occurred reported in Dose Escalation DLBCL only Cohort 3 Not Defined arm.	0.00% 0/6 • From Baseline Up to Approximately 3 Years Reported: Safety Population. During the Safety Follow-up Period, non-Serious Adverse Events occurred at the 5% frequency threshold. There was no non-SAEs occurred reported in Dose Escalation DLBCL only Cohort 3 Not Defined arm.	0.00% 0/7 • From Baseline Up to Approximately 3 Years Reported: Safety Population. During the Safety Follow-up Period, non-Serious Adverse Events occurred at the 5% frequency threshold. There was no non-SAEs occurred reported in Dose Escalation DLBCL only Cohort 3 Not Defined arm.	16.7% 1/6 • Number of events 1 • From Baseline Up to Approximately 3 Years Reported: Safety Population. During the Safety Follow-up Period, non-Serious Adverse Events occurred at the 5% frequency threshold. There was no non-SAEs occurred reported in Dose Escalation DLBCL only Cohort 3 Not Defined arm.	0.00% 0/1 • From Baseline Up to Approximately 3 Years Reported: Safety Population. During the Safety Follow-up Period, non-Serious Adverse Events occurred at the 5% frequency threshold. There was no non-SAEs occurred reported in Dose Escalation DLBCL only Cohort 3 Not Defined arm.
Infections and infestations UPPER RESPIRATORY TRACT INFECTION	11.1% 1/9 • Number of events 1 • From Baseline Up to Approximately 3 Years Reported: Safety Population. During the Safety Follow-up Period, non-Serious Adverse Events occurred at the 5% frequency threshold. There was no non-SAEs occurred reported in Dose Escalation DLBCL only Cohort 3 Not Defined arm.	0.00% 0/6 • From Baseline Up to Approximately 3 Years Reported: Safety Population. During the Safety Follow-up Period, non-Serious Adverse Events occurred at the 5% frequency threshold. There was no non-SAEs occurred reported in Dose Escalation DLBCL only Cohort 3 Not Defined arm.	0.00% 0/7 • From Baseline Up to Approximately 3 Years Reported: Safety Population. During the Safety Follow-up Period, non-Serious Adverse Events occurred at the 5% frequency threshold. There was no non-SAEs occurred reported in Dose Escalation DLBCL only Cohort 3 Not Defined arm.	0.00% 0/6 • From Baseline Up to Approximately 3 Years Reported: Safety Population. During the Safety Follow-up Period, non-Serious Adverse Events occurred at the 5% frequency threshold. There was no non-SAEs occurred reported in Dose Escalation DLBCL only Cohort 3 Not Defined arm.	0.00% 0/1 • From Baseline Up to Approximately 3 Years Reported: Safety Population. During the Safety Follow-up Period, non-Serious Adverse Events occurred at the 5% frequency threshold. There was no non-SAEs occurred reported in Dose Escalation DLBCL only Cohort 3 Not Defined arm.
Injury, poisoning and procedural complications INFUSION RELATED REACTION	0.00% 0/9 • From Baseline Up to Approximately 3 Years Reported: Safety Population. During the Safety Follow-up Period, non-Serious Adverse Events occurred at the 5% frequency threshold. There was no non-SAEs occurred reported in Dose Escalation DLBCL only Cohort 3 Not Defined arm.	16.7% 1/6 • Number of events 1 • From Baseline Up to Approximately 3 Years Reported: Safety Population. During the Safety Follow-up Period, non-Serious Adverse Events occurred at the 5% frequency threshold. There was no non-SAEs occurred reported in Dose Escalation DLBCL only Cohort 3 Not Defined arm.	0.00% 0/7 • From Baseline Up to Approximately 3 Years Reported: Safety Population. During the Safety Follow-up Period, non-Serious Adverse Events occurred at the 5% frequency threshold. There was no non-SAEs occurred reported in Dose Escalation DLBCL only Cohort 3 Not Defined arm.	0.00% 0/6 • From Baseline Up to Approximately 3 Years Reported: Safety Population. During the Safety Follow-up Period, non-Serious Adverse Events occurred at the 5% frequency threshold. There was no non-SAEs occurred reported in Dose Escalation DLBCL only Cohort 3 Not Defined arm.	0.00% 0/1 • From Baseline Up to Approximately 3 Years Reported: Safety Population. During the Safety Follow-up Period, non-Serious Adverse Events occurred at the 5% frequency threshold. There was no non-SAEs occurred reported in Dose Escalation DLBCL only Cohort 3 Not Defined arm.
Investigations ALANINE AMINOTRANSFERASE INCREASED	11.1% 1/9 • Number of events 1 • From Baseline Up to Approximately 3 Years Reported: Safety Population. During the Safety Follow-up Period, non-Serious Adverse Events occurred at the 5% frequency threshold. There was no non-SAEs occurred reported in Dose Escalation DLBCL only Cohort 3 Not Defined arm.	0.00% 0/6 • From Baseline Up to Approximately 3 Years Reported: Safety Population. During the Safety Follow-up Period, non-Serious Adverse Events occurred at the 5% frequency threshold. There was no non-SAEs occurred reported in Dose Escalation DLBCL only Cohort 3 Not Defined arm.	0.00% 0/7 • From Baseline Up to Approximately 3 Years Reported: Safety Population. During the Safety Follow-up Period, non-Serious Adverse Events occurred at the 5% frequency threshold. There was no non-SAEs occurred reported in Dose Escalation DLBCL only Cohort 3 Not Defined arm.	0.00% 0/6 • From Baseline Up to Approximately 3 Years Reported: Safety Population. During the Safety Follow-up Period, non-Serious Adverse Events occurred at the 5% frequency threshold. There was no non-SAEs occurred reported in Dose Escalation DLBCL only Cohort 3 Not Defined arm.	0.00% 0/1 • From Baseline Up to Approximately 3 Years Reported: Safety Population. During the Safety Follow-up Period, non-Serious Adverse Events occurred at the 5% frequency threshold. There was no non-SAEs occurred reported in Dose Escalation DLBCL only Cohort 3 Not Defined arm.
Investigations TRANSAMINASES INCREASED	0.00% 0/9 • From Baseline Up to Approximately 3 Years Reported: Safety Population. During the Safety Follow-up Period, non-Serious Adverse Events occurred at the 5% frequency threshold. There was no non-SAEs occurred reported in Dose Escalation DLBCL only Cohort 3 Not Defined arm.	16.7% 1/6 • Number of events 1 • From Baseline Up to Approximately 3 Years Reported: Safety Population. During the Safety Follow-up Period, non-Serious Adverse Events occurred at the 5% frequency threshold. There was no non-SAEs occurred reported in Dose Escalation DLBCL only Cohort 3 Not Defined arm.	0.00% 0/7 • From Baseline Up to Approximately 3 Years Reported: Safety Population. During the Safety Follow-up Period, non-Serious Adverse Events occurred at the 5% frequency threshold. There was no non-SAEs occurred reported in Dose Escalation DLBCL only Cohort 3 Not Defined arm.	0.00% 0/6 • From Baseline Up to Approximately 3 Years Reported: Safety Population. During the Safety Follow-up Period, non-Serious Adverse Events occurred at the 5% frequency threshold. There was no non-SAEs occurred reported in Dose Escalation DLBCL only Cohort 3 Not Defined arm.	0.00% 0/1 • From Baseline Up to Approximately 3 Years Reported: Safety Population. During the Safety Follow-up Period, non-Serious Adverse Events occurred at the 5% frequency threshold. There was no non-SAEs occurred reported in Dose Escalation DLBCL only Cohort 3 Not Defined arm.
Musculoskeletal and connective tissue disorders OSTEOARTHRITIS	11.1% 1/9 • Number of events 1 • From Baseline Up to Approximately 3 Years Reported: Safety Population. During the Safety Follow-up Period, non-Serious Adverse Events occurred at the 5% frequency threshold. There was no non-SAEs occurred reported in Dose Escalation DLBCL only Cohort 3 Not Defined arm.	0.00% 0/6 • From Baseline Up to Approximately 3 Years Reported: Safety Population. During the Safety Follow-up Period, non-Serious Adverse Events occurred at the 5% frequency threshold. There was no non-SAEs occurred reported in Dose Escalation DLBCL only Cohort 3 Not Defined arm.	0.00% 0/7 • From Baseline Up to Approximately 3 Years Reported: Safety Population. During the Safety Follow-up Period, non-Serious Adverse Events occurred at the 5% frequency threshold. There was no non-SAEs occurred reported in Dose Escalation DLBCL only Cohort 3 Not Defined arm.	0.00% 0/6 • From Baseline Up to Approximately 3 Years Reported: Safety Population. During the Safety Follow-up Period, non-Serious Adverse Events occurred at the 5% frequency threshold. There was no non-SAEs occurred reported in Dose Escalation DLBCL only Cohort 3 Not Defined arm.	0.00% 0/1 • From Baseline Up to Approximately 3 Years Reported: Safety Population. During the Safety Follow-up Period, non-Serious Adverse Events occurred at the 5% frequency threshold. There was no non-SAEs occurred reported in Dose Escalation DLBCL only Cohort 3 Not Defined arm.
Nervous system disorders HEADACHE	11.1% 1/9 • Number of events 1 • From Baseline Up to Approximately 3 Years Reported: Safety Population. During the Safety Follow-up Period, non-Serious Adverse Events occurred at the 5% frequency threshold. There was no non-SAEs occurred reported in Dose Escalation DLBCL only Cohort 3 Not Defined arm.	0.00% 0/6 • From Baseline Up to Approximately 3 Years Reported: Safety Population. During the Safety Follow-up Period, non-Serious Adverse Events occurred at the 5% frequency threshold. There was no non-SAEs occurred reported in Dose Escalation DLBCL only Cohort 3 Not Defined arm.	0.00% 0/7 • From Baseline Up to Approximately 3 Years Reported: Safety Population. During the Safety Follow-up Period, non-Serious Adverse Events occurred at the 5% frequency threshold. There was no non-SAEs occurred reported in Dose Escalation DLBCL only Cohort 3 Not Defined arm.	0.00% 0/6 • From Baseline Up to Approximately 3 Years Reported: Safety Population. During the Safety Follow-up Period, non-Serious Adverse Events occurred at the 5% frequency threshold. There was no non-SAEs occurred reported in Dose Escalation DLBCL only Cohort 3 Not Defined arm.	0.00% 0/1 • From Baseline Up to Approximately 3 Years Reported: Safety Population. During the Safety Follow-up Period, non-Serious Adverse Events occurred at the 5% frequency threshold. There was no non-SAEs occurred reported in Dose Escalation DLBCL only Cohort 3 Not Defined arm.
Nervous system disorders SYNCOPE	0.00% 0/9 • From Baseline Up to Approximately 3 Years Reported: Safety Population. During the Safety Follow-up Period, non-Serious Adverse Events occurred at the 5% frequency threshold. There was no non-SAEs occurred reported in Dose Escalation DLBCL only Cohort 3 Not Defined arm.	0.00% 0/6 • From Baseline Up to Approximately 3 Years Reported: Safety Population. During the Safety Follow-up Period, non-Serious Adverse Events occurred at the 5% frequency threshold. There was no non-SAEs occurred reported in Dose Escalation DLBCL only Cohort 3 Not Defined arm.	0.00% 0/7 • From Baseline Up to Approximately 3 Years Reported: Safety Population. During the Safety Follow-up Period, non-Serious Adverse Events occurred at the 5% frequency threshold. There was no non-SAEs occurred reported in Dose Escalation DLBCL only Cohort 3 Not Defined arm.	16.7% 1/6 • Number of events 1 • From Baseline Up to Approximately 3 Years Reported: Safety Population. During the Safety Follow-up Period, non-Serious Adverse Events occurred at the 5% frequency threshold. There was no non-SAEs occurred reported in Dose Escalation DLBCL only Cohort 3 Not Defined arm.	0.00% 0/1 • From Baseline Up to Approximately 3 Years Reported: Safety Population. During the Safety Follow-up Period, non-Serious Adverse Events occurred at the 5% frequency threshold. There was no non-SAEs occurred reported in Dose Escalation DLBCL only Cohort 3 Not Defined arm.

Other adverse events

Measure	Dose Escalation DLBCL and FL Safety Cohort n=9 participants at risk Idasanutlin 100 mg + Venetoclax 200 mg + Obinutuzumab 1000 mg	Dose Escalation DLBCL and FL Cohort 1 n=6 participants at risk Idasanutlin 100 mg + Venetoclax 200 mg + Obinutuzumab 1000 mg	Dose Escalation DLBCL and FL Cohort 2 n=7 participants at risk Idasanutlin 150 mg + Venetoclax 200 mg + Obinutuzumab 1000 mg	Dose Escalation DLBCL and FL Cohort 3 n=6 participants at risk Idasanutlin 100 mg + Venetoclax 400 mg + Obinutuzumab 1000 mg	Not Defined for DLBCL or FL Subgroups Cohort 3 n=1 participants at risk Idasanutlin 100 mg+ Venetoclax 200mg + obinutuzumab 1000 mg
Blood and lymphatic system disorders ANAEMIA	44.4% 4/9 • Number of events 5 • From Baseline Up to Approximately 3 Years Reported: Safety Population. During the Safety Follow-up Period, non-Serious Adverse Events occurred at the 5% frequency threshold. There was no non-SAEs occurred reported in Dose Escalation DLBCL only Cohort 3 Not Defined arm.	16.7% 1/6 • Number of events 1 • From Baseline Up to Approximately 3 Years Reported: Safety Population. During the Safety Follow-up Period, non-Serious Adverse Events occurred at the 5% frequency threshold. There was no non-SAEs occurred reported in Dose Escalation DLBCL only Cohort 3 Not Defined arm.	57.1% 4/7 • Number of events 4 • From Baseline Up to Approximately 3 Years Reported: Safety Population. During the Safety Follow-up Period, non-Serious Adverse Events occurred at the 5% frequency threshold. There was no non-SAEs occurred reported in Dose Escalation DLBCL only Cohort 3 Not Defined arm.	50.0% 3/6 • Number of events 6 • From Baseline Up to Approximately 3 Years Reported: Safety Population. During the Safety Follow-up Period, non-Serious Adverse Events occurred at the 5% frequency threshold. There was no non-SAEs occurred reported in Dose Escalation DLBCL only Cohort 3 Not Defined arm.	0.00% 0/1 • From Baseline Up to Approximately 3 Years Reported: Safety Population. During the Safety Follow-up Period, non-Serious Adverse Events occurred at the 5% frequency threshold. There was no non-SAEs occurred reported in Dose Escalation DLBCL only Cohort 3 Not Defined arm.
Blood and lymphatic system disorders LEUKOPENIA	33.3% 3/9 • Number of events 3 • From Baseline Up to Approximately 3 Years Reported: Safety Population. During the Safety Follow-up Period, non-Serious Adverse Events occurred at the 5% frequency threshold. There was no non-SAEs occurred reported in Dose Escalation DLBCL only Cohort 3 Not Defined arm.	16.7% 1/6 • Number of events 1 • From Baseline Up to Approximately 3 Years Reported: Safety Population. During the Safety Follow-up Period, non-Serious Adverse Events occurred at the 5% frequency threshold. There was no non-SAEs occurred reported in Dose Escalation DLBCL only Cohort 3 Not Defined arm.	42.9% 3/7 • Number of events 8 • From Baseline Up to Approximately 3 Years Reported: Safety Population. During the Safety Follow-up Period, non-Serious Adverse Events occurred at the 5% frequency threshold. There was no non-SAEs occurred reported in Dose Escalation DLBCL only Cohort 3 Not Defined arm.	16.7% 1/6 • Number of events 1 • From Baseline Up to Approximately 3 Years Reported: Safety Population. During the Safety Follow-up Period, non-Serious Adverse Events occurred at the 5% frequency threshold. There was no non-SAEs occurred reported in Dose Escalation DLBCL only Cohort 3 Not Defined arm.	0.00% 0/1 • From Baseline Up to Approximately 3 Years Reported: Safety Population. During the Safety Follow-up Period, non-Serious Adverse Events occurred at the 5% frequency threshold. There was no non-SAEs occurred reported in Dose Escalation DLBCL only Cohort 3 Not Defined arm.
Blood and lymphatic system disorders LYMPHOPENIA	0.00% 0/9 • From Baseline Up to Approximately 3 Years Reported: Safety Population. During the Safety Follow-up Period, non-Serious Adverse Events occurred at the 5% frequency threshold. There was no non-SAEs occurred reported in Dose Escalation DLBCL only Cohort 3 Not Defined arm.	0.00% 0/6 • From Baseline Up to Approximately 3 Years Reported: Safety Population. During the Safety Follow-up Period, non-Serious Adverse Events occurred at the 5% frequency threshold. There was no non-SAEs occurred reported in Dose Escalation DLBCL only Cohort 3 Not Defined arm.	0.00% 0/7 • From Baseline Up to Approximately 3 Years Reported: Safety Population. During the Safety Follow-up Period, non-Serious Adverse Events occurred at the 5% frequency threshold. There was no non-SAEs occurred reported in Dose Escalation DLBCL only Cohort 3 Not Defined arm.	33.3% 2/6 • Number of events 2 • From Baseline Up to Approximately 3 Years Reported: Safety Population. During the Safety Follow-up Period, non-Serious Adverse Events occurred at the 5% frequency threshold. There was no non-SAEs occurred reported in Dose Escalation DLBCL only Cohort 3 Not Defined arm.	0.00% 0/1 • From Baseline Up to Approximately 3 Years Reported: Safety Population. During the Safety Follow-up Period, non-Serious Adverse Events occurred at the 5% frequency threshold. There was no non-SAEs occurred reported in Dose Escalation DLBCL only Cohort 3 Not Defined arm.
Blood and lymphatic system disorders NEUTROPENIA	77.8% 7/9 • Number of events 13 • From Baseline Up to Approximately 3 Years Reported: Safety Population. During the Safety Follow-up Period, non-Serious Adverse Events occurred at the 5% frequency threshold. There was no non-SAEs occurred reported in Dose Escalation DLBCL only Cohort 3 Not Defined arm.	83.3% 5/6 • Number of events 8 • From Baseline Up to Approximately 3 Years Reported: Safety Population. During the Safety Follow-up Period, non-Serious Adverse Events occurred at the 5% frequency threshold. There was no non-SAEs occurred reported in Dose Escalation DLBCL only Cohort 3 Not Defined arm.	100.0% 7/7 • Number of events 20 • From Baseline Up to Approximately 3 Years Reported: Safety Population. During the Safety Follow-up Period, non-Serious Adverse Events occurred at the 5% frequency threshold. There was no non-SAEs occurred reported in Dose Escalation DLBCL only Cohort 3 Not Defined arm.	83.3% 5/6 • Number of events 21 • From Baseline Up to Approximately 3 Years Reported: Safety Population. During the Safety Follow-up Period, non-Serious Adverse Events occurred at the 5% frequency threshold. There was no non-SAEs occurred reported in Dose Escalation DLBCL only Cohort 3 Not Defined arm.	0.00% 0/1 • From Baseline Up to Approximately 3 Years Reported: Safety Population. During the Safety Follow-up Period, non-Serious Adverse Events occurred at the 5% frequency threshold. There was no non-SAEs occurred reported in Dose Escalation DLBCL only Cohort 3 Not Defined arm.
Blood and lymphatic system disorders THROMBOCYTOPENIA	77.8% 7/9 • Number of events 9 • From Baseline Up to Approximately 3 Years Reported: Safety Population. During the Safety Follow-up Period, non-Serious Adverse Events occurred at the 5% frequency threshold. There was no non-SAEs occurred reported in Dose Escalation DLBCL only Cohort 3 Not Defined arm.	66.7% 4/6 • Number of events 5 • From Baseline Up to Approximately 3 Years Reported: Safety Population. During the Safety Follow-up Period, non-Serious Adverse Events occurred at the 5% frequency threshold. There was no non-SAEs occurred reported in Dose Escalation DLBCL only Cohort 3 Not Defined arm.	100.0% 7/7 • Number of events 13 • From Baseline Up to Approximately 3 Years Reported: Safety Population. During the Safety Follow-up Period, non-Serious Adverse Events occurred at the 5% frequency threshold. There was no non-SAEs occurred reported in Dose Escalation DLBCL only Cohort 3 Not Defined arm.	83.3% 5/6 • Number of events 6 • From Baseline Up to Approximately 3 Years Reported: Safety Population. During the Safety Follow-up Period, non-Serious Adverse Events occurred at the 5% frequency threshold. There was no non-SAEs occurred reported in Dose Escalation DLBCL only Cohort 3 Not Defined arm.	0.00% 0/1 • From Baseline Up to Approximately 3 Years Reported: Safety Population. During the Safety Follow-up Period, non-Serious Adverse Events occurred at the 5% frequency threshold. There was no non-SAEs occurred reported in Dose Escalation DLBCL only Cohort 3 Not Defined arm.
Cardiac disorders ATRIAL FIBRILLATION	0.00% 0/9 • From Baseline Up to Approximately 3 Years Reported: Safety Population. During the Safety Follow-up Period, non-Serious Adverse Events occurred at the 5% frequency threshold. There was no non-SAEs occurred reported in Dose Escalation DLBCL only Cohort 3 Not Defined arm.	16.7% 1/6 • Number of events 1 • From Baseline Up to Approximately 3 Years Reported: Safety Population. During the Safety Follow-up Period, non-Serious Adverse Events occurred at the 5% frequency threshold. There was no non-SAEs occurred reported in Dose Escalation DLBCL only Cohort 3 Not Defined arm.	0.00% 0/7 • From Baseline Up to Approximately 3 Years Reported: Safety Population. During the Safety Follow-up Period, non-Serious Adverse Events occurred at the 5% frequency threshold. There was no non-SAEs occurred reported in Dose Escalation DLBCL only Cohort 3 Not Defined arm.	16.7% 1/6 • Number of events 1 • From Baseline Up to Approximately 3 Years Reported: Safety Population. During the Safety Follow-up Period, non-Serious Adverse Events occurred at the 5% frequency threshold. There was no non-SAEs occurred reported in Dose Escalation DLBCL only Cohort 3 Not Defined arm.	0.00% 0/1 • From Baseline Up to Approximately 3 Years Reported: Safety Population. During the Safety Follow-up Period, non-Serious Adverse Events occurred at the 5% frequency threshold. There was no non-SAEs occurred reported in Dose Escalation DLBCL only Cohort 3 Not Defined arm.
Endocrine disorders HYPERTHYROIDISM	0.00% 0/9 • From Baseline Up to Approximately 3 Years Reported: Safety Population. During the Safety Follow-up Period, non-Serious Adverse Events occurred at the 5% frequency threshold. There was no non-SAEs occurred reported in Dose Escalation DLBCL only Cohort 3 Not Defined arm.	0.00% 0/6 • From Baseline Up to Approximately 3 Years Reported: Safety Population. During the Safety Follow-up Period, non-Serious Adverse Events occurred at the 5% frequency threshold. There was no non-SAEs occurred reported in Dose Escalation DLBCL only Cohort 3 Not Defined arm.	14.3% 1/7 • Number of events 1 • From Baseline Up to Approximately 3 Years Reported: Safety Population. During the Safety Follow-up Period, non-Serious Adverse Events occurred at the 5% frequency threshold. There was no non-SAEs occurred reported in Dose Escalation DLBCL only Cohort 3 Not Defined arm.	0.00% 0/6 • From Baseline Up to Approximately 3 Years Reported: Safety Population. During the Safety Follow-up Period, non-Serious Adverse Events occurred at the 5% frequency threshold. There was no non-SAEs occurred reported in Dose Escalation DLBCL only Cohort 3 Not Defined arm.	0.00% 0/1 • From Baseline Up to Approximately 3 Years Reported: Safety Population. During the Safety Follow-up Period, non-Serious Adverse Events occurred at the 5% frequency threshold. There was no non-SAEs occurred reported in Dose Escalation DLBCL only Cohort 3 Not Defined arm.
Eye disorders EYE DISORDER	11.1% 1/9 • Number of events 1 • From Baseline Up to Approximately 3 Years Reported: Safety Population. During the Safety Follow-up Period, non-Serious Adverse Events occurred at the 5% frequency threshold. There was no non-SAEs occurred reported in Dose Escalation DLBCL only Cohort 3 Not Defined arm.	0.00% 0/6 • From Baseline Up to Approximately 3 Years Reported: Safety Population. During the Safety Follow-up Period, non-Serious Adverse Events occurred at the 5% frequency threshold. There was no non-SAEs occurred reported in Dose Escalation DLBCL only Cohort 3 Not Defined arm.	0.00% 0/7 • From Baseline Up to Approximately 3 Years Reported: Safety Population. During the Safety Follow-up Period, non-Serious Adverse Events occurred at the 5% frequency threshold. There was no non-SAEs occurred reported in Dose Escalation DLBCL only Cohort 3 Not Defined arm.	0.00% 0/6 • From Baseline Up to Approximately 3 Years Reported: Safety Population. During the Safety Follow-up Period, non-Serious Adverse Events occurred at the 5% frequency threshold. There was no non-SAEs occurred reported in Dose Escalation DLBCL only Cohort 3 Not Defined arm.	0.00% 0/1 • From Baseline Up to Approximately 3 Years Reported: Safety Population. During the Safety Follow-up Period, non-Serious Adverse Events occurred at the 5% frequency threshold. There was no non-SAEs occurred reported in Dose Escalation DLBCL only Cohort 3 Not Defined arm.
Eye disorders EYE PAIN	11.1% 1/9 • Number of events 1 • From Baseline Up to Approximately 3 Years Reported: Safety Population. During the Safety Follow-up Period, non-Serious Adverse Events occurred at the 5% frequency threshold. There was no non-SAEs occurred reported in Dose Escalation DLBCL only Cohort 3 Not Defined arm.	0.00% 0/6 • From Baseline Up to Approximately 3 Years Reported: Safety Population. During the Safety Follow-up Period, non-Serious Adverse Events occurred at the 5% frequency threshold. There was no non-SAEs occurred reported in Dose Escalation DLBCL only Cohort 3 Not Defined arm.	0.00% 0/7 • From Baseline Up to Approximately 3 Years Reported: Safety Population. During the Safety Follow-up Period, non-Serious Adverse Events occurred at the 5% frequency threshold. There was no non-SAEs occurred reported in Dose Escalation DLBCL only Cohort 3 Not Defined arm.	0.00% 0/6 • From Baseline Up to Approximately 3 Years Reported: Safety Population. During the Safety Follow-up Period, non-Serious Adverse Events occurred at the 5% frequency threshold. There was no non-SAEs occurred reported in Dose Escalation DLBCL only Cohort 3 Not Defined arm.	0.00% 0/1 • From Baseline Up to Approximately 3 Years Reported: Safety Population. During the Safety Follow-up Period, non-Serious Adverse Events occurred at the 5% frequency threshold. There was no non-SAEs occurred reported in Dose Escalation DLBCL only Cohort 3 Not Defined arm.
Eye disorders PHOTOPHOBIA	11.1% 1/9 • Number of events 1 • From Baseline Up to Approximately 3 Years Reported: Safety Population. During the Safety Follow-up Period, non-Serious Adverse Events occurred at the 5% frequency threshold. There was no non-SAEs occurred reported in Dose Escalation DLBCL only Cohort 3 Not Defined arm.	0.00% 0/6 • From Baseline Up to Approximately 3 Years Reported: Safety Population. During the Safety Follow-up Period, non-Serious Adverse Events occurred at the 5% frequency threshold. There was no non-SAEs occurred reported in Dose Escalation DLBCL only Cohort 3 Not Defined arm.	0.00% 0/7 • From Baseline Up to Approximately 3 Years Reported: Safety Population. During the Safety Follow-up Period, non-Serious Adverse Events occurred at the 5% frequency threshold. There was no non-SAEs occurred reported in Dose Escalation DLBCL only Cohort 3 Not Defined arm.	0.00% 0/6 • From Baseline Up to Approximately 3 Years Reported: Safety Population. During the Safety Follow-up Period, non-Serious Adverse Events occurred at the 5% frequency threshold. There was no non-SAEs occurred reported in Dose Escalation DLBCL only Cohort 3 Not Defined arm.	0.00% 0/1 • From Baseline Up to Approximately 3 Years Reported: Safety Population. During the Safety Follow-up Period, non-Serious Adverse Events occurred at the 5% frequency threshold. There was no non-SAEs occurred reported in Dose Escalation DLBCL only Cohort 3 Not Defined arm.
Eye disorders VISION BLURRED	11.1% 1/9 • Number of events 1 • From Baseline Up to Approximately 3 Years Reported: Safety Population. During the Safety Follow-up Period, non-Serious Adverse Events occurred at the 5% frequency threshold. There was no non-SAEs occurred reported in Dose Escalation DLBCL only Cohort 3 Not Defined arm.	16.7% 1/6 • Number of events 1 • From Baseline Up to Approximately 3 Years Reported: Safety Population. During the Safety Follow-up Period, non-Serious Adverse Events occurred at the 5% frequency threshold. There was no non-SAEs occurred reported in Dose Escalation DLBCL only Cohort 3 Not Defined arm.	0.00% 0/7 • From Baseline Up to Approximately 3 Years Reported: Safety Population. During the Safety Follow-up Period, non-Serious Adverse Events occurred at the 5% frequency threshold. There was no non-SAEs occurred reported in Dose Escalation DLBCL only Cohort 3 Not Defined arm.	0.00% 0/6 • From Baseline Up to Approximately 3 Years Reported: Safety Population. During the Safety Follow-up Period, non-Serious Adverse Events occurred at the 5% frequency threshold. There was no non-SAEs occurred reported in Dose Escalation DLBCL only Cohort 3 Not Defined arm.	0.00% 0/1 • From Baseline Up to Approximately 3 Years Reported: Safety Population. During the Safety Follow-up Period, non-Serious Adverse Events occurred at the 5% frequency threshold. There was no non-SAEs occurred reported in Dose Escalation DLBCL only Cohort 3 Not Defined arm.
Gastrointestinal disorders ABDOMINAL DISCOMFORT	0.00% 0/9 • From Baseline Up to Approximately 3 Years Reported: Safety Population. During the Safety Follow-up Period, non-Serious Adverse Events occurred at the 5% frequency threshold. There was no non-SAEs occurred reported in Dose Escalation DLBCL only Cohort 3 Not Defined arm.	16.7% 1/6 • Number of events 1 • From Baseline Up to Approximately 3 Years Reported: Safety Population. During the Safety Follow-up Period, non-Serious Adverse Events occurred at the 5% frequency threshold. There was no non-SAEs occurred reported in Dose Escalation DLBCL only Cohort 3 Not Defined arm.	14.3% 1/7 • Number of events 2 • From Baseline Up to Approximately 3 Years Reported: Safety Population. During the Safety Follow-up Period, non-Serious Adverse Events occurred at the 5% frequency threshold. There was no non-SAEs occurred reported in Dose Escalation DLBCL only Cohort 3 Not Defined arm.	0.00% 0/6 • From Baseline Up to Approximately 3 Years Reported: Safety Population. During the Safety Follow-up Period, non-Serious Adverse Events occurred at the 5% frequency threshold. There was no non-SAEs occurred reported in Dose Escalation DLBCL only Cohort 3 Not Defined arm.	0.00% 0/1 • From Baseline Up to Approximately 3 Years Reported: Safety Population. During the Safety Follow-up Period, non-Serious Adverse Events occurred at the 5% frequency threshold. There was no non-SAEs occurred reported in Dose Escalation DLBCL only Cohort 3 Not Defined arm.
Gastrointestinal disorders ABDOMINAL PAIN	33.3% 3/9 • Number of events 3 • From Baseline Up to Approximately 3 Years Reported: Safety Population. During the Safety Follow-up Period, non-Serious Adverse Events occurred at the 5% frequency threshold. There was no non-SAEs occurred reported in Dose Escalation DLBCL only Cohort 3 Not Defined arm.	0.00% 0/6 • From Baseline Up to Approximately 3 Years Reported: Safety Population. During the Safety Follow-up Period, non-Serious Adverse Events occurred at the 5% frequency threshold. There was no non-SAEs occurred reported in Dose Escalation DLBCL only Cohort 3 Not Defined arm.	0.00% 0/7 • From Baseline Up to Approximately 3 Years Reported: Safety Population. During the Safety Follow-up Period, non-Serious Adverse Events occurred at the 5% frequency threshold. There was no non-SAEs occurred reported in Dose Escalation DLBCL only Cohort 3 Not Defined arm.	0.00% 0/6 • From Baseline Up to Approximately 3 Years Reported: Safety Population. During the Safety Follow-up Period, non-Serious Adverse Events occurred at the 5% frequency threshold. There was no non-SAEs occurred reported in Dose Escalation DLBCL only Cohort 3 Not Defined arm.	0.00% 0/1 • From Baseline Up to Approximately 3 Years Reported: Safety Population. During the Safety Follow-up Period, non-Serious Adverse Events occurred at the 5% frequency threshold. There was no non-SAEs occurred reported in Dose Escalation DLBCL only Cohort 3 Not Defined arm.
Gastrointestinal disorders ANAL INCONTINENCE	0.00% 0/9 • From Baseline Up to Approximately 3 Years Reported: Safety Population. During the Safety Follow-up Period, non-Serious Adverse Events occurred at the 5% frequency threshold. There was no non-SAEs occurred reported in Dose Escalation DLBCL only Cohort 3 Not Defined arm.	16.7% 1/6 • Number of events 1 • From Baseline Up to Approximately 3 Years Reported: Safety Population. During the Safety Follow-up Period, non-Serious Adverse Events occurred at the 5% frequency threshold. There was no non-SAEs occurred reported in Dose Escalation DLBCL only Cohort 3 Not Defined arm.	0.00% 0/7 • From Baseline Up to Approximately 3 Years Reported: Safety Population. During the Safety Follow-up Period, non-Serious Adverse Events occurred at the 5% frequency threshold. There was no non-SAEs occurred reported in Dose Escalation DLBCL only Cohort 3 Not Defined arm.	0.00% 0/6 • From Baseline Up to Approximately 3 Years Reported: Safety Population. During the Safety Follow-up Period, non-Serious Adverse Events occurred at the 5% frequency threshold. There was no non-SAEs occurred reported in Dose Escalation DLBCL only Cohort 3 Not Defined arm.	0.00% 0/1 • From Baseline Up to Approximately 3 Years Reported: Safety Population. During the Safety Follow-up Period, non-Serious Adverse Events occurred at the 5% frequency threshold. There was no non-SAEs occurred reported in Dose Escalation DLBCL only Cohort 3 Not Defined arm.
Gastrointestinal disorders CONSTIPATION	22.2% 2/9 • Number of events 2 • From Baseline Up to Approximately 3 Years Reported: Safety Population. During the Safety Follow-up Period, non-Serious Adverse Events occurred at the 5% frequency threshold. There was no non-SAEs occurred reported in Dose Escalation DLBCL only Cohort 3 Not Defined arm.	16.7% 1/6 • Number of events 1 • From Baseline Up to Approximately 3 Years Reported: Safety Population. During the Safety Follow-up Period, non-Serious Adverse Events occurred at the 5% frequency threshold. There was no non-SAEs occurred reported in Dose Escalation DLBCL only Cohort 3 Not Defined arm.	0.00% 0/7 • From Baseline Up to Approximately 3 Years Reported: Safety Population. During the Safety Follow-up Period, non-Serious Adverse Events occurred at the 5% frequency threshold. There was no non-SAEs occurred reported in Dose Escalation DLBCL only Cohort 3 Not Defined arm.	33.3% 2/6 • Number of events 2 • From Baseline Up to Approximately 3 Years Reported: Safety Population. During the Safety Follow-up Period, non-Serious Adverse Events occurred at the 5% frequency threshold. There was no non-SAEs occurred reported in Dose Escalation DLBCL only Cohort 3 Not Defined arm.	0.00% 0/1 • From Baseline Up to Approximately 3 Years Reported: Safety Population. During the Safety Follow-up Period, non-Serious Adverse Events occurred at the 5% frequency threshold. There was no non-SAEs occurred reported in Dose Escalation DLBCL only Cohort 3 Not Defined arm.
Gastrointestinal disorders DIARRHOEA	55.6% 5/9 • Number of events 9 • From Baseline Up to Approximately 3 Years Reported: Safety Population. During the Safety Follow-up Period, non-Serious Adverse Events occurred at the 5% frequency threshold. There was no non-SAEs occurred reported in Dose Escalation DLBCL only Cohort 3 Not Defined arm.	50.0% 3/6 • Number of events 3 • From Baseline Up to Approximately 3 Years Reported: Safety Population. During the Safety Follow-up Period, non-Serious Adverse Events occurred at the 5% frequency threshold. There was no non-SAEs occurred reported in Dose Escalation DLBCL only Cohort 3 Not Defined arm.	57.1% 4/7 • Number of events 6 • From Baseline Up to Approximately 3 Years Reported: Safety Population. During the Safety Follow-up Period, non-Serious Adverse Events occurred at the 5% frequency threshold. There was no non-SAEs occurred reported in Dose Escalation DLBCL only Cohort 3 Not Defined arm.	66.7% 4/6 • Number of events 10 • From Baseline Up to Approximately 3 Years Reported: Safety Population. During the Safety Follow-up Period, non-Serious Adverse Events occurred at the 5% frequency threshold. There was no non-SAEs occurred reported in Dose Escalation DLBCL only Cohort 3 Not Defined arm.	0.00% 0/1 • From Baseline Up to Approximately 3 Years Reported: Safety Population. During the Safety Follow-up Period, non-Serious Adverse Events occurred at the 5% frequency threshold. There was no non-SAEs occurred reported in Dose Escalation DLBCL only Cohort 3 Not Defined arm.
Gastrointestinal disorders DYSPEPSIA	0.00% 0/9 • From Baseline Up to Approximately 3 Years Reported: Safety Population. During the Safety Follow-up Period, non-Serious Adverse Events occurred at the 5% frequency threshold. There was no non-SAEs occurred reported in Dose Escalation DLBCL only Cohort 3 Not Defined arm.	0.00% 0/6 • From Baseline Up to Approximately 3 Years Reported: Safety Population. During the Safety Follow-up Period, non-Serious Adverse Events occurred at the 5% frequency threshold. There was no non-SAEs occurred reported in Dose Escalation DLBCL only Cohort 3 Not Defined arm.	0.00% 0/7 • From Baseline Up to Approximately 3 Years Reported: Safety Population. During the Safety Follow-up Period, non-Serious Adverse Events occurred at the 5% frequency threshold. There was no non-SAEs occurred reported in Dose Escalation DLBCL only Cohort 3 Not Defined arm.	16.7% 1/6 • Number of events 2 • From Baseline Up to Approximately 3 Years Reported: Safety Population. During the Safety Follow-up Period, non-Serious Adverse Events occurred at the 5% frequency threshold. There was no non-SAEs occurred reported in Dose Escalation DLBCL only Cohort 3 Not Defined arm.	0.00% 0/1 • From Baseline Up to Approximately 3 Years Reported: Safety Population. During the Safety Follow-up Period, non-Serious Adverse Events occurred at the 5% frequency threshold. There was no non-SAEs occurred reported in Dose Escalation DLBCL only Cohort 3 Not Defined arm.
Gastrointestinal disorders FLATULENCE	11.1% 1/9 • Number of events 1 • From Baseline Up to Approximately 3 Years Reported: Safety Population. During the Safety Follow-up Period, non-Serious Adverse Events occurred at the 5% frequency threshold. There was no non-SAEs occurred reported in Dose Escalation DLBCL only Cohort 3 Not Defined arm.	0.00% 0/6 • From Baseline Up to Approximately 3 Years Reported: Safety Population. During the Safety Follow-up Period, non-Serious Adverse Events occurred at the 5% frequency threshold. There was no non-SAEs occurred reported in Dose Escalation DLBCL only Cohort 3 Not Defined arm.	0.00% 0/7 • From Baseline Up to Approximately 3 Years Reported: Safety Population. During the Safety Follow-up Period, non-Serious Adverse Events occurred at the 5% frequency threshold. There was no non-SAEs occurred reported in Dose Escalation DLBCL only Cohort 3 Not Defined arm.	0.00% 0/6 • From Baseline Up to Approximately 3 Years Reported: Safety Population. During the Safety Follow-up Period, non-Serious Adverse Events occurred at the 5% frequency threshold. There was no non-SAEs occurred reported in Dose Escalation DLBCL only Cohort 3 Not Defined arm.	0.00% 0/1 • From Baseline Up to Approximately 3 Years Reported: Safety Population. During the Safety Follow-up Period, non-Serious Adverse Events occurred at the 5% frequency threshold. There was no non-SAEs occurred reported in Dose Escalation DLBCL only Cohort 3 Not Defined arm.
Gastrointestinal disorders GASTROOESOPHAGEAL REFLUX DISEASE	33.3% 3/9 • Number of events 3 • From Baseline Up to Approximately 3 Years Reported: Safety Population. During the Safety Follow-up Period, non-Serious Adverse Events occurred at the 5% frequency threshold. There was no non-SAEs occurred reported in Dose Escalation DLBCL only Cohort 3 Not Defined arm.	0.00% 0/6 • From Baseline Up to Approximately 3 Years Reported: Safety Population. During the Safety Follow-up Period, non-Serious Adverse Events occurred at the 5% frequency threshold. There was no non-SAEs occurred reported in Dose Escalation DLBCL only Cohort 3 Not Defined arm.	0.00% 0/7 • From Baseline Up to Approximately 3 Years Reported: Safety Population. During the Safety Follow-up Period, non-Serious Adverse Events occurred at the 5% frequency threshold. There was no non-SAEs occurred reported in Dose Escalation DLBCL only Cohort 3 Not Defined arm.	0.00% 0/6 • From Baseline Up to Approximately 3 Years Reported: Safety Population. During the Safety Follow-up Period, non-Serious Adverse Events occurred at the 5% frequency threshold. There was no non-SAEs occurred reported in Dose Escalation DLBCL only Cohort 3 Not Defined arm.	0.00% 0/1 • From Baseline Up to Approximately 3 Years Reported: Safety Population. During the Safety Follow-up Period, non-Serious Adverse Events occurred at the 5% frequency threshold. There was no non-SAEs occurred reported in Dose Escalation DLBCL only Cohort 3 Not Defined arm.
Gastrointestinal disorders MOUTH ULCERATION	0.00% 0/9 • From Baseline Up to Approximately 3 Years Reported: Safety Population. During the Safety Follow-up Period, non-Serious Adverse Events occurred at the 5% frequency threshold. There was no non-SAEs occurred reported in Dose Escalation DLBCL only Cohort 3 Not Defined arm.	0.00% 0/6 • From Baseline Up to Approximately 3 Years Reported: Safety Population. During the Safety Follow-up Period, non-Serious Adverse Events occurred at the 5% frequency threshold. There was no non-SAEs occurred reported in Dose Escalation DLBCL only Cohort 3 Not Defined arm.	14.3% 1/7 • Number of events 1 • From Baseline Up to Approximately 3 Years Reported: Safety Population. During the Safety Follow-up Period, non-Serious Adverse Events occurred at the 5% frequency threshold. There was no non-SAEs occurred reported in Dose Escalation DLBCL only Cohort 3 Not Defined arm.	0.00% 0/6 • From Baseline Up to Approximately 3 Years Reported: Safety Population. During the Safety Follow-up Period, non-Serious Adverse Events occurred at the 5% frequency threshold. There was no non-SAEs occurred reported in Dose Escalation DLBCL only Cohort 3 Not Defined arm.	0.00% 0/1 • From Baseline Up to Approximately 3 Years Reported: Safety Population. During the Safety Follow-up Period, non-Serious Adverse Events occurred at the 5% frequency threshold. There was no non-SAEs occurred reported in Dose Escalation DLBCL only Cohort 3 Not Defined arm.
Gastrointestinal disorders NAUSEA	66.7% 6/9 • Number of events 14 • From Baseline Up to Approximately 3 Years Reported: Safety Population. During the Safety Follow-up Period, non-Serious Adverse Events occurred at the 5% frequency threshold. There was no non-SAEs occurred reported in Dose Escalation DLBCL only Cohort 3 Not Defined arm.	66.7% 4/6 • Number of events 6 • From Baseline Up to Approximately 3 Years Reported: Safety Population. During the Safety Follow-up Period, non-Serious Adverse Events occurred at the 5% frequency threshold. There was no non-SAEs occurred reported in Dose Escalation DLBCL only Cohort 3 Not Defined arm.	42.9% 3/7 • Number of events 3 • From Baseline Up to Approximately 3 Years Reported: Safety Population. During the Safety Follow-up Period, non-Serious Adverse Events occurred at the 5% frequency threshold. There was no non-SAEs occurred reported in Dose Escalation DLBCL only Cohort 3 Not Defined arm.	50.0% 3/6 • Number of events 8 • From Baseline Up to Approximately 3 Years Reported: Safety Population. During the Safety Follow-up Period, non-Serious Adverse Events occurred at the 5% frequency threshold. There was no non-SAEs occurred reported in Dose Escalation DLBCL only Cohort 3 Not Defined arm.	0.00% 0/1 • From Baseline Up to Approximately 3 Years Reported: Safety Population. During the Safety Follow-up Period, non-Serious Adverse Events occurred at the 5% frequency threshold. There was no non-SAEs occurred reported in Dose Escalation DLBCL only Cohort 3 Not Defined arm.
Gastrointestinal disorders ODYNOPHAGIA	11.1% 1/9 • Number of events 1 • From Baseline Up to Approximately 3 Years Reported: Safety Population. During the Safety Follow-up Period, non-Serious Adverse Events occurred at the 5% frequency threshold. There was no non-SAEs occurred reported in Dose Escalation DLBCL only Cohort 3 Not Defined arm.	0.00% 0/6 • From Baseline Up to Approximately 3 Years Reported: Safety Population. During the Safety Follow-up Period, non-Serious Adverse Events occurred at the 5% frequency threshold. There was no non-SAEs occurred reported in Dose Escalation DLBCL only Cohort 3 Not Defined arm.	0.00% 0/7 • From Baseline Up to Approximately 3 Years Reported: Safety Population. During the Safety Follow-up Period, non-Serious Adverse Events occurred at the 5% frequency threshold. There was no non-SAEs occurred reported in Dose Escalation DLBCL only Cohort 3 Not Defined arm.	0.00% 0/6 • From Baseline Up to Approximately 3 Years Reported: Safety Population. During the Safety Follow-up Period, non-Serious Adverse Events occurred at the 5% frequency threshold. There was no non-SAEs occurred reported in Dose Escalation DLBCL only Cohort 3 Not Defined arm.	0.00% 0/1 • From Baseline Up to Approximately 3 Years Reported: Safety Population. During the Safety Follow-up Period, non-Serious Adverse Events occurred at the 5% frequency threshold. There was no non-SAEs occurred reported in Dose Escalation DLBCL only Cohort 3 Not Defined arm.
Gastrointestinal disorders STOMATITIS	11.1% 1/9 • Number of events 1 • From Baseline Up to Approximately 3 Years Reported: Safety Population. During the Safety Follow-up Period, non-Serious Adverse Events occurred at the 5% frequency threshold. There was no non-SAEs occurred reported in Dose Escalation DLBCL only Cohort 3 Not Defined arm.	0.00% 0/6 • From Baseline Up to Approximately 3 Years Reported: Safety Population. During the Safety Follow-up Period, non-Serious Adverse Events occurred at the 5% frequency threshold. There was no non-SAEs occurred reported in Dose Escalation DLBCL only Cohort 3 Not Defined arm.	0.00% 0/7 • From Baseline Up to Approximately 3 Years Reported: Safety Population. During the Safety Follow-up Period, non-Serious Adverse Events occurred at the 5% frequency threshold. There was no non-SAEs occurred reported in Dose Escalation DLBCL only Cohort 3 Not Defined arm.	0.00% 0/6 • From Baseline Up to Approximately 3 Years Reported: Safety Population. During the Safety Follow-up Period, non-Serious Adverse Events occurred at the 5% frequency threshold. There was no non-SAEs occurred reported in Dose Escalation DLBCL only Cohort 3 Not Defined arm.	0.00% 0/1 • From Baseline Up to Approximately 3 Years Reported: Safety Population. During the Safety Follow-up Period, non-Serious Adverse Events occurred at the 5% frequency threshold. There was no non-SAEs occurred reported in Dose Escalation DLBCL only Cohort 3 Not Defined arm.
Gastrointestinal disorders TONGUE HAEMATOMA	0.00% 0/9 • From Baseline Up to Approximately 3 Years Reported: Safety Population. During the Safety Follow-up Period, non-Serious Adverse Events occurred at the 5% frequency threshold. There was no non-SAEs occurred reported in Dose Escalation DLBCL only Cohort 3 Not Defined arm.	0.00% 0/6 • From Baseline Up to Approximately 3 Years Reported: Safety Population. During the Safety Follow-up Period, non-Serious Adverse Events occurred at the 5% frequency threshold. There was no non-SAEs occurred reported in Dose Escalation DLBCL only Cohort 3 Not Defined arm.	14.3% 1/7 • Number of events 2 • From Baseline Up to Approximately 3 Years Reported: Safety Population. During the Safety Follow-up Period, non-Serious Adverse Events occurred at the 5% frequency threshold. There was no non-SAEs occurred reported in Dose Escalation DLBCL only Cohort 3 Not Defined arm.	0.00% 0/6 • From Baseline Up to Approximately 3 Years Reported: Safety Population. During the Safety Follow-up Period, non-Serious Adverse Events occurred at the 5% frequency threshold. There was no non-SAEs occurred reported in Dose Escalation DLBCL only Cohort 3 Not Defined arm.	0.00% 0/1 • From Baseline Up to Approximately 3 Years Reported: Safety Population. During the Safety Follow-up Period, non-Serious Adverse Events occurred at the 5% frequency threshold. There was no non-SAEs occurred reported in Dose Escalation DLBCL only Cohort 3 Not Defined arm.
Gastrointestinal disorders VOMITING	33.3% 3/9 • Number of events 5 • From Baseline Up to Approximately 3 Years Reported: Safety Population. During the Safety Follow-up Period, non-Serious Adverse Events occurred at the 5% frequency threshold. There was no non-SAEs occurred reported in Dose Escalation DLBCL only Cohort 3 Not Defined arm.	50.0% 3/6 • Number of events 3 • From Baseline Up to Approximately 3 Years Reported: Safety Population. During the Safety Follow-up Period, non-Serious Adverse Events occurred at the 5% frequency threshold. There was no non-SAEs occurred reported in Dose Escalation DLBCL only Cohort 3 Not Defined arm.	14.3% 1/7 • Number of events 1 • From Baseline Up to Approximately 3 Years Reported: Safety Population. During the Safety Follow-up Period, non-Serious Adverse Events occurred at the 5% frequency threshold. There was no non-SAEs occurred reported in Dose Escalation DLBCL only Cohort 3 Not Defined arm.	33.3% 2/6 • Number of events 2 • From Baseline Up to Approximately 3 Years Reported: Safety Population. During the Safety Follow-up Period, non-Serious Adverse Events occurred at the 5% frequency threshold. There was no non-SAEs occurred reported in Dose Escalation DLBCL only Cohort 3 Not Defined arm.	0.00% 0/1 • From Baseline Up to Approximately 3 Years Reported: Safety Population. During the Safety Follow-up Period, non-Serious Adverse Events occurred at the 5% frequency threshold. There was no non-SAEs occurred reported in Dose Escalation DLBCL only Cohort 3 Not Defined arm.
General disorders CHEST PAIN	0.00% 0/9 • From Baseline Up to Approximately 3 Years Reported: Safety Population. During the Safety Follow-up Period, non-Serious Adverse Events occurred at the 5% frequency threshold. There was no non-SAEs occurred reported in Dose Escalation DLBCL only Cohort 3 Not Defined arm.	50.0% 3/6 • Number of events 3 • From Baseline Up to Approximately 3 Years Reported: Safety Population. During the Safety Follow-up Period, non-Serious Adverse Events occurred at the 5% frequency threshold. There was no non-SAEs occurred reported in Dose Escalation DLBCL only Cohort 3 Not Defined arm.	0.00% 0/7 • From Baseline Up to Approximately 3 Years Reported: Safety Population. During the Safety Follow-up Period, non-Serious Adverse Events occurred at the 5% frequency threshold. There was no non-SAEs occurred reported in Dose Escalation DLBCL only Cohort 3 Not Defined arm.	0.00% 0/6 • From Baseline Up to Approximately 3 Years Reported: Safety Population. During the Safety Follow-up Period, non-Serious Adverse Events occurred at the 5% frequency threshold. There was no non-SAEs occurred reported in Dose Escalation DLBCL only Cohort 3 Not Defined arm.	0.00% 0/1 • From Baseline Up to Approximately 3 Years Reported: Safety Population. During the Safety Follow-up Period, non-Serious Adverse Events occurred at the 5% frequency threshold. There was no non-SAEs occurred reported in Dose Escalation DLBCL only Cohort 3 Not Defined arm.
General disorders CHILLS	11.1% 1/9 • Number of events 1 • From Baseline Up to Approximately 3 Years Reported: Safety Population. During the Safety Follow-up Period, non-Serious Adverse Events occurred at the 5% frequency threshold. There was no non-SAEs occurred reported in Dose Escalation DLBCL only Cohort 3 Not Defined arm.	0.00% 0/6 • From Baseline Up to Approximately 3 Years Reported: Safety Population. During the Safety Follow-up Period, non-Serious Adverse Events occurred at the 5% frequency threshold. There was no non-SAEs occurred reported in Dose Escalation DLBCL only Cohort 3 Not Defined arm.	0.00% 0/7 • From Baseline Up to Approximately 3 Years Reported: Safety Population. During the Safety Follow-up Period, non-Serious Adverse Events occurred at the 5% frequency threshold. There was no non-SAEs occurred reported in Dose Escalation DLBCL only Cohort 3 Not Defined arm.	16.7% 1/6 • Number of events 1 • From Baseline Up to Approximately 3 Years Reported: Safety Population. During the Safety Follow-up Period, non-Serious Adverse Events occurred at the 5% frequency threshold. There was no non-SAEs occurred reported in Dose Escalation DLBCL only Cohort 3 Not Defined arm.	0.00% 0/1 • From Baseline Up to Approximately 3 Years Reported: Safety Population. During the Safety Follow-up Period, non-Serious Adverse Events occurred at the 5% frequency threshold. There was no non-SAEs occurred reported in Dose Escalation DLBCL only Cohort 3 Not Defined arm.
General disorders FATIGUE	11.1% 1/9 • Number of events 1 • From Baseline Up to Approximately 3 Years Reported: Safety Population. During the Safety Follow-up Period, non-Serious Adverse Events occurred at the 5% frequency threshold. There was no non-SAEs occurred reported in Dose Escalation DLBCL only Cohort 3 Not Defined arm.	50.0% 3/6 • Number of events 3 • From Baseline Up to Approximately 3 Years Reported: Safety Population. During the Safety Follow-up Period, non-Serious Adverse Events occurred at the 5% frequency threshold. There was no non-SAEs occurred reported in Dose Escalation DLBCL only Cohort 3 Not Defined arm.	42.9% 3/7 • Number of events 3 • From Baseline Up to Approximately 3 Years Reported: Safety Population. During the Safety Follow-up Period, non-Serious Adverse Events occurred at the 5% frequency threshold. There was no non-SAEs occurred reported in Dose Escalation DLBCL only Cohort 3 Not Defined arm.	16.7% 1/6 • Number of events 1 • From Baseline Up to Approximately 3 Years Reported: Safety Population. During the Safety Follow-up Period, non-Serious Adverse Events occurred at the 5% frequency threshold. There was no non-SAEs occurred reported in Dose Escalation DLBCL only Cohort 3 Not Defined arm.	0.00% 0/1 • From Baseline Up to Approximately 3 Years Reported: Safety Population. During the Safety Follow-up Period, non-Serious Adverse Events occurred at the 5% frequency threshold. There was no non-SAEs occurred reported in Dose Escalation DLBCL only Cohort 3 Not Defined arm.
General disorders NON-CARDIAC CHEST PAIN	11.1% 1/9 • Number of events 2 • From Baseline Up to Approximately 3 Years Reported: Safety Population. During the Safety Follow-up Period, non-Serious Adverse Events occurred at the 5% frequency threshold. There was no non-SAEs occurred reported in Dose Escalation DLBCL only Cohort 3 Not Defined arm.	0.00% 0/6 • From Baseline Up to Approximately 3 Years Reported: Safety Population. During the Safety Follow-up Period, non-Serious Adverse Events occurred at the 5% frequency threshold. There was no non-SAEs occurred reported in Dose Escalation DLBCL only Cohort 3 Not Defined arm.	0.00% 0/7 • From Baseline Up to Approximately 3 Years Reported: Safety Population. During the Safety Follow-up Period, non-Serious Adverse Events occurred at the 5% frequency threshold. There was no non-SAEs occurred reported in Dose Escalation DLBCL only Cohort 3 Not Defined arm.	0.00% 0/6 • From Baseline Up to Approximately 3 Years Reported: Safety Population. During the Safety Follow-up Period, non-Serious Adverse Events occurred at the 5% frequency threshold. There was no non-SAEs occurred reported in Dose Escalation DLBCL only Cohort 3 Not Defined arm.	0.00% 0/1 • From Baseline Up to Approximately 3 Years Reported: Safety Population. During the Safety Follow-up Period, non-Serious Adverse Events occurred at the 5% frequency threshold. There was no non-SAEs occurred reported in Dose Escalation DLBCL only Cohort 3 Not Defined arm.
General disorders OEDEMA	0.00% 0/9 • From Baseline Up to Approximately 3 Years Reported: Safety Population. During the Safety Follow-up Period, non-Serious Adverse Events occurred at the 5% frequency threshold. There was no non-SAEs occurred reported in Dose Escalation DLBCL only Cohort 3 Not Defined arm.	16.7% 1/6 • Number of events 1 • From Baseline Up to Approximately 3 Years Reported: Safety Population. During the Safety Follow-up Period, non-Serious Adverse Events occurred at the 5% frequency threshold. There was no non-SAEs occurred reported in Dose Escalation DLBCL only Cohort 3 Not Defined arm.	0.00% 0/7 • From Baseline Up to Approximately 3 Years Reported: Safety Population. During the Safety Follow-up Period, non-Serious Adverse Events occurred at the 5% frequency threshold. There was no non-SAEs occurred reported in Dose Escalation DLBCL only Cohort 3 Not Defined arm.	0.00% 0/6 • From Baseline Up to Approximately 3 Years Reported: Safety Population. During the Safety Follow-up Period, non-Serious Adverse Events occurred at the 5% frequency threshold. There was no non-SAEs occurred reported in Dose Escalation DLBCL only Cohort 3 Not Defined arm.	0.00% 0/1 • From Baseline Up to Approximately 3 Years Reported: Safety Population. During the Safety Follow-up Period, non-Serious Adverse Events occurred at the 5% frequency threshold. There was no non-SAEs occurred reported in Dose Escalation DLBCL only Cohort 3 Not Defined arm.
General disorders PAIN	11.1% 1/9 • Number of events 1 • From Baseline Up to Approximately 3 Years Reported: Safety Population. During the Safety Follow-up Period, non-Serious Adverse Events occurred at the 5% frequency threshold. There was no non-SAEs occurred reported in Dose Escalation DLBCL only Cohort 3 Not Defined arm.	0.00% 0/6 • From Baseline Up to Approximately 3 Years Reported: Safety Population. During the Safety Follow-up Period, non-Serious Adverse Events occurred at the 5% frequency threshold. There was no non-SAEs occurred reported in Dose Escalation DLBCL only Cohort 3 Not Defined arm.	0.00% 0/7 • From Baseline Up to Approximately 3 Years Reported: Safety Population. During the Safety Follow-up Period, non-Serious Adverse Events occurred at the 5% frequency threshold. There was no non-SAEs occurred reported in Dose Escalation DLBCL only Cohort 3 Not Defined arm.	0.00% 0/6 • From Baseline Up to Approximately 3 Years Reported: Safety Population. During the Safety Follow-up Period, non-Serious Adverse Events occurred at the 5% frequency threshold. There was no non-SAEs occurred reported in Dose Escalation DLBCL only Cohort 3 Not Defined arm.	0.00% 0/1 • From Baseline Up to Approximately 3 Years Reported: Safety Population. During the Safety Follow-up Period, non-Serious Adverse Events occurred at the 5% frequency threshold. There was no non-SAEs occurred reported in Dose Escalation DLBCL only Cohort 3 Not Defined arm.
General disorders PYREXIA	0.00% 0/9 • From Baseline Up to Approximately 3 Years Reported: Safety Population. During the Safety Follow-up Period, non-Serious Adverse Events occurred at the 5% frequency threshold. There was no non-SAEs occurred reported in Dose Escalation DLBCL only Cohort 3 Not Defined arm.	16.7% 1/6 • Number of events 1 • From Baseline Up to Approximately 3 Years Reported: Safety Population. During the Safety Follow-up Period, non-Serious Adverse Events occurred at the 5% frequency threshold. There was no non-SAEs occurred reported in Dose Escalation DLBCL only Cohort 3 Not Defined arm.	0.00% 0/7 • From Baseline Up to Approximately 3 Years Reported: Safety Population. During the Safety Follow-up Period, non-Serious Adverse Events occurred at the 5% frequency threshold. There was no non-SAEs occurred reported in Dose Escalation DLBCL only Cohort 3 Not Defined arm.	0.00% 0/6 • From Baseline Up to Approximately 3 Years Reported: Safety Population. During the Safety Follow-up Period, non-Serious Adverse Events occurred at the 5% frequency threshold. There was no non-SAEs occurred reported in Dose Escalation DLBCL only Cohort 3 Not Defined arm.	0.00% 0/1 • From Baseline Up to Approximately 3 Years Reported: Safety Population. During the Safety Follow-up Period, non-Serious Adverse Events occurred at the 5% frequency threshold. There was no non-SAEs occurred reported in Dose Escalation DLBCL only Cohort 3 Not Defined arm.
General disorders UNEVALUABLE EVENT	0.00% 0/9 • From Baseline Up to Approximately 3 Years Reported: Safety Population. During the Safety Follow-up Period, non-Serious Adverse Events occurred at the 5% frequency threshold. There was no non-SAEs occurred reported in Dose Escalation DLBCL only Cohort 3 Not Defined arm.	0.00% 0/6 • From Baseline Up to Approximately 3 Years Reported: Safety Population. During the Safety Follow-up Period, non-Serious Adverse Events occurred at the 5% frequency threshold. There was no non-SAEs occurred reported in Dose Escalation DLBCL only Cohort 3 Not Defined arm.	0.00% 0/7 • From Baseline Up to Approximately 3 Years Reported: Safety Population. During the Safety Follow-up Period, non-Serious Adverse Events occurred at the 5% frequency threshold. There was no non-SAEs occurred reported in Dose Escalation DLBCL only Cohort 3 Not Defined arm.	16.7% 1/6 • Number of events 1 • From Baseline Up to Approximately 3 Years Reported: Safety Population. During the Safety Follow-up Period, non-Serious Adverse Events occurred at the 5% frequency threshold. There was no non-SAEs occurred reported in Dose Escalation DLBCL only Cohort 3 Not Defined arm.	0.00% 0/1 • From Baseline Up to Approximately 3 Years Reported: Safety Population. During the Safety Follow-up Period, non-Serious Adverse Events occurred at the 5% frequency threshold. There was no non-SAEs occurred reported in Dose Escalation DLBCL only Cohort 3 Not Defined arm.
Infections and infestations CELLULITIS	0.00% 0/9 • From Baseline Up to Approximately 3 Years Reported: Safety Population. During the Safety Follow-up Period, non-Serious Adverse Events occurred at the 5% frequency threshold. There was no non-SAEs occurred reported in Dose Escalation DLBCL only Cohort 3 Not Defined arm.	0.00% 0/6 • From Baseline Up to Approximately 3 Years Reported: Safety Population. During the Safety Follow-up Period, non-Serious Adverse Events occurred at the 5% frequency threshold. There was no non-SAEs occurred reported in Dose Escalation DLBCL only Cohort 3 Not Defined arm.	0.00% 0/7 • From Baseline Up to Approximately 3 Years Reported: Safety Population. During the Safety Follow-up Period, non-Serious Adverse Events occurred at the 5% frequency threshold. There was no non-SAEs occurred reported in Dose Escalation DLBCL only Cohort 3 Not Defined arm.	16.7% 1/6 • Number of events 1 • From Baseline Up to Approximately 3 Years Reported: Safety Population. During the Safety Follow-up Period, non-Serious Adverse Events occurred at the 5% frequency threshold. There was no non-SAEs occurred reported in Dose Escalation DLBCL only Cohort 3 Not Defined arm.	0.00% 0/1 • From Baseline Up to Approximately 3 Years Reported: Safety Population. During the Safety Follow-up Period, non-Serious Adverse Events occurred at the 5% frequency threshold. There was no non-SAEs occurred reported in Dose Escalation DLBCL only Cohort 3 Not Defined arm.
Infections and infestations CLOSTRIDIUM DIFFICILE COLITIS	0.00% 0/9 • From Baseline Up to Approximately 3 Years Reported: Safety Population. During the Safety Follow-up Period, non-Serious Adverse Events occurred at the 5% frequency threshold. There was no non-SAEs occurred reported in Dose Escalation DLBCL only Cohort 3 Not Defined arm.	16.7% 1/6 • Number of events 1 • From Baseline Up to Approximately 3 Years Reported: Safety Population. During the Safety Follow-up Period, non-Serious Adverse Events occurred at the 5% frequency threshold. There was no non-SAEs occurred reported in Dose Escalation DLBCL only Cohort 3 Not Defined arm.	0.00% 0/7 • From Baseline Up to Approximately 3 Years Reported: Safety Population. During the Safety Follow-up Period, non-Serious Adverse Events occurred at the 5% frequency threshold. There was no non-SAEs occurred reported in Dose Escalation DLBCL only Cohort 3 Not Defined arm.	0.00% 0/6 • From Baseline Up to Approximately 3 Years Reported: Safety Population. During the Safety Follow-up Period, non-Serious Adverse Events occurred at the 5% frequency threshold. There was no non-SAEs occurred reported in Dose Escalation DLBCL only Cohort 3 Not Defined arm.	0.00% 0/1 • From Baseline Up to Approximately 3 Years Reported: Safety Population. During the Safety Follow-up Period, non-Serious Adverse Events occurred at the 5% frequency threshold. There was no non-SAEs occurred reported in Dose Escalation DLBCL only Cohort 3 Not Defined arm.
Infections and infestations GASTROENTERITIS	0.00% 0/9 • From Baseline Up to Approximately 3 Years Reported: Safety Population. During the Safety Follow-up Period, non-Serious Adverse Events occurred at the 5% frequency threshold. There was no non-SAEs occurred reported in Dose Escalation DLBCL only Cohort 3 Not Defined arm.	0.00% 0/6 • From Baseline Up to Approximately 3 Years Reported: Safety Population. During the Safety Follow-up Period, non-Serious Adverse Events occurred at the 5% frequency threshold. There was no non-SAEs occurred reported in Dose Escalation DLBCL only Cohort 3 Not Defined arm.	14.3% 1/7 • Number of events 1 • From Baseline Up to Approximately 3 Years Reported: Safety Population. During the Safety Follow-up Period, non-Serious Adverse Events occurred at the 5% frequency threshold. There was no non-SAEs occurred reported in Dose Escalation DLBCL only Cohort 3 Not Defined arm.	0.00% 0/6 • From Baseline Up to Approximately 3 Years Reported: Safety Population. During the Safety Follow-up Period, non-Serious Adverse Events occurred at the 5% frequency threshold. There was no non-SAEs occurred reported in Dose Escalation DLBCL only Cohort 3 Not Defined arm.	0.00% 0/1 • From Baseline Up to Approximately 3 Years Reported: Safety Population. During the Safety Follow-up Period, non-Serious Adverse Events occurred at the 5% frequency threshold. There was no non-SAEs occurred reported in Dose Escalation DLBCL only Cohort 3 Not Defined arm.
Infections and infestations GASTROENTERITIS NOROVIRUS	0.00% 0/9 • From Baseline Up to Approximately 3 Years Reported: Safety Population. During the Safety Follow-up Period, non-Serious Adverse Events occurred at the 5% frequency threshold. There was no non-SAEs occurred reported in Dose Escalation DLBCL only Cohort 3 Not Defined arm.	16.7% 1/6 • Number of events 1 • From Baseline Up to Approximately 3 Years Reported: Safety Population. During the Safety Follow-up Period, non-Serious Adverse Events occurred at the 5% frequency threshold. There was no non-SAEs occurred reported in Dose Escalation DLBCL only Cohort 3 Not Defined arm.	0.00% 0/7 • From Baseline Up to Approximately 3 Years Reported: Safety Population. During the Safety Follow-up Period, non-Serious Adverse Events occurred at the 5% frequency threshold. There was no non-SAEs occurred reported in Dose Escalation DLBCL only Cohort 3 Not Defined arm.	0.00% 0/6 • From Baseline Up to Approximately 3 Years Reported: Safety Population. During the Safety Follow-up Period, non-Serious Adverse Events occurred at the 5% frequency threshold. There was no non-SAEs occurred reported in Dose Escalation DLBCL only Cohort 3 Not Defined arm.	0.00% 0/1 • From Baseline Up to Approximately 3 Years Reported: Safety Population. During the Safety Follow-up Period, non-Serious Adverse Events occurred at the 5% frequency threshold. There was no non-SAEs occurred reported in Dose Escalation DLBCL only Cohort 3 Not Defined arm.
Infections and infestations HERPES ZOSTER	0.00% 0/9 • From Baseline Up to Approximately 3 Years Reported: Safety Population. During the Safety Follow-up Period, non-Serious Adverse Events occurred at the 5% frequency threshold. There was no non-SAEs occurred reported in Dose Escalation DLBCL only Cohort 3 Not Defined arm.	0.00% 0/6 • From Baseline Up to Approximately 3 Years Reported: Safety Population. During the Safety Follow-up Period, non-Serious Adverse Events occurred at the 5% frequency threshold. There was no non-SAEs occurred reported in Dose Escalation DLBCL only Cohort 3 Not Defined arm.	14.3% 1/7 • Number of events 1 • From Baseline Up to Approximately 3 Years Reported: Safety Population. During the Safety Follow-up Period, non-Serious Adverse Events occurred at the 5% frequency threshold. There was no non-SAEs occurred reported in Dose Escalation DLBCL only Cohort 3 Not Defined arm.	16.7% 1/6 • Number of events 1 • From Baseline Up to Approximately 3 Years Reported: Safety Population. During the Safety Follow-up Period, non-Serious Adverse Events occurred at the 5% frequency threshold. There was no non-SAEs occurred reported in Dose Escalation DLBCL only Cohort 3 Not Defined arm.	0.00% 0/1 • From Baseline Up to Approximately 3 Years Reported: Safety Population. During the Safety Follow-up Period, non-Serious Adverse Events occurred at the 5% frequency threshold. There was no non-SAEs occurred reported in Dose Escalation DLBCL only Cohort 3 Not Defined arm.
Infections and infestations INFECTION	0.00% 0/9 • From Baseline Up to Approximately 3 Years Reported: Safety Population. During the Safety Follow-up Period, non-Serious Adverse Events occurred at the 5% frequency threshold. There was no non-SAEs occurred reported in Dose Escalation DLBCL only Cohort 3 Not Defined arm.	16.7% 1/6 • Number of events 1 • From Baseline Up to Approximately 3 Years Reported: Safety Population. During the Safety Follow-up Period, non-Serious Adverse Events occurred at the 5% frequency threshold. There was no non-SAEs occurred reported in Dose Escalation DLBCL only Cohort 3 Not Defined arm.	0.00% 0/7 • From Baseline Up to Approximately 3 Years Reported: Safety Population. During the Safety Follow-up Period, non-Serious Adverse Events occurred at the 5% frequency threshold. There was no non-SAEs occurred reported in Dose Escalation DLBCL only Cohort 3 Not Defined arm.	0.00% 0/6 • From Baseline Up to Approximately 3 Years Reported: Safety Population. During the Safety Follow-up Period, non-Serious Adverse Events occurred at the 5% frequency threshold. There was no non-SAEs occurred reported in Dose Escalation DLBCL only Cohort 3 Not Defined arm.	0.00% 0/1 • From Baseline Up to Approximately 3 Years Reported: Safety Population. During the Safety Follow-up Period, non-Serious Adverse Events occurred at the 5% frequency threshold. There was no non-SAEs occurred reported in Dose Escalation DLBCL only Cohort 3 Not Defined arm.
Infections and infestations MUCOSAL INFECTION	11.1% 1/9 • Number of events 1 • From Baseline Up to Approximately 3 Years Reported: Safety Population. During the Safety Follow-up Period, non-Serious Adverse Events occurred at the 5% frequency threshold. There was no non-SAEs occurred reported in Dose Escalation DLBCL only Cohort 3 Not Defined arm.	0.00% 0/6 • From Baseline Up to Approximately 3 Years Reported: Safety Population. During the Safety Follow-up Period, non-Serious Adverse Events occurred at the 5% frequency threshold. There was no non-SAEs occurred reported in Dose Escalation DLBCL only Cohort 3 Not Defined arm.	14.3% 1/7 • Number of events 1 • From Baseline Up to Approximately 3 Years Reported: Safety Population. During the Safety Follow-up Period, non-Serious Adverse Events occurred at the 5% frequency threshold. There was no non-SAEs occurred reported in Dose Escalation DLBCL only Cohort 3 Not Defined arm.	0.00% 0/6 • From Baseline Up to Approximately 3 Years Reported: Safety Population. During the Safety Follow-up Period, non-Serious Adverse Events occurred at the 5% frequency threshold. There was no non-SAEs occurred reported in Dose Escalation DLBCL only Cohort 3 Not Defined arm.	0.00% 0/1 • From Baseline Up to Approximately 3 Years Reported: Safety Population. During the Safety Follow-up Period, non-Serious Adverse Events occurred at the 5% frequency threshold. There was no non-SAEs occurred reported in Dose Escalation DLBCL only Cohort 3 Not Defined arm.
Infections and infestations ORAL CANDIDIASIS	0.00% 0/9 • From Baseline Up to Approximately 3 Years Reported: Safety Population. During the Safety Follow-up Period, non-Serious Adverse Events occurred at the 5% frequency threshold. There was no non-SAEs occurred reported in Dose Escalation DLBCL only Cohort 3 Not Defined arm.	0.00% 0/6 • From Baseline Up to Approximately 3 Years Reported: Safety Population. During the Safety Follow-up Period, non-Serious Adverse Events occurred at the 5% frequency threshold. There was no non-SAEs occurred reported in Dose Escalation DLBCL only Cohort 3 Not Defined arm.	14.3% 1/7 • Number of events 1 • From Baseline Up to Approximately 3 Years Reported: Safety Population. During the Safety Follow-up Period, non-Serious Adverse Events occurred at the 5% frequency threshold. There was no non-SAEs occurred reported in Dose Escalation DLBCL only Cohort 3 Not Defined arm.	0.00% 0/6 • From Baseline Up to Approximately 3 Years Reported: Safety Population. During the Safety Follow-up Period, non-Serious Adverse Events occurred at the 5% frequency threshold. There was no non-SAEs occurred reported in Dose Escalation DLBCL only Cohort 3 Not Defined arm.	0.00% 0/1 • From Baseline Up to Approximately 3 Years Reported: Safety Population. During the Safety Follow-up Period, non-Serious Adverse Events occurred at the 5% frequency threshold. There was no non-SAEs occurred reported in Dose Escalation DLBCL only Cohort 3 Not Defined arm.
Infections and infestations RESPIRATORY TRACT INFECTION	11.1% 1/9 • Number of events 3 • From Baseline Up to Approximately 3 Years Reported: Safety Population. During the Safety Follow-up Period, non-Serious Adverse Events occurred at the 5% frequency threshold. There was no non-SAEs occurred reported in Dose Escalation DLBCL only Cohort 3 Not Defined arm.	0.00% 0/6 • From Baseline Up to Approximately 3 Years Reported: Safety Population. During the Safety Follow-up Period, non-Serious Adverse Events occurred at the 5% frequency threshold. There was no non-SAEs occurred reported in Dose Escalation DLBCL only Cohort 3 Not Defined arm.	14.3% 1/7 • Number of events 1 • From Baseline Up to Approximately 3 Years Reported: Safety Population. During the Safety Follow-up Period, non-Serious Adverse Events occurred at the 5% frequency threshold. There was no non-SAEs occurred reported in Dose Escalation DLBCL only Cohort 3 Not Defined arm.	0.00% 0/6 • From Baseline Up to Approximately 3 Years Reported: Safety Population. During the Safety Follow-up Period, non-Serious Adverse Events occurred at the 5% frequency threshold. There was no non-SAEs occurred reported in Dose Escalation DLBCL only Cohort 3 Not Defined arm.	0.00% 0/1 • From Baseline Up to Approximately 3 Years Reported: Safety Population. During the Safety Follow-up Period, non-Serious Adverse Events occurred at the 5% frequency threshold. There was no non-SAEs occurred reported in Dose Escalation DLBCL only Cohort 3 Not Defined arm.
Infections and infestations SINUSITIS	11.1% 1/9 • Number of events 1 • From Baseline Up to Approximately 3 Years Reported: Safety Population. During the Safety Follow-up Period, non-Serious Adverse Events occurred at the 5% frequency threshold. There was no non-SAEs occurred reported in Dose Escalation DLBCL only Cohort 3 Not Defined arm.	0.00% 0/6 • From Baseline Up to Approximately 3 Years Reported: Safety Population. During the Safety Follow-up Period, non-Serious Adverse Events occurred at the 5% frequency threshold. There was no non-SAEs occurred reported in Dose Escalation DLBCL only Cohort 3 Not Defined arm.	0.00% 0/7 • From Baseline Up to Approximately 3 Years Reported: Safety Population. During the Safety Follow-up Period, non-Serious Adverse Events occurred at the 5% frequency threshold. There was no non-SAEs occurred reported in Dose Escalation DLBCL only Cohort 3 Not Defined arm.	0.00% 0/6 • From Baseline Up to Approximately 3 Years Reported: Safety Population. During the Safety Follow-up Period, non-Serious Adverse Events occurred at the 5% frequency threshold. There was no non-SAEs occurred reported in Dose Escalation DLBCL only Cohort 3 Not Defined arm.	0.00% 0/1 • From Baseline Up to Approximately 3 Years Reported: Safety Population. During the Safety Follow-up Period, non-Serious Adverse Events occurred at the 5% frequency threshold. There was no non-SAEs occurred reported in Dose Escalation DLBCL only Cohort 3 Not Defined arm.
Infections and infestations UPPER RESPIRATORY TRACT INFECTION	33.3% 3/9 • Number of events 4 • From Baseline Up to Approximately 3 Years Reported: Safety Population. During the Safety Follow-up Period, non-Serious Adverse Events occurred at the 5% frequency threshold. There was no non-SAEs occurred reported in Dose Escalation DLBCL only Cohort 3 Not Defined arm.	16.7% 1/6 • Number of events 1 • From Baseline Up to Approximately 3 Years Reported: Safety Population. During the Safety Follow-up Period, non-Serious Adverse Events occurred at the 5% frequency threshold. There was no non-SAEs occurred reported in Dose Escalation DLBCL only Cohort 3 Not Defined arm.	0.00% 0/7 • From Baseline Up to Approximately 3 Years Reported: Safety Population. During the Safety Follow-up Period, non-Serious Adverse Events occurred at the 5% frequency threshold. There was no non-SAEs occurred reported in Dose Escalation DLBCL only Cohort 3 Not Defined arm.	0.00% 0/6 • From Baseline Up to Approximately 3 Years Reported: Safety Population. During the Safety Follow-up Period, non-Serious Adverse Events occurred at the 5% frequency threshold. There was no non-SAEs occurred reported in Dose Escalation DLBCL only Cohort 3 Not Defined arm.	0.00% 0/1 • From Baseline Up to Approximately 3 Years Reported: Safety Population. During the Safety Follow-up Period, non-Serious Adverse Events occurred at the 5% frequency threshold. There was no non-SAEs occurred reported in Dose Escalation DLBCL only Cohort 3 Not Defined arm.
Infections and infestations WOUND INFECTION	0.00% 0/9 • From Baseline Up to Approximately 3 Years Reported: Safety Population. During the Safety Follow-up Period, non-Serious Adverse Events occurred at the 5% frequency threshold. There was no non-SAEs occurred reported in Dose Escalation DLBCL only Cohort 3 Not Defined arm.	16.7% 1/6 • Number of events 2 • From Baseline Up to Approximately 3 Years Reported: Safety Population. During the Safety Follow-up Period, non-Serious Adverse Events occurred at the 5% frequency threshold. There was no non-SAEs occurred reported in Dose Escalation DLBCL only Cohort 3 Not Defined arm.	0.00% 0/7 • From Baseline Up to Approximately 3 Years Reported: Safety Population. During the Safety Follow-up Period, non-Serious Adverse Events occurred at the 5% frequency threshold. There was no non-SAEs occurred reported in Dose Escalation DLBCL only Cohort 3 Not Defined arm.	0.00% 0/6 • From Baseline Up to Approximately 3 Years Reported: Safety Population. During the Safety Follow-up Period, non-Serious Adverse Events occurred at the 5% frequency threshold. There was no non-SAEs occurred reported in Dose Escalation DLBCL only Cohort 3 Not Defined arm.	0.00% 0/1 • From Baseline Up to Approximately 3 Years Reported: Safety Population. During the Safety Follow-up Period, non-Serious Adverse Events occurred at the 5% frequency threshold. There was no non-SAEs occurred reported in Dose Escalation DLBCL only Cohort 3 Not Defined arm.
Injury, poisoning and procedural complications ACCIDENTAL OVERDOSE	0.00% 0/9 • From Baseline Up to Approximately 3 Years Reported: Safety Population. During the Safety Follow-up Period, non-Serious Adverse Events occurred at the 5% frequency threshold. There was no non-SAEs occurred reported in Dose Escalation DLBCL only Cohort 3 Not Defined arm.	16.7% 1/6 • Number of events 4 • From Baseline Up to Approximately 3 Years Reported: Safety Population. During the Safety Follow-up Period, non-Serious Adverse Events occurred at the 5% frequency threshold. There was no non-SAEs occurred reported in Dose Escalation DLBCL only Cohort 3 Not Defined arm.	0.00% 0/7 • From Baseline Up to Approximately 3 Years Reported: Safety Population. During the Safety Follow-up Period, non-Serious Adverse Events occurred at the 5% frequency threshold. There was no non-SAEs occurred reported in Dose Escalation DLBCL only Cohort 3 Not Defined arm.	16.7% 1/6 • Number of events 1 • From Baseline Up to Approximately 3 Years Reported: Safety Population. During the Safety Follow-up Period, non-Serious Adverse Events occurred at the 5% frequency threshold. There was no non-SAEs occurred reported in Dose Escalation DLBCL only Cohort 3 Not Defined arm.	0.00% 0/1 • From Baseline Up to Approximately 3 Years Reported: Safety Population. During the Safety Follow-up Period, non-Serious Adverse Events occurred at the 5% frequency threshold. There was no non-SAEs occurred reported in Dose Escalation DLBCL only Cohort 3 Not Defined arm.
Injury, poisoning and procedural complications CONTUSION	11.1% 1/9 • Number of events 1 • From Baseline Up to Approximately 3 Years Reported: Safety Population. During the Safety Follow-up Period, non-Serious Adverse Events occurred at the 5% frequency threshold. There was no non-SAEs occurred reported in Dose Escalation DLBCL only Cohort 3 Not Defined arm.	0.00% 0/6 • From Baseline Up to Approximately 3 Years Reported: Safety Population. During the Safety Follow-up Period, non-Serious Adverse Events occurred at the 5% frequency threshold. There was no non-SAEs occurred reported in Dose Escalation DLBCL only Cohort 3 Not Defined arm.	0.00% 0/7 • From Baseline Up to Approximately 3 Years Reported: Safety Population. During the Safety Follow-up Period, non-Serious Adverse Events occurred at the 5% frequency threshold. There was no non-SAEs occurred reported in Dose Escalation DLBCL only Cohort 3 Not Defined arm.	0.00% 0/6 • From Baseline Up to Approximately 3 Years Reported: Safety Population. During the Safety Follow-up Period, non-Serious Adverse Events occurred at the 5% frequency threshold. There was no non-SAEs occurred reported in Dose Escalation DLBCL only Cohort 3 Not Defined arm.	0.00% 0/1 • From Baseline Up to Approximately 3 Years Reported: Safety Population. During the Safety Follow-up Period, non-Serious Adverse Events occurred at the 5% frequency threshold. There was no non-SAEs occurred reported in Dose Escalation DLBCL only Cohort 3 Not Defined arm.
Injury, poisoning and procedural complications INFUSION RELATED REACTION	33.3% 3/9 • Number of events 3 • From Baseline Up to Approximately 3 Years Reported: Safety Population. During the Safety Follow-up Period, non-Serious Adverse Events occurred at the 5% frequency threshold. There was no non-SAEs occurred reported in Dose Escalation DLBCL only Cohort 3 Not Defined arm.	0.00% 0/6 • From Baseline Up to Approximately 3 Years Reported: Safety Population. During the Safety Follow-up Period, non-Serious Adverse Events occurred at the 5% frequency threshold. There was no non-SAEs occurred reported in Dose Escalation DLBCL only Cohort 3 Not Defined arm.	0.00% 0/7 • From Baseline Up to Approximately 3 Years Reported: Safety Population. During the Safety Follow-up Period, non-Serious Adverse Events occurred at the 5% frequency threshold. There was no non-SAEs occurred reported in Dose Escalation DLBCL only Cohort 3 Not Defined arm.	16.7% 1/6 • Number of events 1 • From Baseline Up to Approximately 3 Years Reported: Safety Population. During the Safety Follow-up Period, non-Serious Adverse Events occurred at the 5% frequency threshold. There was no non-SAEs occurred reported in Dose Escalation DLBCL only Cohort 3 Not Defined arm.	0.00% 0/1 • From Baseline Up to Approximately 3 Years Reported: Safety Population. During the Safety Follow-up Period, non-Serious Adverse Events occurred at the 5% frequency threshold. There was no non-SAEs occurred reported in Dose Escalation DLBCL only Cohort 3 Not Defined arm.
Injury, poisoning and procedural complications MEDICATION ERROR	0.00% 0/9 • From Baseline Up to Approximately 3 Years Reported: Safety Population. During the Safety Follow-up Period, non-Serious Adverse Events occurred at the 5% frequency threshold. There was no non-SAEs occurred reported in Dose Escalation DLBCL only Cohort 3 Not Defined arm.	0.00% 0/6 • From Baseline Up to Approximately 3 Years Reported: Safety Population. During the Safety Follow-up Period, non-Serious Adverse Events occurred at the 5% frequency threshold. There was no non-SAEs occurred reported in Dose Escalation DLBCL only Cohort 3 Not Defined arm.	14.3% 1/7 • Number of events 1 • From Baseline Up to Approximately 3 Years Reported: Safety Population. During the Safety Follow-up Period, non-Serious Adverse Events occurred at the 5% frequency threshold. There was no non-SAEs occurred reported in Dose Escalation DLBCL only Cohort 3 Not Defined arm.	0.00% 0/6 • From Baseline Up to Approximately 3 Years Reported: Safety Population. During the Safety Follow-up Period, non-Serious Adverse Events occurred at the 5% frequency threshold. There was no non-SAEs occurred reported in Dose Escalation DLBCL only Cohort 3 Not Defined arm.	0.00% 0/1 • From Baseline Up to Approximately 3 Years Reported: Safety Population. During the Safety Follow-up Period, non-Serious Adverse Events occurred at the 5% frequency threshold. There was no non-SAEs occurred reported in Dose Escalation DLBCL only Cohort 3 Not Defined arm.
Injury, poisoning and procedural complications PRODUCT ADMINISTRATION ERROR	0.00% 0/9 • From Baseline Up to Approximately 3 Years Reported: Safety Population. During the Safety Follow-up Period, non-Serious Adverse Events occurred at the 5% frequency threshold. There was no non-SAEs occurred reported in Dose Escalation DLBCL only Cohort 3 Not Defined arm.	0.00% 0/6 • From Baseline Up to Approximately 3 Years Reported: Safety Population. During the Safety Follow-up Period, non-Serious Adverse Events occurred at the 5% frequency threshold. There was no non-SAEs occurred reported in Dose Escalation DLBCL only Cohort 3 Not Defined arm.	14.3% 1/7 • Number of events 1 • From Baseline Up to Approximately 3 Years Reported: Safety Population. During the Safety Follow-up Period, non-Serious Adverse Events occurred at the 5% frequency threshold. There was no non-SAEs occurred reported in Dose Escalation DLBCL only Cohort 3 Not Defined arm.	0.00% 0/6 • From Baseline Up to Approximately 3 Years Reported: Safety Population. During the Safety Follow-up Period, non-Serious Adverse Events occurred at the 5% frequency threshold. There was no non-SAEs occurred reported in Dose Escalation DLBCL only Cohort 3 Not Defined arm.	0.00% 0/1 • From Baseline Up to Approximately 3 Years Reported: Safety Population. During the Safety Follow-up Period, non-Serious Adverse Events occurred at the 5% frequency threshold. There was no non-SAEs occurred reported in Dose Escalation DLBCL only Cohort 3 Not Defined arm.
Injury, poisoning and procedural complications PRODUCT DOSE OMISSION	0.00% 0/9 • From Baseline Up to Approximately 3 Years Reported: Safety Population. During the Safety Follow-up Period, non-Serious Adverse Events occurred at the 5% frequency threshold. There was no non-SAEs occurred reported in Dose Escalation DLBCL only Cohort 3 Not Defined arm.	0.00% 0/6 • From Baseline Up to Approximately 3 Years Reported: Safety Population. During the Safety Follow-up Period, non-Serious Adverse Events occurred at the 5% frequency threshold. There was no non-SAEs occurred reported in Dose Escalation DLBCL only Cohort 3 Not Defined arm.	0.00% 0/7 • From Baseline Up to Approximately 3 Years Reported: Safety Population. During the Safety Follow-up Period, non-Serious Adverse Events occurred at the 5% frequency threshold. There was no non-SAEs occurred reported in Dose Escalation DLBCL only Cohort 3 Not Defined arm.	16.7% 1/6 • Number of events 1 • From Baseline Up to Approximately 3 Years Reported: Safety Population. During the Safety Follow-up Period, non-Serious Adverse Events occurred at the 5% frequency threshold. There was no non-SAEs occurred reported in Dose Escalation DLBCL only Cohort 3 Not Defined arm.	0.00% 0/1 • From Baseline Up to Approximately 3 Years Reported: Safety Population. During the Safety Follow-up Period, non-Serious Adverse Events occurred at the 5% frequency threshold. There was no non-SAEs occurred reported in Dose Escalation DLBCL only Cohort 3 Not Defined arm.
Injury, poisoning and procedural complications SKIN ABRASION	0.00% 0/9 • From Baseline Up to Approximately 3 Years Reported: Safety Population. During the Safety Follow-up Period, non-Serious Adverse Events occurred at the 5% frequency threshold. There was no non-SAEs occurred reported in Dose Escalation DLBCL only Cohort 3 Not Defined arm.	0.00% 0/6 • From Baseline Up to Approximately 3 Years Reported: Safety Population. During the Safety Follow-up Period, non-Serious Adverse Events occurred at the 5% frequency threshold. There was no non-SAEs occurred reported in Dose Escalation DLBCL only Cohort 3 Not Defined arm.	0.00% 0/7 • From Baseline Up to Approximately 3 Years Reported: Safety Population. During the Safety Follow-up Period, non-Serious Adverse Events occurred at the 5% frequency threshold. There was no non-SAEs occurred reported in Dose Escalation DLBCL only Cohort 3 Not Defined arm.	16.7% 1/6 • Number of events 1 • From Baseline Up to Approximately 3 Years Reported: Safety Population. During the Safety Follow-up Period, non-Serious Adverse Events occurred at the 5% frequency threshold. There was no non-SAEs occurred reported in Dose Escalation DLBCL only Cohort 3 Not Defined arm.	0.00% 0/1 • From Baseline Up to Approximately 3 Years Reported: Safety Population. During the Safety Follow-up Period, non-Serious Adverse Events occurred at the 5% frequency threshold. There was no non-SAEs occurred reported in Dose Escalation DLBCL only Cohort 3 Not Defined arm.
Injury, poisoning and procedural complications WOUND COMPLICATION	0.00% 0/9 • From Baseline Up to Approximately 3 Years Reported: Safety Population. During the Safety Follow-up Period, non-Serious Adverse Events occurred at the 5% frequency threshold. There was no non-SAEs occurred reported in Dose Escalation DLBCL only Cohort 3 Not Defined arm.	16.7% 1/6 • Number of events 1 • From Baseline Up to Approximately 3 Years Reported: Safety Population. During the Safety Follow-up Period, non-Serious Adverse Events occurred at the 5% frequency threshold. There was no non-SAEs occurred reported in Dose Escalation DLBCL only Cohort 3 Not Defined arm.	0.00% 0/7 • From Baseline Up to Approximately 3 Years Reported: Safety Population. During the Safety Follow-up Period, non-Serious Adverse Events occurred at the 5% frequency threshold. There was no non-SAEs occurred reported in Dose Escalation DLBCL only Cohort 3 Not Defined arm.	0.00% 0/6 • From Baseline Up to Approximately 3 Years Reported: Safety Population. During the Safety Follow-up Period, non-Serious Adverse Events occurred at the 5% frequency threshold. There was no non-SAEs occurred reported in Dose Escalation DLBCL only Cohort 3 Not Defined arm.	0.00% 0/1 • From Baseline Up to Approximately 3 Years Reported: Safety Population. During the Safety Follow-up Period, non-Serious Adverse Events occurred at the 5% frequency threshold. There was no non-SAEs occurred reported in Dose Escalation DLBCL only Cohort 3 Not Defined arm.
Injury, poisoning and procedural complications WRONG TECHNIQUE IN PRODUCT USAGE PROCESS	0.00% 0/9 • From Baseline Up to Approximately 3 Years Reported: Safety Population. During the Safety Follow-up Period, non-Serious Adverse Events occurred at the 5% frequency threshold. There was no non-SAEs occurred reported in Dose Escalation DLBCL only Cohort 3 Not Defined arm.	0.00% 0/6 • From Baseline Up to Approximately 3 Years Reported: Safety Population. During the Safety Follow-up Period, non-Serious Adverse Events occurred at the 5% frequency threshold. There was no non-SAEs occurred reported in Dose Escalation DLBCL only Cohort 3 Not Defined arm.	0.00% 0/7 • From Baseline Up to Approximately 3 Years Reported: Safety Population. During the Safety Follow-up Period, non-Serious Adverse Events occurred at the 5% frequency threshold. There was no non-SAEs occurred reported in Dose Escalation DLBCL only Cohort 3 Not Defined arm.	16.7% 1/6 • Number of events 1 • From Baseline Up to Approximately 3 Years Reported: Safety Population. During the Safety Follow-up Period, non-Serious Adverse Events occurred at the 5% frequency threshold. There was no non-SAEs occurred reported in Dose Escalation DLBCL only Cohort 3 Not Defined arm.	0.00% 0/1 • From Baseline Up to Approximately 3 Years Reported: Safety Population. During the Safety Follow-up Period, non-Serious Adverse Events occurred at the 5% frequency threshold. There was no non-SAEs occurred reported in Dose Escalation DLBCL only Cohort 3 Not Defined arm.
Investigations ALANINE AMINOTRANSFERASE	0.00% 0/9 • From Baseline Up to Approximately 3 Years Reported: Safety Population. During the Safety Follow-up Period, non-Serious Adverse Events occurred at the 5% frequency threshold. There was no non-SAEs occurred reported in Dose Escalation DLBCL only Cohort 3 Not Defined arm.	0.00% 0/6 • From Baseline Up to Approximately 3 Years Reported: Safety Population. During the Safety Follow-up Period, non-Serious Adverse Events occurred at the 5% frequency threshold. There was no non-SAEs occurred reported in Dose Escalation DLBCL only Cohort 3 Not Defined arm.	0.00% 0/7 • From Baseline Up to Approximately 3 Years Reported: Safety Population. During the Safety Follow-up Period, non-Serious Adverse Events occurred at the 5% frequency threshold. There was no non-SAEs occurred reported in Dose Escalation DLBCL only Cohort 3 Not Defined arm.	16.7% 1/6 • Number of events 1 • From Baseline Up to Approximately 3 Years Reported: Safety Population. During the Safety Follow-up Period, non-Serious Adverse Events occurred at the 5% frequency threshold. There was no non-SAEs occurred reported in Dose Escalation DLBCL only Cohort 3 Not Defined arm.	0.00% 0/1 • From Baseline Up to Approximately 3 Years Reported: Safety Population. During the Safety Follow-up Period, non-Serious Adverse Events occurred at the 5% frequency threshold. There was no non-SAEs occurred reported in Dose Escalation DLBCL only Cohort 3 Not Defined arm.
Investigations ALANINE AMINOTRANSFERASE INCREASED	11.1% 1/9 • Number of events 1 • From Baseline Up to Approximately 3 Years Reported: Safety Population. During the Safety Follow-up Period, non-Serious Adverse Events occurred at the 5% frequency threshold. There was no non-SAEs occurred reported in Dose Escalation DLBCL only Cohort 3 Not Defined arm.	0.00% 0/6 • From Baseline Up to Approximately 3 Years Reported: Safety Population. During the Safety Follow-up Period, non-Serious Adverse Events occurred at the 5% frequency threshold. There was no non-SAEs occurred reported in Dose Escalation DLBCL only Cohort 3 Not Defined arm.	14.3% 1/7 • Number of events 2 • From Baseline Up to Approximately 3 Years Reported: Safety Population. During the Safety Follow-up Period, non-Serious Adverse Events occurred at the 5% frequency threshold. There was no non-SAEs occurred reported in Dose Escalation DLBCL only Cohort 3 Not Defined arm.	0.00% 0/6 • From Baseline Up to Approximately 3 Years Reported: Safety Population. During the Safety Follow-up Period, non-Serious Adverse Events occurred at the 5% frequency threshold. There was no non-SAEs occurred reported in Dose Escalation DLBCL only Cohort 3 Not Defined arm.	0.00% 0/1 • From Baseline Up to Approximately 3 Years Reported: Safety Population. During the Safety Follow-up Period, non-Serious Adverse Events occurred at the 5% frequency threshold. There was no non-SAEs occurred reported in Dose Escalation DLBCL only Cohort 3 Not Defined arm.
Investigations AMYLASE INCREASED	0.00% 0/9 • From Baseline Up to Approximately 3 Years Reported: Safety Population. During the Safety Follow-up Period, non-Serious Adverse Events occurred at the 5% frequency threshold. There was no non-SAEs occurred reported in Dose Escalation DLBCL only Cohort 3 Not Defined arm.	0.00% 0/6 • From Baseline Up to Approximately 3 Years Reported: Safety Population. During the Safety Follow-up Period, non-Serious Adverse Events occurred at the 5% frequency threshold. There was no non-SAEs occurred reported in Dose Escalation DLBCL only Cohort 3 Not Defined arm.	0.00% 0/7 • From Baseline Up to Approximately 3 Years Reported: Safety Population. During the Safety Follow-up Period, non-Serious Adverse Events occurred at the 5% frequency threshold. There was no non-SAEs occurred reported in Dose Escalation DLBCL only Cohort 3 Not Defined arm.	16.7% 1/6 • Number of events 1 • From Baseline Up to Approximately 3 Years Reported: Safety Population. During the Safety Follow-up Period, non-Serious Adverse Events occurred at the 5% frequency threshold. There was no non-SAEs occurred reported in Dose Escalation DLBCL only Cohort 3 Not Defined arm.	0.00% 0/1 • From Baseline Up to Approximately 3 Years Reported: Safety Population. During the Safety Follow-up Period, non-Serious Adverse Events occurred at the 5% frequency threshold. There was no non-SAEs occurred reported in Dose Escalation DLBCL only Cohort 3 Not Defined arm.
Investigations ASPARTATE AMINOTRANSFERASE INCREASED	22.2% 2/9 • Number of events 3 • From Baseline Up to Approximately 3 Years Reported: Safety Population. During the Safety Follow-up Period, non-Serious Adverse Events occurred at the 5% frequency threshold. There was no non-SAEs occurred reported in Dose Escalation DLBCL only Cohort 3 Not Defined arm.	0.00% 0/6 • From Baseline Up to Approximately 3 Years Reported: Safety Population. During the Safety Follow-up Period, non-Serious Adverse Events occurred at the 5% frequency threshold. There was no non-SAEs occurred reported in Dose Escalation DLBCL only Cohort 3 Not Defined arm.	14.3% 1/7 • Number of events 1 • From Baseline Up to Approximately 3 Years Reported: Safety Population. During the Safety Follow-up Period, non-Serious Adverse Events occurred at the 5% frequency threshold. There was no non-SAEs occurred reported in Dose Escalation DLBCL only Cohort 3 Not Defined arm.	16.7% 1/6 • Number of events 1 • From Baseline Up to Approximately 3 Years Reported: Safety Population. During the Safety Follow-up Period, non-Serious Adverse Events occurred at the 5% frequency threshold. There was no non-SAEs occurred reported in Dose Escalation DLBCL only Cohort 3 Not Defined arm.	0.00% 0/1 • From Baseline Up to Approximately 3 Years Reported: Safety Population. During the Safety Follow-up Period, non-Serious Adverse Events occurred at the 5% frequency threshold. There was no non-SAEs occurred reported in Dose Escalation DLBCL only Cohort 3 Not Defined arm.
Investigations BLOOD ALKALINE PHOSPHATASE INCREASED	11.1% 1/9 • Number of events 1 • From Baseline Up to Approximately 3 Years Reported: Safety Population. During the Safety Follow-up Period, non-Serious Adverse Events occurred at the 5% frequency threshold. There was no non-SAEs occurred reported in Dose Escalation DLBCL only Cohort 3 Not Defined arm.	0.00% 0/6 • From Baseline Up to Approximately 3 Years Reported: Safety Population. During the Safety Follow-up Period, non-Serious Adverse Events occurred at the 5% frequency threshold. There was no non-SAEs occurred reported in Dose Escalation DLBCL only Cohort 3 Not Defined arm.	0.00% 0/7 • From Baseline Up to Approximately 3 Years Reported: Safety Population. During the Safety Follow-up Period, non-Serious Adverse Events occurred at the 5% frequency threshold. There was no non-SAEs occurred reported in Dose Escalation DLBCL only Cohort 3 Not Defined arm.	0.00% 0/6 • From Baseline Up to Approximately 3 Years Reported: Safety Population. During the Safety Follow-up Period, non-Serious Adverse Events occurred at the 5% frequency threshold. There was no non-SAEs occurred reported in Dose Escalation DLBCL only Cohort 3 Not Defined arm.	0.00% 0/1 • From Baseline Up to Approximately 3 Years Reported: Safety Population. During the Safety Follow-up Period, non-Serious Adverse Events occurred at the 5% frequency threshold. There was no non-SAEs occurred reported in Dose Escalation DLBCL only Cohort 3 Not Defined arm.
Investigations BLOOD BILIRUBIN INCREASED	11.1% 1/9 • Number of events 1 • From Baseline Up to Approximately 3 Years Reported: Safety Population. During the Safety Follow-up Period, non-Serious Adverse Events occurred at the 5% frequency threshold. There was no non-SAEs occurred reported in Dose Escalation DLBCL only Cohort 3 Not Defined arm.	0.00% 0/6 • From Baseline Up to Approximately 3 Years Reported: Safety Population. During the Safety Follow-up Period, non-Serious Adverse Events occurred at the 5% frequency threshold. There was no non-SAEs occurred reported in Dose Escalation DLBCL only Cohort 3 Not Defined arm.	14.3% 1/7 • Number of events 1 • From Baseline Up to Approximately 3 Years Reported: Safety Population. During the Safety Follow-up Period, non-Serious Adverse Events occurred at the 5% frequency threshold. There was no non-SAEs occurred reported in Dose Escalation DLBCL only Cohort 3 Not Defined arm.	0.00% 0/6 • From Baseline Up to Approximately 3 Years Reported: Safety Population. During the Safety Follow-up Period, non-Serious Adverse Events occurred at the 5% frequency threshold. There was no non-SAEs occurred reported in Dose Escalation DLBCL only Cohort 3 Not Defined arm.	0.00% 0/1 • From Baseline Up to Approximately 3 Years Reported: Safety Population. During the Safety Follow-up Period, non-Serious Adverse Events occurred at the 5% frequency threshold. There was no non-SAEs occurred reported in Dose Escalation DLBCL only Cohort 3 Not Defined arm.
Investigations LYMPHOCYTE COUNT DECREASED	11.1% 1/9 • Number of events 3 • From Baseline Up to Approximately 3 Years Reported: Safety Population. During the Safety Follow-up Period, non-Serious Adverse Events occurred at the 5% frequency threshold. There was no non-SAEs occurred reported in Dose Escalation DLBCL only Cohort 3 Not Defined arm.	0.00% 0/6 • From Baseline Up to Approximately 3 Years Reported: Safety Population. During the Safety Follow-up Period, non-Serious Adverse Events occurred at the 5% frequency threshold. There was no non-SAEs occurred reported in Dose Escalation DLBCL only Cohort 3 Not Defined arm.	0.00% 0/7 • From Baseline Up to Approximately 3 Years Reported: Safety Population. During the Safety Follow-up Period, non-Serious Adverse Events occurred at the 5% frequency threshold. There was no non-SAEs occurred reported in Dose Escalation DLBCL only Cohort 3 Not Defined arm.	16.7% 1/6 • Number of events 1 • From Baseline Up to Approximately 3 Years Reported: Safety Population. During the Safety Follow-up Period, non-Serious Adverse Events occurred at the 5% frequency threshold. There was no non-SAEs occurred reported in Dose Escalation DLBCL only Cohort 3 Not Defined arm.	0.00% 0/1 • From Baseline Up to Approximately 3 Years Reported: Safety Population. During the Safety Follow-up Period, non-Serious Adverse Events occurred at the 5% frequency threshold. There was no non-SAEs occurred reported in Dose Escalation DLBCL only Cohort 3 Not Defined arm.
Investigations NEUTROPHIL COUNT DECREASED	0.00% 0/9 • From Baseline Up to Approximately 3 Years Reported: Safety Population. During the Safety Follow-up Period, non-Serious Adverse Events occurred at the 5% frequency threshold. There was no non-SAEs occurred reported in Dose Escalation DLBCL only Cohort 3 Not Defined arm.	0.00% 0/6 • From Baseline Up to Approximately 3 Years Reported: Safety Population. During the Safety Follow-up Period, non-Serious Adverse Events occurred at the 5% frequency threshold. There was no non-SAEs occurred reported in Dose Escalation DLBCL only Cohort 3 Not Defined arm.	0.00% 0/7 • From Baseline Up to Approximately 3 Years Reported: Safety Population. During the Safety Follow-up Period, non-Serious Adverse Events occurred at the 5% frequency threshold. There was no non-SAEs occurred reported in Dose Escalation DLBCL only Cohort 3 Not Defined arm.	16.7% 1/6 • Number of events 3 • From Baseline Up to Approximately 3 Years Reported: Safety Population. During the Safety Follow-up Period, non-Serious Adverse Events occurred at the 5% frequency threshold. There was no non-SAEs occurred reported in Dose Escalation DLBCL only Cohort 3 Not Defined arm.	0.00% 0/1 • From Baseline Up to Approximately 3 Years Reported: Safety Population. During the Safety Follow-up Period, non-Serious Adverse Events occurred at the 5% frequency threshold. There was no non-SAEs occurred reported in Dose Escalation DLBCL only Cohort 3 Not Defined arm.
Investigations PLATELET COUNT DECREASED	11.1% 1/9 • Number of events 4 • From Baseline Up to Approximately 3 Years Reported: Safety Population. During the Safety Follow-up Period, non-Serious Adverse Events occurred at the 5% frequency threshold. There was no non-SAEs occurred reported in Dose Escalation DLBCL only Cohort 3 Not Defined arm.	0.00% 0/6 • From Baseline Up to Approximately 3 Years Reported: Safety Population. During the Safety Follow-up Period, non-Serious Adverse Events occurred at the 5% frequency threshold. There was no non-SAEs occurred reported in Dose Escalation DLBCL only Cohort 3 Not Defined arm.	0.00% 0/7 • From Baseline Up to Approximately 3 Years Reported: Safety Population. During the Safety Follow-up Period, non-Serious Adverse Events occurred at the 5% frequency threshold. There was no non-SAEs occurred reported in Dose Escalation DLBCL only Cohort 3 Not Defined arm.	0.00% 0/6 • From Baseline Up to Approximately 3 Years Reported: Safety Population. During the Safety Follow-up Period, non-Serious Adverse Events occurred at the 5% frequency threshold. There was no non-SAEs occurred reported in Dose Escalation DLBCL only Cohort 3 Not Defined arm.	0.00% 0/1 • From Baseline Up to Approximately 3 Years Reported: Safety Population. During the Safety Follow-up Period, non-Serious Adverse Events occurred at the 5% frequency threshold. There was no non-SAEs occurred reported in Dose Escalation DLBCL only Cohort 3 Not Defined arm.
Investigations RESPIROVIRUS TEST POSITIVE	0.00% 0/9 • From Baseline Up to Approximately 3 Years Reported: Safety Population. During the Safety Follow-up Period, non-Serious Adverse Events occurred at the 5% frequency threshold. There was no non-SAEs occurred reported in Dose Escalation DLBCL only Cohort 3 Not Defined arm.	0.00% 0/6 • From Baseline Up to Approximately 3 Years Reported: Safety Population. During the Safety Follow-up Period, non-Serious Adverse Events occurred at the 5% frequency threshold. There was no non-SAEs occurred reported in Dose Escalation DLBCL only Cohort 3 Not Defined arm.	0.00% 0/7 • From Baseline Up to Approximately 3 Years Reported: Safety Population. During the Safety Follow-up Period, non-Serious Adverse Events occurred at the 5% frequency threshold. There was no non-SAEs occurred reported in Dose Escalation DLBCL only Cohort 3 Not Defined arm.	16.7% 1/6 • Number of events 1 • From Baseline Up to Approximately 3 Years Reported: Safety Population. During the Safety Follow-up Period, non-Serious Adverse Events occurred at the 5% frequency threshold. There was no non-SAEs occurred reported in Dose Escalation DLBCL only Cohort 3 Not Defined arm.	0.00% 0/1 • From Baseline Up to Approximately 3 Years Reported: Safety Population. During the Safety Follow-up Period, non-Serious Adverse Events occurred at the 5% frequency threshold. There was no non-SAEs occurred reported in Dose Escalation DLBCL only Cohort 3 Not Defined arm.
Investigations SERUM FERRITIN INCREASED	11.1% 1/9 • Number of events 1 • From Baseline Up to Approximately 3 Years Reported: Safety Population. During the Safety Follow-up Period, non-Serious Adverse Events occurred at the 5% frequency threshold. There was no non-SAEs occurred reported in Dose Escalation DLBCL only Cohort 3 Not Defined arm.	0.00% 0/6 • From Baseline Up to Approximately 3 Years Reported: Safety Population. During the Safety Follow-up Period, non-Serious Adverse Events occurred at the 5% frequency threshold. There was no non-SAEs occurred reported in Dose Escalation DLBCL only Cohort 3 Not Defined arm.	0.00% 0/7 • From Baseline Up to Approximately 3 Years Reported: Safety Population. During the Safety Follow-up Period, non-Serious Adverse Events occurred at the 5% frequency threshold. There was no non-SAEs occurred reported in Dose Escalation DLBCL only Cohort 3 Not Defined arm.	0.00% 0/6 • From Baseline Up to Approximately 3 Years Reported: Safety Population. During the Safety Follow-up Period, non-Serious Adverse Events occurred at the 5% frequency threshold. There was no non-SAEs occurred reported in Dose Escalation DLBCL only Cohort 3 Not Defined arm.	0.00% 0/1 • From Baseline Up to Approximately 3 Years Reported: Safety Population. During the Safety Follow-up Period, non-Serious Adverse Events occurred at the 5% frequency threshold. There was no non-SAEs occurred reported in Dose Escalation DLBCL only Cohort 3 Not Defined arm.
Investigations WEIGHT DECREASED	11.1% 1/9 • Number of events 1 • From Baseline Up to Approximately 3 Years Reported: Safety Population. During the Safety Follow-up Period, non-Serious Adverse Events occurred at the 5% frequency threshold. There was no non-SAEs occurred reported in Dose Escalation DLBCL only Cohort 3 Not Defined arm.	0.00% 0/6 • From Baseline Up to Approximately 3 Years Reported: Safety Population. During the Safety Follow-up Period, non-Serious Adverse Events occurred at the 5% frequency threshold. There was no non-SAEs occurred reported in Dose Escalation DLBCL only Cohort 3 Not Defined arm.	0.00% 0/7 • From Baseline Up to Approximately 3 Years Reported: Safety Population. During the Safety Follow-up Period, non-Serious Adverse Events occurred at the 5% frequency threshold. There was no non-SAEs occurred reported in Dose Escalation DLBCL only Cohort 3 Not Defined arm.	0.00% 0/6 • From Baseline Up to Approximately 3 Years Reported: Safety Population. During the Safety Follow-up Period, non-Serious Adverse Events occurred at the 5% frequency threshold. There was no non-SAEs occurred reported in Dose Escalation DLBCL only Cohort 3 Not Defined arm.	0.00% 0/1 • From Baseline Up to Approximately 3 Years Reported: Safety Population. During the Safety Follow-up Period, non-Serious Adverse Events occurred at the 5% frequency threshold. There was no non-SAEs occurred reported in Dose Escalation DLBCL only Cohort 3 Not Defined arm.
Investigations WHITE BLOOD CELL COUNT DECREASED	11.1% 1/9 • Number of events 4 • From Baseline Up to Approximately 3 Years Reported: Safety Population. During the Safety Follow-up Period, non-Serious Adverse Events occurred at the 5% frequency threshold. There was no non-SAEs occurred reported in Dose Escalation DLBCL only Cohort 3 Not Defined arm.	0.00% 0/6 • From Baseline Up to Approximately 3 Years Reported: Safety Population. During the Safety Follow-up Period, non-Serious Adverse Events occurred at the 5% frequency threshold. There was no non-SAEs occurred reported in Dose Escalation DLBCL only Cohort 3 Not Defined arm.	14.3% 1/7 • Number of events 5 • From Baseline Up to Approximately 3 Years Reported: Safety Population. During the Safety Follow-up Period, non-Serious Adverse Events occurred at the 5% frequency threshold. There was no non-SAEs occurred reported in Dose Escalation DLBCL only Cohort 3 Not Defined arm.	33.3% 2/6 • Number of events 7 • From Baseline Up to Approximately 3 Years Reported: Safety Population. During the Safety Follow-up Period, non-Serious Adverse Events occurred at the 5% frequency threshold. There was no non-SAEs occurred reported in Dose Escalation DLBCL only Cohort 3 Not Defined arm.	0.00% 0/1 • From Baseline Up to Approximately 3 Years Reported: Safety Population. During the Safety Follow-up Period, non-Serious Adverse Events occurred at the 5% frequency threshold. There was no non-SAEs occurred reported in Dose Escalation DLBCL only Cohort 3 Not Defined arm.
Metabolism and nutrition disorders DECREASED APPETITE	11.1% 1/9 • Number of events 1 • From Baseline Up to Approximately 3 Years Reported: Safety Population. During the Safety Follow-up Period, non-Serious Adverse Events occurred at the 5% frequency threshold. There was no non-SAEs occurred reported in Dose Escalation DLBCL only Cohort 3 Not Defined arm.	16.7% 1/6 • Number of events 1 • From Baseline Up to Approximately 3 Years Reported: Safety Population. During the Safety Follow-up Period, non-Serious Adverse Events occurred at the 5% frequency threshold. There was no non-SAEs occurred reported in Dose Escalation DLBCL only Cohort 3 Not Defined arm.	28.6% 2/7 • Number of events 2 • From Baseline Up to Approximately 3 Years Reported: Safety Population. During the Safety Follow-up Period, non-Serious Adverse Events occurred at the 5% frequency threshold. There was no non-SAEs occurred reported in Dose Escalation DLBCL only Cohort 3 Not Defined arm.	0.00% 0/6 • From Baseline Up to Approximately 3 Years Reported: Safety Population. During the Safety Follow-up Period, non-Serious Adverse Events occurred at the 5% frequency threshold. There was no non-SAEs occurred reported in Dose Escalation DLBCL only Cohort 3 Not Defined arm.	0.00% 0/1 • From Baseline Up to Approximately 3 Years Reported: Safety Population. During the Safety Follow-up Period, non-Serious Adverse Events occurred at the 5% frequency threshold. There was no non-SAEs occurred reported in Dose Escalation DLBCL only Cohort 3 Not Defined arm.
Metabolism and nutrition disorders DIABETES MELLITUS	11.1% 1/9 • Number of events 1 • From Baseline Up to Approximately 3 Years Reported: Safety Population. During the Safety Follow-up Period, non-Serious Adverse Events occurred at the 5% frequency threshold. There was no non-SAEs occurred reported in Dose Escalation DLBCL only Cohort 3 Not Defined arm.	0.00% 0/6 • From Baseline Up to Approximately 3 Years Reported: Safety Population. During the Safety Follow-up Period, non-Serious Adverse Events occurred at the 5% frequency threshold. There was no non-SAEs occurred reported in Dose Escalation DLBCL only Cohort 3 Not Defined arm.	0.00% 0/7 • From Baseline Up to Approximately 3 Years Reported: Safety Population. During the Safety Follow-up Period, non-Serious Adverse Events occurred at the 5% frequency threshold. There was no non-SAEs occurred reported in Dose Escalation DLBCL only Cohort 3 Not Defined arm.	0.00% 0/6 • From Baseline Up to Approximately 3 Years Reported: Safety Population. During the Safety Follow-up Period, non-Serious Adverse Events occurred at the 5% frequency threshold. There was no non-SAEs occurred reported in Dose Escalation DLBCL only Cohort 3 Not Defined arm.	0.00% 0/1 • From Baseline Up to Approximately 3 Years Reported: Safety Population. During the Safety Follow-up Period, non-Serious Adverse Events occurred at the 5% frequency threshold. There was no non-SAEs occurred reported in Dose Escalation DLBCL only Cohort 3 Not Defined arm.
Metabolism and nutrition disorders GOUT	0.00% 0/9 • From Baseline Up to Approximately 3 Years Reported: Safety Population. During the Safety Follow-up Period, non-Serious Adverse Events occurred at the 5% frequency threshold. There was no non-SAEs occurred reported in Dose Escalation DLBCL only Cohort 3 Not Defined arm.	0.00% 0/6 • From Baseline Up to Approximately 3 Years Reported: Safety Population. During the Safety Follow-up Period, non-Serious Adverse Events occurred at the 5% frequency threshold. There was no non-SAEs occurred reported in Dose Escalation DLBCL only Cohort 3 Not Defined arm.	0.00% 0/7 • From Baseline Up to Approximately 3 Years Reported: Safety Population. During the Safety Follow-up Period, non-Serious Adverse Events occurred at the 5% frequency threshold. There was no non-SAEs occurred reported in Dose Escalation DLBCL only Cohort 3 Not Defined arm.	16.7% 1/6 • Number of events 1 • From Baseline Up to Approximately 3 Years Reported: Safety Population. During the Safety Follow-up Period, non-Serious Adverse Events occurred at the 5% frequency threshold. There was no non-SAEs occurred reported in Dose Escalation DLBCL only Cohort 3 Not Defined arm.	0.00% 0/1 • From Baseline Up to Approximately 3 Years Reported: Safety Population. During the Safety Follow-up Period, non-Serious Adverse Events occurred at the 5% frequency threshold. There was no non-SAEs occurred reported in Dose Escalation DLBCL only Cohort 3 Not Defined arm.
Metabolism and nutrition disorders HYPERCALCAEMIA	11.1% 1/9 • Number of events 1 • From Baseline Up to Approximately 3 Years Reported: Safety Population. During the Safety Follow-up Period, non-Serious Adverse Events occurred at the 5% frequency threshold. There was no non-SAEs occurred reported in Dose Escalation DLBCL only Cohort 3 Not Defined arm.	0.00% 0/6 • From Baseline Up to Approximately 3 Years Reported: Safety Population. During the Safety Follow-up Period, non-Serious Adverse Events occurred at the 5% frequency threshold. There was no non-SAEs occurred reported in Dose Escalation DLBCL only Cohort 3 Not Defined arm.	0.00% 0/7 • From Baseline Up to Approximately 3 Years Reported: Safety Population. During the Safety Follow-up Period, non-Serious Adverse Events occurred at the 5% frequency threshold. There was no non-SAEs occurred reported in Dose Escalation DLBCL only Cohort 3 Not Defined arm.	0.00% 0/6 • From Baseline Up to Approximately 3 Years Reported: Safety Population. During the Safety Follow-up Period, non-Serious Adverse Events occurred at the 5% frequency threshold. There was no non-SAEs occurred reported in Dose Escalation DLBCL only Cohort 3 Not Defined arm.	0.00% 0/1 • From Baseline Up to Approximately 3 Years Reported: Safety Population. During the Safety Follow-up Period, non-Serious Adverse Events occurred at the 5% frequency threshold. There was no non-SAEs occurred reported in Dose Escalation DLBCL only Cohort 3 Not Defined arm.
Metabolism and nutrition disorders HYPERGLYCAEMIA	11.1% 1/9 • Number of events 1 • From Baseline Up to Approximately 3 Years Reported: Safety Population. During the Safety Follow-up Period, non-Serious Adverse Events occurred at the 5% frequency threshold. There was no non-SAEs occurred reported in Dose Escalation DLBCL only Cohort 3 Not Defined arm.	0.00% 0/6 • From Baseline Up to Approximately 3 Years Reported: Safety Population. During the Safety Follow-up Period, non-Serious Adverse Events occurred at the 5% frequency threshold. There was no non-SAEs occurred reported in Dose Escalation DLBCL only Cohort 3 Not Defined arm.	0.00% 0/7 • From Baseline Up to Approximately 3 Years Reported: Safety Population. During the Safety Follow-up Period, non-Serious Adverse Events occurred at the 5% frequency threshold. There was no non-SAEs occurred reported in Dose Escalation DLBCL only Cohort 3 Not Defined arm.	16.7% 1/6 • Number of events 1 • From Baseline Up to Approximately 3 Years Reported: Safety Population. During the Safety Follow-up Period, non-Serious Adverse Events occurred at the 5% frequency threshold. There was no non-SAEs occurred reported in Dose Escalation DLBCL only Cohort 3 Not Defined arm.	0.00% 0/1 • From Baseline Up to Approximately 3 Years Reported: Safety Population. During the Safety Follow-up Period, non-Serious Adverse Events occurred at the 5% frequency threshold. There was no non-SAEs occurred reported in Dose Escalation DLBCL only Cohort 3 Not Defined arm.
Metabolism and nutrition disorders HYPOALBUMINAEMIA	0.00% 0/9 • From Baseline Up to Approximately 3 Years Reported: Safety Population. During the Safety Follow-up Period, non-Serious Adverse Events occurred at the 5% frequency threshold. There was no non-SAEs occurred reported in Dose Escalation DLBCL only Cohort 3 Not Defined arm.	0.00% 0/6 • From Baseline Up to Approximately 3 Years Reported: Safety Population. During the Safety Follow-up Period, non-Serious Adverse Events occurred at the 5% frequency threshold. There was no non-SAEs occurred reported in Dose Escalation DLBCL only Cohort 3 Not Defined arm.	0.00% 0/7 • From Baseline Up to Approximately 3 Years Reported: Safety Population. During the Safety Follow-up Period, non-Serious Adverse Events occurred at the 5% frequency threshold. There was no non-SAEs occurred reported in Dose Escalation DLBCL only Cohort 3 Not Defined arm.	16.7% 1/6 • Number of events 1 • From Baseline Up to Approximately 3 Years Reported: Safety Population. During the Safety Follow-up Period, non-Serious Adverse Events occurred at the 5% frequency threshold. There was no non-SAEs occurred reported in Dose Escalation DLBCL only Cohort 3 Not Defined arm.	0.00% 0/1 • From Baseline Up to Approximately 3 Years Reported: Safety Population. During the Safety Follow-up Period, non-Serious Adverse Events occurred at the 5% frequency threshold. There was no non-SAEs occurred reported in Dose Escalation DLBCL only Cohort 3 Not Defined arm.
Metabolism and nutrition disorders HYPOCALCAEMIA	0.00% 0/9 • From Baseline Up to Approximately 3 Years Reported: Safety Population. During the Safety Follow-up Period, non-Serious Adverse Events occurred at the 5% frequency threshold. There was no non-SAEs occurred reported in Dose Escalation DLBCL only Cohort 3 Not Defined arm.	0.00% 0/6 • From Baseline Up to Approximately 3 Years Reported: Safety Population. During the Safety Follow-up Period, non-Serious Adverse Events occurred at the 5% frequency threshold. There was no non-SAEs occurred reported in Dose Escalation DLBCL only Cohort 3 Not Defined arm.	0.00% 0/7 • From Baseline Up to Approximately 3 Years Reported: Safety Population. During the Safety Follow-up Period, non-Serious Adverse Events occurred at the 5% frequency threshold. There was no non-SAEs occurred reported in Dose Escalation DLBCL only Cohort 3 Not Defined arm.	16.7% 1/6 • Number of events 1 • From Baseline Up to Approximately 3 Years Reported: Safety Population. During the Safety Follow-up Period, non-Serious Adverse Events occurred at the 5% frequency threshold. There was no non-SAEs occurred reported in Dose Escalation DLBCL only Cohort 3 Not Defined arm.	0.00% 0/1 • From Baseline Up to Approximately 3 Years Reported: Safety Population. During the Safety Follow-up Period, non-Serious Adverse Events occurred at the 5% frequency threshold. There was no non-SAEs occurred reported in Dose Escalation DLBCL only Cohort 3 Not Defined arm.
Metabolism and nutrition disorders HYPOKALAEMIA	11.1% 1/9 • Number of events 1 • From Baseline Up to Approximately 3 Years Reported: Safety Population. During the Safety Follow-up Period, non-Serious Adverse Events occurred at the 5% frequency threshold. There was no non-SAEs occurred reported in Dose Escalation DLBCL only Cohort 3 Not Defined arm.	16.7% 1/6 • Number of events 1 • From Baseline Up to Approximately 3 Years Reported: Safety Population. During the Safety Follow-up Period, non-Serious Adverse Events occurred at the 5% frequency threshold. There was no non-SAEs occurred reported in Dose Escalation DLBCL only Cohort 3 Not Defined arm.	0.00% 0/7 • From Baseline Up to Approximately 3 Years Reported: Safety Population. During the Safety Follow-up Period, non-Serious Adverse Events occurred at the 5% frequency threshold. There was no non-SAEs occurred reported in Dose Escalation DLBCL only Cohort 3 Not Defined arm.	0.00% 0/6 • From Baseline Up to Approximately 3 Years Reported: Safety Population. During the Safety Follow-up Period, non-Serious Adverse Events occurred at the 5% frequency threshold. There was no non-SAEs occurred reported in Dose Escalation DLBCL only Cohort 3 Not Defined arm.	0.00% 0/1 • From Baseline Up to Approximately 3 Years Reported: Safety Population. During the Safety Follow-up Period, non-Serious Adverse Events occurred at the 5% frequency threshold. There was no non-SAEs occurred reported in Dose Escalation DLBCL only Cohort 3 Not Defined arm.
Metabolism and nutrition disorders HYPOMAGNESAEMIA	22.2% 2/9 • Number of events 2 • From Baseline Up to Approximately 3 Years Reported: Safety Population. During the Safety Follow-up Period, non-Serious Adverse Events occurred at the 5% frequency threshold. There was no non-SAEs occurred reported in Dose Escalation DLBCL only Cohort 3 Not Defined arm.	0.00% 0/6 • From Baseline Up to Approximately 3 Years Reported: Safety Population. During the Safety Follow-up Period, non-Serious Adverse Events occurred at the 5% frequency threshold. There was no non-SAEs occurred reported in Dose Escalation DLBCL only Cohort 3 Not Defined arm.	0.00% 0/7 • From Baseline Up to Approximately 3 Years Reported: Safety Population. During the Safety Follow-up Period, non-Serious Adverse Events occurred at the 5% frequency threshold. There was no non-SAEs occurred reported in Dose Escalation DLBCL only Cohort 3 Not Defined arm.	0.00% 0/6 • From Baseline Up to Approximately 3 Years Reported: Safety Population. During the Safety Follow-up Period, non-Serious Adverse Events occurred at the 5% frequency threshold. There was no non-SAEs occurred reported in Dose Escalation DLBCL only Cohort 3 Not Defined arm.	0.00% 0/1 • From Baseline Up to Approximately 3 Years Reported: Safety Population. During the Safety Follow-up Period, non-Serious Adverse Events occurred at the 5% frequency threshold. There was no non-SAEs occurred reported in Dose Escalation DLBCL only Cohort 3 Not Defined arm.
Metabolism and nutrition disorders HYPONATRAEMIA	0.00% 0/9 • From Baseline Up to Approximately 3 Years Reported: Safety Population. During the Safety Follow-up Period, non-Serious Adverse Events occurred at the 5% frequency threshold. There was no non-SAEs occurred reported in Dose Escalation DLBCL only Cohort 3 Not Defined arm.	16.7% 1/6 • Number of events 1 • From Baseline Up to Approximately 3 Years Reported: Safety Population. During the Safety Follow-up Period, non-Serious Adverse Events occurred at the 5% frequency threshold. There was no non-SAEs occurred reported in Dose Escalation DLBCL only Cohort 3 Not Defined arm.	0.00% 0/7 • From Baseline Up to Approximately 3 Years Reported: Safety Population. During the Safety Follow-up Period, non-Serious Adverse Events occurred at the 5% frequency threshold. There was no non-SAEs occurred reported in Dose Escalation DLBCL only Cohort 3 Not Defined arm.	0.00% 0/6 • From Baseline Up to Approximately 3 Years Reported: Safety Population. During the Safety Follow-up Period, non-Serious Adverse Events occurred at the 5% frequency threshold. There was no non-SAEs occurred reported in Dose Escalation DLBCL only Cohort 3 Not Defined arm.	0.00% 0/1 • From Baseline Up to Approximately 3 Years Reported: Safety Population. During the Safety Follow-up Period, non-Serious Adverse Events occurred at the 5% frequency threshold. There was no non-SAEs occurred reported in Dose Escalation DLBCL only Cohort 3 Not Defined arm.
Metabolism and nutrition disorders HYPOPHAGIA	11.1% 1/9 • Number of events 1 • From Baseline Up to Approximately 3 Years Reported: Safety Population. During the Safety Follow-up Period, non-Serious Adverse Events occurred at the 5% frequency threshold. There was no non-SAEs occurred reported in Dose Escalation DLBCL only Cohort 3 Not Defined arm.	0.00% 0/6 • From Baseline Up to Approximately 3 Years Reported: Safety Population. During the Safety Follow-up Period, non-Serious Adverse Events occurred at the 5% frequency threshold. There was no non-SAEs occurred reported in Dose Escalation DLBCL only Cohort 3 Not Defined arm.	0.00% 0/7 • From Baseline Up to Approximately 3 Years Reported: Safety Population. During the Safety Follow-up Period, non-Serious Adverse Events occurred at the 5% frequency threshold. There was no non-SAEs occurred reported in Dose Escalation DLBCL only Cohort 3 Not Defined arm.	16.7% 1/6 • Number of events 1 • From Baseline Up to Approximately 3 Years Reported: Safety Population. During the Safety Follow-up Period, non-Serious Adverse Events occurred at the 5% frequency threshold. There was no non-SAEs occurred reported in Dose Escalation DLBCL only Cohort 3 Not Defined arm.	0.00% 0/1 • From Baseline Up to Approximately 3 Years Reported: Safety Population. During the Safety Follow-up Period, non-Serious Adverse Events occurred at the 5% frequency threshold. There was no non-SAEs occurred reported in Dose Escalation DLBCL only Cohort 3 Not Defined arm.
Metabolism and nutrition disorders TUMOUR LYSIS SYNDROME	11.1% 1/9 • Number of events 1 • From Baseline Up to Approximately 3 Years Reported: Safety Population. During the Safety Follow-up Period, non-Serious Adverse Events occurred at the 5% frequency threshold. There was no non-SAEs occurred reported in Dose Escalation DLBCL only Cohort 3 Not Defined arm.	0.00% 0/6 • From Baseline Up to Approximately 3 Years Reported: Safety Population. During the Safety Follow-up Period, non-Serious Adverse Events occurred at the 5% frequency threshold. There was no non-SAEs occurred reported in Dose Escalation DLBCL only Cohort 3 Not Defined arm.	0.00% 0/7 • From Baseline Up to Approximately 3 Years Reported: Safety Population. During the Safety Follow-up Period, non-Serious Adverse Events occurred at the 5% frequency threshold. There was no non-SAEs occurred reported in Dose Escalation DLBCL only Cohort 3 Not Defined arm.	0.00% 0/6 • From Baseline Up to Approximately 3 Years Reported: Safety Population. During the Safety Follow-up Period, non-Serious Adverse Events occurred at the 5% frequency threshold. There was no non-SAEs occurred reported in Dose Escalation DLBCL only Cohort 3 Not Defined arm.	0.00% 0/1 • From Baseline Up to Approximately 3 Years Reported: Safety Population. During the Safety Follow-up Period, non-Serious Adverse Events occurred at the 5% frequency threshold. There was no non-SAEs occurred reported in Dose Escalation DLBCL only Cohort 3 Not Defined arm.
Musculoskeletal and connective tissue disorders ARTHRALGIA	11.1% 1/9 • Number of events 3 • From Baseline Up to Approximately 3 Years Reported: Safety Population. During the Safety Follow-up Period, non-Serious Adverse Events occurred at the 5% frequency threshold. There was no non-SAEs occurred reported in Dose Escalation DLBCL only Cohort 3 Not Defined arm.	0.00% 0/6 • From Baseline Up to Approximately 3 Years Reported: Safety Population. During the Safety Follow-up Period, non-Serious Adverse Events occurred at the 5% frequency threshold. There was no non-SAEs occurred reported in Dose Escalation DLBCL only Cohort 3 Not Defined arm.	0.00% 0/7 • From Baseline Up to Approximately 3 Years Reported: Safety Population. During the Safety Follow-up Period, non-Serious Adverse Events occurred at the 5% frequency threshold. There was no non-SAEs occurred reported in Dose Escalation DLBCL only Cohort 3 Not Defined arm.	0.00% 0/6 • From Baseline Up to Approximately 3 Years Reported: Safety Population. During the Safety Follow-up Period, non-Serious Adverse Events occurred at the 5% frequency threshold. There was no non-SAEs occurred reported in Dose Escalation DLBCL only Cohort 3 Not Defined arm.	0.00% 0/1 • From Baseline Up to Approximately 3 Years Reported: Safety Population. During the Safety Follow-up Period, non-Serious Adverse Events occurred at the 5% frequency threshold. There was no non-SAEs occurred reported in Dose Escalation DLBCL only Cohort 3 Not Defined arm.
Musculoskeletal and connective tissue disorders BACK PAIN	0.00% 0/9 • From Baseline Up to Approximately 3 Years Reported: Safety Population. During the Safety Follow-up Period, non-Serious Adverse Events occurred at the 5% frequency threshold. There was no non-SAEs occurred reported in Dose Escalation DLBCL only Cohort 3 Not Defined arm.	0.00% 0/6 • From Baseline Up to Approximately 3 Years Reported: Safety Population. During the Safety Follow-up Period, non-Serious Adverse Events occurred at the 5% frequency threshold. There was no non-SAEs occurred reported in Dose Escalation DLBCL only Cohort 3 Not Defined arm.	28.6% 2/7 • Number of events 2 • From Baseline Up to Approximately 3 Years Reported: Safety Population. During the Safety Follow-up Period, non-Serious Adverse Events occurred at the 5% frequency threshold. There was no non-SAEs occurred reported in Dose Escalation DLBCL only Cohort 3 Not Defined arm.	0.00% 0/6 • From Baseline Up to Approximately 3 Years Reported: Safety Population. During the Safety Follow-up Period, non-Serious Adverse Events occurred at the 5% frequency threshold. There was no non-SAEs occurred reported in Dose Escalation DLBCL only Cohort 3 Not Defined arm.	0.00% 0/1 • From Baseline Up to Approximately 3 Years Reported: Safety Population. During the Safety Follow-up Period, non-Serious Adverse Events occurred at the 5% frequency threshold. There was no non-SAEs occurred reported in Dose Escalation DLBCL only Cohort 3 Not Defined arm.
Musculoskeletal and connective tissue disorders BONE PAIN	11.1% 1/9 • Number of events 1 • From Baseline Up to Approximately 3 Years Reported: Safety Population. During the Safety Follow-up Period, non-Serious Adverse Events occurred at the 5% frequency threshold. There was no non-SAEs occurred reported in Dose Escalation DLBCL only Cohort 3 Not Defined arm.	0.00% 0/6 • From Baseline Up to Approximately 3 Years Reported: Safety Population. During the Safety Follow-up Period, non-Serious Adverse Events occurred at the 5% frequency threshold. There was no non-SAEs occurred reported in Dose Escalation DLBCL only Cohort 3 Not Defined arm.	0.00% 0/7 • From Baseline Up to Approximately 3 Years Reported: Safety Population. During the Safety Follow-up Period, non-Serious Adverse Events occurred at the 5% frequency threshold. There was no non-SAEs occurred reported in Dose Escalation DLBCL only Cohort 3 Not Defined arm.	16.7% 1/6 • Number of events 1 • From Baseline Up to Approximately 3 Years Reported: Safety Population. During the Safety Follow-up Period, non-Serious Adverse Events occurred at the 5% frequency threshold. There was no non-SAEs occurred reported in Dose Escalation DLBCL only Cohort 3 Not Defined arm.	0.00% 0/1 • From Baseline Up to Approximately 3 Years Reported: Safety Population. During the Safety Follow-up Period, non-Serious Adverse Events occurred at the 5% frequency threshold. There was no non-SAEs occurred reported in Dose Escalation DLBCL only Cohort 3 Not Defined arm.
Musculoskeletal and connective tissue disorders FLANK PAIN	11.1% 1/9 • Number of events 1 • From Baseline Up to Approximately 3 Years Reported: Safety Population. During the Safety Follow-up Period, non-Serious Adverse Events occurred at the 5% frequency threshold. There was no non-SAEs occurred reported in Dose Escalation DLBCL only Cohort 3 Not Defined arm.	0.00% 0/6 • From Baseline Up to Approximately 3 Years Reported: Safety Population. During the Safety Follow-up Period, non-Serious Adverse Events occurred at the 5% frequency threshold. There was no non-SAEs occurred reported in Dose Escalation DLBCL only Cohort 3 Not Defined arm.	0.00% 0/7 • From Baseline Up to Approximately 3 Years Reported: Safety Population. During the Safety Follow-up Period, non-Serious Adverse Events occurred at the 5% frequency threshold. There was no non-SAEs occurred reported in Dose Escalation DLBCL only Cohort 3 Not Defined arm.	0.00% 0/6 • From Baseline Up to Approximately 3 Years Reported: Safety Population. During the Safety Follow-up Period, non-Serious Adverse Events occurred at the 5% frequency threshold. There was no non-SAEs occurred reported in Dose Escalation DLBCL only Cohort 3 Not Defined arm.	0.00% 0/1 • From Baseline Up to Approximately 3 Years Reported: Safety Population. During the Safety Follow-up Period, non-Serious Adverse Events occurred at the 5% frequency threshold. There was no non-SAEs occurred reported in Dose Escalation DLBCL only Cohort 3 Not Defined arm.
Musculoskeletal and connective tissue disorders JOINT STIFFNESS	11.1% 1/9 • Number of events 1 • From Baseline Up to Approximately 3 Years Reported: Safety Population. During the Safety Follow-up Period, non-Serious Adverse Events occurred at the 5% frequency threshold. There was no non-SAEs occurred reported in Dose Escalation DLBCL only Cohort 3 Not Defined arm.	0.00% 0/6 • From Baseline Up to Approximately 3 Years Reported: Safety Population. During the Safety Follow-up Period, non-Serious Adverse Events occurred at the 5% frequency threshold. There was no non-SAEs occurred reported in Dose Escalation DLBCL only Cohort 3 Not Defined arm.	0.00% 0/7 • From Baseline Up to Approximately 3 Years Reported: Safety Population. During the Safety Follow-up Period, non-Serious Adverse Events occurred at the 5% frequency threshold. There was no non-SAEs occurred reported in Dose Escalation DLBCL only Cohort 3 Not Defined arm.	0.00% 0/6 • From Baseline Up to Approximately 3 Years Reported: Safety Population. During the Safety Follow-up Period, non-Serious Adverse Events occurred at the 5% frequency threshold. There was no non-SAEs occurred reported in Dose Escalation DLBCL only Cohort 3 Not Defined arm.	0.00% 0/1 • From Baseline Up to Approximately 3 Years Reported: Safety Population. During the Safety Follow-up Period, non-Serious Adverse Events occurred at the 5% frequency threshold. There was no non-SAEs occurred reported in Dose Escalation DLBCL only Cohort 3 Not Defined arm.
Musculoskeletal and connective tissue disorders MUSCULOSKELETAL PAIN	0.00% 0/9 • From Baseline Up to Approximately 3 Years Reported: Safety Population. During the Safety Follow-up Period, non-Serious Adverse Events occurred at the 5% frequency threshold. There was no non-SAEs occurred reported in Dose Escalation DLBCL only Cohort 3 Not Defined arm.	16.7% 1/6 • Number of events 1 • From Baseline Up to Approximately 3 Years Reported: Safety Population. During the Safety Follow-up Period, non-Serious Adverse Events occurred at the 5% frequency threshold. There was no non-SAEs occurred reported in Dose Escalation DLBCL only Cohort 3 Not Defined arm.	0.00% 0/7 • From Baseline Up to Approximately 3 Years Reported: Safety Population. During the Safety Follow-up Period, non-Serious Adverse Events occurred at the 5% frequency threshold. There was no non-SAEs occurred reported in Dose Escalation DLBCL only Cohort 3 Not Defined arm.	0.00% 0/6 • From Baseline Up to Approximately 3 Years Reported: Safety Population. During the Safety Follow-up Period, non-Serious Adverse Events occurred at the 5% frequency threshold. There was no non-SAEs occurred reported in Dose Escalation DLBCL only Cohort 3 Not Defined arm.	0.00% 0/1 • From Baseline Up to Approximately 3 Years Reported: Safety Population. During the Safety Follow-up Period, non-Serious Adverse Events occurred at the 5% frequency threshold. There was no non-SAEs occurred reported in Dose Escalation DLBCL only Cohort 3 Not Defined arm.
Musculoskeletal and connective tissue disorders MYALGIA	11.1% 1/9 • Number of events 1 • From Baseline Up to Approximately 3 Years Reported: Safety Population. During the Safety Follow-up Period, non-Serious Adverse Events occurred at the 5% frequency threshold. There was no non-SAEs occurred reported in Dose Escalation DLBCL only Cohort 3 Not Defined arm.	0.00% 0/6 • From Baseline Up to Approximately 3 Years Reported: Safety Population. During the Safety Follow-up Period, non-Serious Adverse Events occurred at the 5% frequency threshold. There was no non-SAEs occurred reported in Dose Escalation DLBCL only Cohort 3 Not Defined arm.	0.00% 0/7 • From Baseline Up to Approximately 3 Years Reported: Safety Population. During the Safety Follow-up Period, non-Serious Adverse Events occurred at the 5% frequency threshold. There was no non-SAEs occurred reported in Dose Escalation DLBCL only Cohort 3 Not Defined arm.	0.00% 0/6 • From Baseline Up to Approximately 3 Years Reported: Safety Population. During the Safety Follow-up Period, non-Serious Adverse Events occurred at the 5% frequency threshold. There was no non-SAEs occurred reported in Dose Escalation DLBCL only Cohort 3 Not Defined arm.	0.00% 0/1 • From Baseline Up to Approximately 3 Years Reported: Safety Population. During the Safety Follow-up Period, non-Serious Adverse Events occurred at the 5% frequency threshold. There was no non-SAEs occurred reported in Dose Escalation DLBCL only Cohort 3 Not Defined arm.
Musculoskeletal and connective tissue disorders PAIN IN EXTREMITY	22.2% 2/9 • Number of events 4 • From Baseline Up to Approximately 3 Years Reported: Safety Population. During the Safety Follow-up Period, non-Serious Adverse Events occurred at the 5% frequency threshold. There was no non-SAEs occurred reported in Dose Escalation DLBCL only Cohort 3 Not Defined arm.	0.00% 0/6 • From Baseline Up to Approximately 3 Years Reported: Safety Population. During the Safety Follow-up Period, non-Serious Adverse Events occurred at the 5% frequency threshold. There was no non-SAEs occurred reported in Dose Escalation DLBCL only Cohort 3 Not Defined arm.	0.00% 0/7 • From Baseline Up to Approximately 3 Years Reported: Safety Population. During the Safety Follow-up Period, non-Serious Adverse Events occurred at the 5% frequency threshold. There was no non-SAEs occurred reported in Dose Escalation DLBCL only Cohort 3 Not Defined arm.	16.7% 1/6 • Number of events 1 • From Baseline Up to Approximately 3 Years Reported: Safety Population. During the Safety Follow-up Period, non-Serious Adverse Events occurred at the 5% frequency threshold. There was no non-SAEs occurred reported in Dose Escalation DLBCL only Cohort 3 Not Defined arm.	0.00% 0/1 • From Baseline Up to Approximately 3 Years Reported: Safety Population. During the Safety Follow-up Period, non-Serious Adverse Events occurred at the 5% frequency threshold. There was no non-SAEs occurred reported in Dose Escalation DLBCL only Cohort 3 Not Defined arm.
Musculoskeletal and connective tissue disorders SPINAL OSTEOARTHRITIS	0.00% 0/9 • From Baseline Up to Approximately 3 Years Reported: Safety Population. During the Safety Follow-up Period, non-Serious Adverse Events occurred at the 5% frequency threshold. There was no non-SAEs occurred reported in Dose Escalation DLBCL only Cohort 3 Not Defined arm.	0.00% 0/6 • From Baseline Up to Approximately 3 Years Reported: Safety Population. During the Safety Follow-up Period, non-Serious Adverse Events occurred at the 5% frequency threshold. There was no non-SAEs occurred reported in Dose Escalation DLBCL only Cohort 3 Not Defined arm.	0.00% 0/7 • From Baseline Up to Approximately 3 Years Reported: Safety Population. During the Safety Follow-up Period, non-Serious Adverse Events occurred at the 5% frequency threshold. There was no non-SAEs occurred reported in Dose Escalation DLBCL only Cohort 3 Not Defined arm.	16.7% 1/6 • Number of events 1 • From Baseline Up to Approximately 3 Years Reported: Safety Population. During the Safety Follow-up Period, non-Serious Adverse Events occurred at the 5% frequency threshold. There was no non-SAEs occurred reported in Dose Escalation DLBCL only Cohort 3 Not Defined arm.	0.00% 0/1 • From Baseline Up to Approximately 3 Years Reported: Safety Population. During the Safety Follow-up Period, non-Serious Adverse Events occurred at the 5% frequency threshold. There was no non-SAEs occurred reported in Dose Escalation DLBCL only Cohort 3 Not Defined arm.
Musculoskeletal and connective tissue disorders VERTEBRAL FORAMINAL STENOSIS	0.00% 0/9 • From Baseline Up to Approximately 3 Years Reported: Safety Population. During the Safety Follow-up Period, non-Serious Adverse Events occurred at the 5% frequency threshold. There was no non-SAEs occurred reported in Dose Escalation DLBCL only Cohort 3 Not Defined arm.	0.00% 0/6 • From Baseline Up to Approximately 3 Years Reported: Safety Population. During the Safety Follow-up Period, non-Serious Adverse Events occurred at the 5% frequency threshold. There was no non-SAEs occurred reported in Dose Escalation DLBCL only Cohort 3 Not Defined arm.	0.00% 0/7 • From Baseline Up to Approximately 3 Years Reported: Safety Population. During the Safety Follow-up Period, non-Serious Adverse Events occurred at the 5% frequency threshold. There was no non-SAEs occurred reported in Dose Escalation DLBCL only Cohort 3 Not Defined arm.	16.7% 1/6 • Number of events 1 • From Baseline Up to Approximately 3 Years Reported: Safety Population. During the Safety Follow-up Period, non-Serious Adverse Events occurred at the 5% frequency threshold. There was no non-SAEs occurred reported in Dose Escalation DLBCL only Cohort 3 Not Defined arm.	0.00% 0/1 • From Baseline Up to Approximately 3 Years Reported: Safety Population. During the Safety Follow-up Period, non-Serious Adverse Events occurred at the 5% frequency threshold. There was no non-SAEs occurred reported in Dose Escalation DLBCL only Cohort 3 Not Defined arm.
Nervous system disorders DIZZINESS	22.2% 2/9 • Number of events 4 • From Baseline Up to Approximately 3 Years Reported: Safety Population. During the Safety Follow-up Period, non-Serious Adverse Events occurred at the 5% frequency threshold. There was no non-SAEs occurred reported in Dose Escalation DLBCL only Cohort 3 Not Defined arm.	16.7% 1/6 • Number of events 1 • From Baseline Up to Approximately 3 Years Reported: Safety Population. During the Safety Follow-up Period, non-Serious Adverse Events occurred at the 5% frequency threshold. There was no non-SAEs occurred reported in Dose Escalation DLBCL only Cohort 3 Not Defined arm.	14.3% 1/7 • Number of events 1 • From Baseline Up to Approximately 3 Years Reported: Safety Population. During the Safety Follow-up Period, non-Serious Adverse Events occurred at the 5% frequency threshold. There was no non-SAEs occurred reported in Dose Escalation DLBCL only Cohort 3 Not Defined arm.	0.00% 0/6 • From Baseline Up to Approximately 3 Years Reported: Safety Population. During the Safety Follow-up Period, non-Serious Adverse Events occurred at the 5% frequency threshold. There was no non-SAEs occurred reported in Dose Escalation DLBCL only Cohort 3 Not Defined arm.	0.00% 0/1 • From Baseline Up to Approximately 3 Years Reported: Safety Population. During the Safety Follow-up Period, non-Serious Adverse Events occurred at the 5% frequency threshold. There was no non-SAEs occurred reported in Dose Escalation DLBCL only Cohort 3 Not Defined arm.
Nervous system disorders HEADACHE	33.3% 3/9 • Number of events 5 • From Baseline Up to Approximately 3 Years Reported: Safety Population. During the Safety Follow-up Period, non-Serious Adverse Events occurred at the 5% frequency threshold. There was no non-SAEs occurred reported in Dose Escalation DLBCL only Cohort 3 Not Defined arm.	16.7% 1/6 • Number of events 2 • From Baseline Up to Approximately 3 Years Reported: Safety Population. During the Safety Follow-up Period, non-Serious Adverse Events occurred at the 5% frequency threshold. There was no non-SAEs occurred reported in Dose Escalation DLBCL only Cohort 3 Not Defined arm.	28.6% 2/7 • Number of events 2 • From Baseline Up to Approximately 3 Years Reported: Safety Population. During the Safety Follow-up Period, non-Serious Adverse Events occurred at the 5% frequency threshold. There was no non-SAEs occurred reported in Dose Escalation DLBCL only Cohort 3 Not Defined arm.	16.7% 1/6 • Number of events 1 • From Baseline Up to Approximately 3 Years Reported: Safety Population. During the Safety Follow-up Period, non-Serious Adverse Events occurred at the 5% frequency threshold. There was no non-SAEs occurred reported in Dose Escalation DLBCL only Cohort 3 Not Defined arm.	0.00% 0/1 • From Baseline Up to Approximately 3 Years Reported: Safety Population. During the Safety Follow-up Period, non-Serious Adverse Events occurred at the 5% frequency threshold. There was no non-SAEs occurred reported in Dose Escalation DLBCL only Cohort 3 Not Defined arm.
Nervous system disorders NEURALGIA	11.1% 1/9 • Number of events 1 • From Baseline Up to Approximately 3 Years Reported: Safety Population. During the Safety Follow-up Period, non-Serious Adverse Events occurred at the 5% frequency threshold. There was no non-SAEs occurred reported in Dose Escalation DLBCL only Cohort 3 Not Defined arm.	0.00% 0/6 • From Baseline Up to Approximately 3 Years Reported: Safety Population. During the Safety Follow-up Period, non-Serious Adverse Events occurred at the 5% frequency threshold. There was no non-SAEs occurred reported in Dose Escalation DLBCL only Cohort 3 Not Defined arm.	0.00% 0/7 • From Baseline Up to Approximately 3 Years Reported: Safety Population. During the Safety Follow-up Period, non-Serious Adverse Events occurred at the 5% frequency threshold. There was no non-SAEs occurred reported in Dose Escalation DLBCL only Cohort 3 Not Defined arm.	0.00% 0/6 • From Baseline Up to Approximately 3 Years Reported: Safety Population. During the Safety Follow-up Period, non-Serious Adverse Events occurred at the 5% frequency threshold. There was no non-SAEs occurred reported in Dose Escalation DLBCL only Cohort 3 Not Defined arm.	0.00% 0/1 • From Baseline Up to Approximately 3 Years Reported: Safety Population. During the Safety Follow-up Period, non-Serious Adverse Events occurred at the 5% frequency threshold. There was no non-SAEs occurred reported in Dose Escalation DLBCL only Cohort 3 Not Defined arm.
Nervous system disorders NEUROPATHY PERIPHERAL	11.1% 1/9 • Number of events 1 • From Baseline Up to Approximately 3 Years Reported: Safety Population. During the Safety Follow-up Period, non-Serious Adverse Events occurred at the 5% frequency threshold. There was no non-SAEs occurred reported in Dose Escalation DLBCL only Cohort 3 Not Defined arm.	0.00% 0/6 • From Baseline Up to Approximately 3 Years Reported: Safety Population. During the Safety Follow-up Period, non-Serious Adverse Events occurred at the 5% frequency threshold. There was no non-SAEs occurred reported in Dose Escalation DLBCL only Cohort 3 Not Defined arm.	0.00% 0/7 • From Baseline Up to Approximately 3 Years Reported: Safety Population. During the Safety Follow-up Period, non-Serious Adverse Events occurred at the 5% frequency threshold. There was no non-SAEs occurred reported in Dose Escalation DLBCL only Cohort 3 Not Defined arm.	0.00% 0/6 • From Baseline Up to Approximately 3 Years Reported: Safety Population. During the Safety Follow-up Period, non-Serious Adverse Events occurred at the 5% frequency threshold. There was no non-SAEs occurred reported in Dose Escalation DLBCL only Cohort 3 Not Defined arm.	0.00% 0/1 • From Baseline Up to Approximately 3 Years Reported: Safety Population. During the Safety Follow-up Period, non-Serious Adverse Events occurred at the 5% frequency threshold. There was no non-SAEs occurred reported in Dose Escalation DLBCL only Cohort 3 Not Defined arm.
Nervous system disorders PARAESTHESIA	11.1% 1/9 • Number of events 1 • From Baseline Up to Approximately 3 Years Reported: Safety Population. During the Safety Follow-up Period, non-Serious Adverse Events occurred at the 5% frequency threshold. There was no non-SAEs occurred reported in Dose Escalation DLBCL only Cohort 3 Not Defined arm.	16.7% 1/6 • Number of events 1 • From Baseline Up to Approximately 3 Years Reported: Safety Population. During the Safety Follow-up Period, non-Serious Adverse Events occurred at the 5% frequency threshold. There was no non-SAEs occurred reported in Dose Escalation DLBCL only Cohort 3 Not Defined arm.	0.00% 0/7 • From Baseline Up to Approximately 3 Years Reported: Safety Population. During the Safety Follow-up Period, non-Serious Adverse Events occurred at the 5% frequency threshold. There was no non-SAEs occurred reported in Dose Escalation DLBCL only Cohort 3 Not Defined arm.	0.00% 0/6 • From Baseline Up to Approximately 3 Years Reported: Safety Population. During the Safety Follow-up Period, non-Serious Adverse Events occurred at the 5% frequency threshold. There was no non-SAEs occurred reported in Dose Escalation DLBCL only Cohort 3 Not Defined arm.	0.00% 0/1 • From Baseline Up to Approximately 3 Years Reported: Safety Population. During the Safety Follow-up Period, non-Serious Adverse Events occurred at the 5% frequency threshold. There was no non-SAEs occurred reported in Dose Escalation DLBCL only Cohort 3 Not Defined arm.
Nervous system disorders RADICULAR PAIN	0.00% 0/9 • From Baseline Up to Approximately 3 Years Reported: Safety Population. During the Safety Follow-up Period, non-Serious Adverse Events occurred at the 5% frequency threshold. There was no non-SAEs occurred reported in Dose Escalation DLBCL only Cohort 3 Not Defined arm.	0.00% 0/6 • From Baseline Up to Approximately 3 Years Reported: Safety Population. During the Safety Follow-up Period, non-Serious Adverse Events occurred at the 5% frequency threshold. There was no non-SAEs occurred reported in Dose Escalation DLBCL only Cohort 3 Not Defined arm.	0.00% 0/7 • From Baseline Up to Approximately 3 Years Reported: Safety Population. During the Safety Follow-up Period, non-Serious Adverse Events occurred at the 5% frequency threshold. There was no non-SAEs occurred reported in Dose Escalation DLBCL only Cohort 3 Not Defined arm.	16.7% 1/6 • Number of events 1 • From Baseline Up to Approximately 3 Years Reported: Safety Population. During the Safety Follow-up Period, non-Serious Adverse Events occurred at the 5% frequency threshold. There was no non-SAEs occurred reported in Dose Escalation DLBCL only Cohort 3 Not Defined arm.	0.00% 0/1 • From Baseline Up to Approximately 3 Years Reported: Safety Population. During the Safety Follow-up Period, non-Serious Adverse Events occurred at the 5% frequency threshold. There was no non-SAEs occurred reported in Dose Escalation DLBCL only Cohort 3 Not Defined arm.
Nervous system disorders SYNCOPE	0.00% 0/9 • From Baseline Up to Approximately 3 Years Reported: Safety Population. During the Safety Follow-up Period, non-Serious Adverse Events occurred at the 5% frequency threshold. There was no non-SAEs occurred reported in Dose Escalation DLBCL only Cohort 3 Not Defined arm.	16.7% 1/6 • Number of events 1 • From Baseline Up to Approximately 3 Years Reported: Safety Population. During the Safety Follow-up Period, non-Serious Adverse Events occurred at the 5% frequency threshold. There was no non-SAEs occurred reported in Dose Escalation DLBCL only Cohort 3 Not Defined arm.	0.00% 0/7 • From Baseline Up to Approximately 3 Years Reported: Safety Population. During the Safety Follow-up Period, non-Serious Adverse Events occurred at the 5% frequency threshold. There was no non-SAEs occurred reported in Dose Escalation DLBCL only Cohort 3 Not Defined arm.	0.00% 0/6 • From Baseline Up to Approximately 3 Years Reported: Safety Population. During the Safety Follow-up Period, non-Serious Adverse Events occurred at the 5% frequency threshold. There was no non-SAEs occurred reported in Dose Escalation DLBCL only Cohort 3 Not Defined arm.	0.00% 0/1 • From Baseline Up to Approximately 3 Years Reported: Safety Population. During the Safety Follow-up Period, non-Serious Adverse Events occurred at the 5% frequency threshold. There was no non-SAEs occurred reported in Dose Escalation DLBCL only Cohort 3 Not Defined arm.
Nervous system disorders TRANSIENT ISCHAEMIC ATTACK	0.00% 0/9 • From Baseline Up to Approximately 3 Years Reported: Safety Population. During the Safety Follow-up Period, non-Serious Adverse Events occurred at the 5% frequency threshold. There was no non-SAEs occurred reported in Dose Escalation DLBCL only Cohort 3 Not Defined arm.	16.7% 1/6 • Number of events 1 • From Baseline Up to Approximately 3 Years Reported: Safety Population. During the Safety Follow-up Period, non-Serious Adverse Events occurred at the 5% frequency threshold. There was no non-SAEs occurred reported in Dose Escalation DLBCL only Cohort 3 Not Defined arm.	0.00% 0/7 • From Baseline Up to Approximately 3 Years Reported: Safety Population. During the Safety Follow-up Period, non-Serious Adverse Events occurred at the 5% frequency threshold. There was no non-SAEs occurred reported in Dose Escalation DLBCL only Cohort 3 Not Defined arm.	0.00% 0/6 • From Baseline Up to Approximately 3 Years Reported: Safety Population. During the Safety Follow-up Period, non-Serious Adverse Events occurred at the 5% frequency threshold. There was no non-SAEs occurred reported in Dose Escalation DLBCL only Cohort 3 Not Defined arm.	0.00% 0/1 • From Baseline Up to Approximately 3 Years Reported: Safety Population. During the Safety Follow-up Period, non-Serious Adverse Events occurred at the 5% frequency threshold. There was no non-SAEs occurred reported in Dose Escalation DLBCL only Cohort 3 Not Defined arm.
Psychiatric disorders ANXIETY	11.1% 1/9 • Number of events 1 • From Baseline Up to Approximately 3 Years Reported: Safety Population. During the Safety Follow-up Period, non-Serious Adverse Events occurred at the 5% frequency threshold. There was no non-SAEs occurred reported in Dose Escalation DLBCL only Cohort 3 Not Defined arm.	0.00% 0/6 • From Baseline Up to Approximately 3 Years Reported: Safety Population. During the Safety Follow-up Period, non-Serious Adverse Events occurred at the 5% frequency threshold. There was no non-SAEs occurred reported in Dose Escalation DLBCL only Cohort 3 Not Defined arm.	0.00% 0/7 • From Baseline Up to Approximately 3 Years Reported: Safety Population. During the Safety Follow-up Period, non-Serious Adverse Events occurred at the 5% frequency threshold. There was no non-SAEs occurred reported in Dose Escalation DLBCL only Cohort 3 Not Defined arm.	0.00% 0/6 • From Baseline Up to Approximately 3 Years Reported: Safety Population. During the Safety Follow-up Period, non-Serious Adverse Events occurred at the 5% frequency threshold. There was no non-SAEs occurred reported in Dose Escalation DLBCL only Cohort 3 Not Defined arm.	0.00% 0/1 • From Baseline Up to Approximately 3 Years Reported: Safety Population. During the Safety Follow-up Period, non-Serious Adverse Events occurred at the 5% frequency threshold. There was no non-SAEs occurred reported in Dose Escalation DLBCL only Cohort 3 Not Defined arm.
Psychiatric disorders DELIRIUM	0.00% 0/9 • From Baseline Up to Approximately 3 Years Reported: Safety Population. During the Safety Follow-up Period, non-Serious Adverse Events occurred at the 5% frequency threshold. There was no non-SAEs occurred reported in Dose Escalation DLBCL only Cohort 3 Not Defined arm.	0.00% 0/6 • From Baseline Up to Approximately 3 Years Reported: Safety Population. During the Safety Follow-up Period, non-Serious Adverse Events occurred at the 5% frequency threshold. There was no non-SAEs occurred reported in Dose Escalation DLBCL only Cohort 3 Not Defined arm.	14.3% 1/7 • Number of events 1 • From Baseline Up to Approximately 3 Years Reported: Safety Population. During the Safety Follow-up Period, non-Serious Adverse Events occurred at the 5% frequency threshold. There was no non-SAEs occurred reported in Dose Escalation DLBCL only Cohort 3 Not Defined arm.	0.00% 0/6 • From Baseline Up to Approximately 3 Years Reported: Safety Population. During the Safety Follow-up Period, non-Serious Adverse Events occurred at the 5% frequency threshold. There was no non-SAEs occurred reported in Dose Escalation DLBCL only Cohort 3 Not Defined arm.	0.00% 0/1 • From Baseline Up to Approximately 3 Years Reported: Safety Population. During the Safety Follow-up Period, non-Serious Adverse Events occurred at the 5% frequency threshold. There was no non-SAEs occurred reported in Dose Escalation DLBCL only Cohort 3 Not Defined arm.
Psychiatric disorders DEPRESSION	0.00% 0/9 • From Baseline Up to Approximately 3 Years Reported: Safety Population. During the Safety Follow-up Period, non-Serious Adverse Events occurred at the 5% frequency threshold. There was no non-SAEs occurred reported in Dose Escalation DLBCL only Cohort 3 Not Defined arm.	0.00% 0/6 • From Baseline Up to Approximately 3 Years Reported: Safety Population. During the Safety Follow-up Period, non-Serious Adverse Events occurred at the 5% frequency threshold. There was no non-SAEs occurred reported in Dose Escalation DLBCL only Cohort 3 Not Defined arm.	0.00% 0/7 • From Baseline Up to Approximately 3 Years Reported: Safety Population. During the Safety Follow-up Period, non-Serious Adverse Events occurred at the 5% frequency threshold. There was no non-SAEs occurred reported in Dose Escalation DLBCL only Cohort 3 Not Defined arm.	16.7% 1/6 • Number of events 1 • From Baseline Up to Approximately 3 Years Reported: Safety Population. During the Safety Follow-up Period, non-Serious Adverse Events occurred at the 5% frequency threshold. There was no non-SAEs occurred reported in Dose Escalation DLBCL only Cohort 3 Not Defined arm.	0.00% 0/1 • From Baseline Up to Approximately 3 Years Reported: Safety Population. During the Safety Follow-up Period, non-Serious Adverse Events occurred at the 5% frequency threshold. There was no non-SAEs occurred reported in Dose Escalation DLBCL only Cohort 3 Not Defined arm.
Psychiatric disorders INSOMNIA	11.1% 1/9 • Number of events 1 • From Baseline Up to Approximately 3 Years Reported: Safety Population. During the Safety Follow-up Period, non-Serious Adverse Events occurred at the 5% frequency threshold. There was no non-SAEs occurred reported in Dose Escalation DLBCL only Cohort 3 Not Defined arm.	0.00% 0/6 • From Baseline Up to Approximately 3 Years Reported: Safety Population. During the Safety Follow-up Period, non-Serious Adverse Events occurred at the 5% frequency threshold. There was no non-SAEs occurred reported in Dose Escalation DLBCL only Cohort 3 Not Defined arm.	0.00% 0/7 • From Baseline Up to Approximately 3 Years Reported: Safety Population. During the Safety Follow-up Period, non-Serious Adverse Events occurred at the 5% frequency threshold. There was no non-SAEs occurred reported in Dose Escalation DLBCL only Cohort 3 Not Defined arm.	0.00% 0/6 • From Baseline Up to Approximately 3 Years Reported: Safety Population. During the Safety Follow-up Period, non-Serious Adverse Events occurred at the 5% frequency threshold. There was no non-SAEs occurred reported in Dose Escalation DLBCL only Cohort 3 Not Defined arm.	0.00% 0/1 • From Baseline Up to Approximately 3 Years Reported: Safety Population. During the Safety Follow-up Period, non-Serious Adverse Events occurred at the 5% frequency threshold. There was no non-SAEs occurred reported in Dose Escalation DLBCL only Cohort 3 Not Defined arm.
Renal and urinary disorders ACUTE KIDNEY INJURY	0.00% 0/9 • From Baseline Up to Approximately 3 Years Reported: Safety Population. During the Safety Follow-up Period, non-Serious Adverse Events occurred at the 5% frequency threshold. There was no non-SAEs occurred reported in Dose Escalation DLBCL only Cohort 3 Not Defined arm.	0.00% 0/6 • From Baseline Up to Approximately 3 Years Reported: Safety Population. During the Safety Follow-up Period, non-Serious Adverse Events occurred at the 5% frequency threshold. There was no non-SAEs occurred reported in Dose Escalation DLBCL only Cohort 3 Not Defined arm.	0.00% 0/7 • From Baseline Up to Approximately 3 Years Reported: Safety Population. During the Safety Follow-up Period, non-Serious Adverse Events occurred at the 5% frequency threshold. There was no non-SAEs occurred reported in Dose Escalation DLBCL only Cohort 3 Not Defined arm.	16.7% 1/6 • Number of events 1 • From Baseline Up to Approximately 3 Years Reported: Safety Population. During the Safety Follow-up Period, non-Serious Adverse Events occurred at the 5% frequency threshold. There was no non-SAEs occurred reported in Dose Escalation DLBCL only Cohort 3 Not Defined arm.	0.00% 0/1 • From Baseline Up to Approximately 3 Years Reported: Safety Population. During the Safety Follow-up Period, non-Serious Adverse Events occurred at the 5% frequency threshold. There was no non-SAEs occurred reported in Dose Escalation DLBCL only Cohort 3 Not Defined arm.
Renal and urinary disorders DYSURIA	11.1% 1/9 • Number of events 2 • From Baseline Up to Approximately 3 Years Reported: Safety Population. During the Safety Follow-up Period, non-Serious Adverse Events occurred at the 5% frequency threshold. There was no non-SAEs occurred reported in Dose Escalation DLBCL only Cohort 3 Not Defined arm.	0.00% 0/6 • From Baseline Up to Approximately 3 Years Reported: Safety Population. During the Safety Follow-up Period, non-Serious Adverse Events occurred at the 5% frequency threshold. There was no non-SAEs occurred reported in Dose Escalation DLBCL only Cohort 3 Not Defined arm.	0.00% 0/7 • From Baseline Up to Approximately 3 Years Reported: Safety Population. During the Safety Follow-up Period, non-Serious Adverse Events occurred at the 5% frequency threshold. There was no non-SAEs occurred reported in Dose Escalation DLBCL only Cohort 3 Not Defined arm.	0.00% 0/6 • From Baseline Up to Approximately 3 Years Reported: Safety Population. During the Safety Follow-up Period, non-Serious Adverse Events occurred at the 5% frequency threshold. There was no non-SAEs occurred reported in Dose Escalation DLBCL only Cohort 3 Not Defined arm.	0.00% 0/1 • From Baseline Up to Approximately 3 Years Reported: Safety Population. During the Safety Follow-up Period, non-Serious Adverse Events occurred at the 5% frequency threshold. There was no non-SAEs occurred reported in Dose Escalation DLBCL only Cohort 3 Not Defined arm.
Renal and urinary disorders HAEMATURIA	0.00% 0/9 • From Baseline Up to Approximately 3 Years Reported: Safety Population. During the Safety Follow-up Period, non-Serious Adverse Events occurred at the 5% frequency threshold. There was no non-SAEs occurred reported in Dose Escalation DLBCL only Cohort 3 Not Defined arm.	16.7% 1/6 • Number of events 1 • From Baseline Up to Approximately 3 Years Reported: Safety Population. During the Safety Follow-up Period, non-Serious Adverse Events occurred at the 5% frequency threshold. There was no non-SAEs occurred reported in Dose Escalation DLBCL only Cohort 3 Not Defined arm.	0.00% 0/7 • From Baseline Up to Approximately 3 Years Reported: Safety Population. During the Safety Follow-up Period, non-Serious Adverse Events occurred at the 5% frequency threshold. There was no non-SAEs occurred reported in Dose Escalation DLBCL only Cohort 3 Not Defined arm.	0.00% 0/6 • From Baseline Up to Approximately 3 Years Reported: Safety Population. During the Safety Follow-up Period, non-Serious Adverse Events occurred at the 5% frequency threshold. There was no non-SAEs occurred reported in Dose Escalation DLBCL only Cohort 3 Not Defined arm.	0.00% 0/1 • From Baseline Up to Approximately 3 Years Reported: Safety Population. During the Safety Follow-up Period, non-Serious Adverse Events occurred at the 5% frequency threshold. There was no non-SAEs occurred reported in Dose Escalation DLBCL only Cohort 3 Not Defined arm.
Renal and urinary disorders MICTURITION URGENCY	0.00% 0/9 • From Baseline Up to Approximately 3 Years Reported: Safety Population. During the Safety Follow-up Period, non-Serious Adverse Events occurred at the 5% frequency threshold. There was no non-SAEs occurred reported in Dose Escalation DLBCL only Cohort 3 Not Defined arm.	0.00% 0/6 • From Baseline Up to Approximately 3 Years Reported: Safety Population. During the Safety Follow-up Period, non-Serious Adverse Events occurred at the 5% frequency threshold. There was no non-SAEs occurred reported in Dose Escalation DLBCL only Cohort 3 Not Defined arm.	0.00% 0/7 • From Baseline Up to Approximately 3 Years Reported: Safety Population. During the Safety Follow-up Period, non-Serious Adverse Events occurred at the 5% frequency threshold. There was no non-SAEs occurred reported in Dose Escalation DLBCL only Cohort 3 Not Defined arm.	16.7% 1/6 • Number of events 1 • From Baseline Up to Approximately 3 Years Reported: Safety Population. During the Safety Follow-up Period, non-Serious Adverse Events occurred at the 5% frequency threshold. There was no non-SAEs occurred reported in Dose Escalation DLBCL only Cohort 3 Not Defined arm.	0.00% 0/1 • From Baseline Up to Approximately 3 Years Reported: Safety Population. During the Safety Follow-up Period, non-Serious Adverse Events occurred at the 5% frequency threshold. There was no non-SAEs occurred reported in Dose Escalation DLBCL only Cohort 3 Not Defined arm.
Renal and urinary disorders URINARY RETENTION	0.00% 0/9 • From Baseline Up to Approximately 3 Years Reported: Safety Population. During the Safety Follow-up Period, non-Serious Adverse Events occurred at the 5% frequency threshold. There was no non-SAEs occurred reported in Dose Escalation DLBCL only Cohort 3 Not Defined arm.	16.7% 1/6 • Number of events 1 • From Baseline Up to Approximately 3 Years Reported: Safety Population. During the Safety Follow-up Period, non-Serious Adverse Events occurred at the 5% frequency threshold. There was no non-SAEs occurred reported in Dose Escalation DLBCL only Cohort 3 Not Defined arm.	0.00% 0/7 • From Baseline Up to Approximately 3 Years Reported: Safety Population. During the Safety Follow-up Period, non-Serious Adverse Events occurred at the 5% frequency threshold. There was no non-SAEs occurred reported in Dose Escalation DLBCL only Cohort 3 Not Defined arm.	0.00% 0/6 • From Baseline Up to Approximately 3 Years Reported: Safety Population. During the Safety Follow-up Period, non-Serious Adverse Events occurred at the 5% frequency threshold. There was no non-SAEs occurred reported in Dose Escalation DLBCL only Cohort 3 Not Defined arm.	0.00% 0/1 • From Baseline Up to Approximately 3 Years Reported: Safety Population. During the Safety Follow-up Period, non-Serious Adverse Events occurred at the 5% frequency threshold. There was no non-SAEs occurred reported in Dose Escalation DLBCL only Cohort 3 Not Defined arm.
Respiratory, thoracic and mediastinal disorders COUGH	22.2% 2/9 • Number of events 2 • From Baseline Up to Approximately 3 Years Reported: Safety Population. During the Safety Follow-up Period, non-Serious Adverse Events occurred at the 5% frequency threshold. There was no non-SAEs occurred reported in Dose Escalation DLBCL only Cohort 3 Not Defined arm.	0.00% 0/6 • From Baseline Up to Approximately 3 Years Reported: Safety Population. During the Safety Follow-up Period, non-Serious Adverse Events occurred at the 5% frequency threshold. There was no non-SAEs occurred reported in Dose Escalation DLBCL only Cohort 3 Not Defined arm.	0.00% 0/7 • From Baseline Up to Approximately 3 Years Reported: Safety Population. During the Safety Follow-up Period, non-Serious Adverse Events occurred at the 5% frequency threshold. There was no non-SAEs occurred reported in Dose Escalation DLBCL only Cohort 3 Not Defined arm.	16.7% 1/6 • Number of events 1 • From Baseline Up to Approximately 3 Years Reported: Safety Population. During the Safety Follow-up Period, non-Serious Adverse Events occurred at the 5% frequency threshold. There was no non-SAEs occurred reported in Dose Escalation DLBCL only Cohort 3 Not Defined arm.	0.00% 0/1 • From Baseline Up to Approximately 3 Years Reported: Safety Population. During the Safety Follow-up Period, non-Serious Adverse Events occurred at the 5% frequency threshold. There was no non-SAEs occurred reported in Dose Escalation DLBCL only Cohort 3 Not Defined arm.
Respiratory, thoracic and mediastinal disorders DYSPNOEA EXERTIONAL	11.1% 1/9 • Number of events 1 • From Baseline Up to Approximately 3 Years Reported: Safety Population. During the Safety Follow-up Period, non-Serious Adverse Events occurred at the 5% frequency threshold. There was no non-SAEs occurred reported in Dose Escalation DLBCL only Cohort 3 Not Defined arm.	0.00% 0/6 • From Baseline Up to Approximately 3 Years Reported: Safety Population. During the Safety Follow-up Period, non-Serious Adverse Events occurred at the 5% frequency threshold. There was no non-SAEs occurred reported in Dose Escalation DLBCL only Cohort 3 Not Defined arm.	0.00% 0/7 • From Baseline Up to Approximately 3 Years Reported: Safety Population. During the Safety Follow-up Period, non-Serious Adverse Events occurred at the 5% frequency threshold. There was no non-SAEs occurred reported in Dose Escalation DLBCL only Cohort 3 Not Defined arm.	0.00% 0/6 • From Baseline Up to Approximately 3 Years Reported: Safety Population. During the Safety Follow-up Period, non-Serious Adverse Events occurred at the 5% frequency threshold. There was no non-SAEs occurred reported in Dose Escalation DLBCL only Cohort 3 Not Defined arm.	0.00% 0/1 • From Baseline Up to Approximately 3 Years Reported: Safety Population. During the Safety Follow-up Period, non-Serious Adverse Events occurred at the 5% frequency threshold. There was no non-SAEs occurred reported in Dose Escalation DLBCL only Cohort 3 Not Defined arm.
Respiratory, thoracic and mediastinal disorders EPISTAXIS	11.1% 1/9 • Number of events 1 • From Baseline Up to Approximately 3 Years Reported: Safety Population. During the Safety Follow-up Period, non-Serious Adverse Events occurred at the 5% frequency threshold. There was no non-SAEs occurred reported in Dose Escalation DLBCL only Cohort 3 Not Defined arm.	0.00% 0/6 • From Baseline Up to Approximately 3 Years Reported: Safety Population. During the Safety Follow-up Period, non-Serious Adverse Events occurred at the 5% frequency threshold. There was no non-SAEs occurred reported in Dose Escalation DLBCL only Cohort 3 Not Defined arm.	0.00% 0/7 • From Baseline Up to Approximately 3 Years Reported: Safety Population. During the Safety Follow-up Period, non-Serious Adverse Events occurred at the 5% frequency threshold. There was no non-SAEs occurred reported in Dose Escalation DLBCL only Cohort 3 Not Defined arm.	0.00% 0/6 • From Baseline Up to Approximately 3 Years Reported: Safety Population. During the Safety Follow-up Period, non-Serious Adverse Events occurred at the 5% frequency threshold. There was no non-SAEs occurred reported in Dose Escalation DLBCL only Cohort 3 Not Defined arm.	0.00% 0/1 • From Baseline Up to Approximately 3 Years Reported: Safety Population. During the Safety Follow-up Period, non-Serious Adverse Events occurred at the 5% frequency threshold. There was no non-SAEs occurred reported in Dose Escalation DLBCL only Cohort 3 Not Defined arm.
Respiratory, thoracic and mediastinal disorders LOWER RESPIRATORY TRACT CONGESTION	11.1% 1/9 • Number of events 1 • From Baseline Up to Approximately 3 Years Reported: Safety Population. During the Safety Follow-up Period, non-Serious Adverse Events occurred at the 5% frequency threshold. There was no non-SAEs occurred reported in Dose Escalation DLBCL only Cohort 3 Not Defined arm.	0.00% 0/6 • From Baseline Up to Approximately 3 Years Reported: Safety Population. During the Safety Follow-up Period, non-Serious Adverse Events occurred at the 5% frequency threshold. There was no non-SAEs occurred reported in Dose Escalation DLBCL only Cohort 3 Not Defined arm.	0.00% 0/7 • From Baseline Up to Approximately 3 Years Reported: Safety Population. During the Safety Follow-up Period, non-Serious Adverse Events occurred at the 5% frequency threshold. There was no non-SAEs occurred reported in Dose Escalation DLBCL only Cohort 3 Not Defined arm.	0.00% 0/6 • From Baseline Up to Approximately 3 Years Reported: Safety Population. During the Safety Follow-up Period, non-Serious Adverse Events occurred at the 5% frequency threshold. There was no non-SAEs occurred reported in Dose Escalation DLBCL only Cohort 3 Not Defined arm.	0.00% 0/1 • From Baseline Up to Approximately 3 Years Reported: Safety Population. During the Safety Follow-up Period, non-Serious Adverse Events occurred at the 5% frequency threshold. There was no non-SAEs occurred reported in Dose Escalation DLBCL only Cohort 3 Not Defined arm.
Respiratory, thoracic and mediastinal disorders NASAL CONGESTION	0.00% 0/9 • From Baseline Up to Approximately 3 Years Reported: Safety Population. During the Safety Follow-up Period, non-Serious Adverse Events occurred at the 5% frequency threshold. There was no non-SAEs occurred reported in Dose Escalation DLBCL only Cohort 3 Not Defined arm.	0.00% 0/6 • From Baseline Up to Approximately 3 Years Reported: Safety Population. During the Safety Follow-up Period, non-Serious Adverse Events occurred at the 5% frequency threshold. There was no non-SAEs occurred reported in Dose Escalation DLBCL only Cohort 3 Not Defined arm.	0.00% 0/7 • From Baseline Up to Approximately 3 Years Reported: Safety Population. During the Safety Follow-up Period, non-Serious Adverse Events occurred at the 5% frequency threshold. There was no non-SAEs occurred reported in Dose Escalation DLBCL only Cohort 3 Not Defined arm.	16.7% 1/6 • Number of events 1 • From Baseline Up to Approximately 3 Years Reported: Safety Population. During the Safety Follow-up Period, non-Serious Adverse Events occurred at the 5% frequency threshold. There was no non-SAEs occurred reported in Dose Escalation DLBCL only Cohort 3 Not Defined arm.	0.00% 0/1 • From Baseline Up to Approximately 3 Years Reported: Safety Population. During the Safety Follow-up Period, non-Serious Adverse Events occurred at the 5% frequency threshold. There was no non-SAEs occurred reported in Dose Escalation DLBCL only Cohort 3 Not Defined arm.
Respiratory, thoracic and mediastinal disorders PRODUCTIVE COUGH	0.00% 0/9 • From Baseline Up to Approximately 3 Years Reported: Safety Population. During the Safety Follow-up Period, non-Serious Adverse Events occurred at the 5% frequency threshold. There was no non-SAEs occurred reported in Dose Escalation DLBCL only Cohort 3 Not Defined arm.	0.00% 0/6 • From Baseline Up to Approximately 3 Years Reported: Safety Population. During the Safety Follow-up Period, non-Serious Adverse Events occurred at the 5% frequency threshold. There was no non-SAEs occurred reported in Dose Escalation DLBCL only Cohort 3 Not Defined arm.	0.00% 0/7 • From Baseline Up to Approximately 3 Years Reported: Safety Population. During the Safety Follow-up Period, non-Serious Adverse Events occurred at the 5% frequency threshold. There was no non-SAEs occurred reported in Dose Escalation DLBCL only Cohort 3 Not Defined arm.	16.7% 1/6 • Number of events 1 • From Baseline Up to Approximately 3 Years Reported: Safety Population. During the Safety Follow-up Period, non-Serious Adverse Events occurred at the 5% frequency threshold. There was no non-SAEs occurred reported in Dose Escalation DLBCL only Cohort 3 Not Defined arm.	0.00% 0/1 • From Baseline Up to Approximately 3 Years Reported: Safety Population. During the Safety Follow-up Period, non-Serious Adverse Events occurred at the 5% frequency threshold. There was no non-SAEs occurred reported in Dose Escalation DLBCL only Cohort 3 Not Defined arm.
Skin and subcutaneous tissue disorders ERYTHEMA	0.00% 0/9 • From Baseline Up to Approximately 3 Years Reported: Safety Population. During the Safety Follow-up Period, non-Serious Adverse Events occurred at the 5% frequency threshold. There was no non-SAEs occurred reported in Dose Escalation DLBCL only Cohort 3 Not Defined arm.	16.7% 1/6 • Number of events 1 • From Baseline Up to Approximately 3 Years Reported: Safety Population. During the Safety Follow-up Period, non-Serious Adverse Events occurred at the 5% frequency threshold. There was no non-SAEs occurred reported in Dose Escalation DLBCL only Cohort 3 Not Defined arm.	14.3% 1/7 • Number of events 1 • From Baseline Up to Approximately 3 Years Reported: Safety Population. During the Safety Follow-up Period, non-Serious Adverse Events occurred at the 5% frequency threshold. There was no non-SAEs occurred reported in Dose Escalation DLBCL only Cohort 3 Not Defined arm.	0.00% 0/6 • From Baseline Up to Approximately 3 Years Reported: Safety Population. During the Safety Follow-up Period, non-Serious Adverse Events occurred at the 5% frequency threshold. There was no non-SAEs occurred reported in Dose Escalation DLBCL only Cohort 3 Not Defined arm.	0.00% 0/1 • From Baseline Up to Approximately 3 Years Reported: Safety Population. During the Safety Follow-up Period, non-Serious Adverse Events occurred at the 5% frequency threshold. There was no non-SAEs occurred reported in Dose Escalation DLBCL only Cohort 3 Not Defined arm.
Skin and subcutaneous tissue disorders ERYTHEMA AB IGNE	0.00% 0/9 • From Baseline Up to Approximately 3 Years Reported: Safety Population. During the Safety Follow-up Period, non-Serious Adverse Events occurred at the 5% frequency threshold. There was no non-SAEs occurred reported in Dose Escalation DLBCL only Cohort 3 Not Defined arm.	0.00% 0/6 • From Baseline Up to Approximately 3 Years Reported: Safety Population. During the Safety Follow-up Period, non-Serious Adverse Events occurred at the 5% frequency threshold. There was no non-SAEs occurred reported in Dose Escalation DLBCL only Cohort 3 Not Defined arm.	14.3% 1/7 • Number of events 1 • From Baseline Up to Approximately 3 Years Reported: Safety Population. During the Safety Follow-up Period, non-Serious Adverse Events occurred at the 5% frequency threshold. There was no non-SAEs occurred reported in Dose Escalation DLBCL only Cohort 3 Not Defined arm.	0.00% 0/6 • From Baseline Up to Approximately 3 Years Reported: Safety Population. During the Safety Follow-up Period, non-Serious Adverse Events occurred at the 5% frequency threshold. There was no non-SAEs occurred reported in Dose Escalation DLBCL only Cohort 3 Not Defined arm.	0.00% 0/1 • From Baseline Up to Approximately 3 Years Reported: Safety Population. During the Safety Follow-up Period, non-Serious Adverse Events occurred at the 5% frequency threshold. There was no non-SAEs occurred reported in Dose Escalation DLBCL only Cohort 3 Not Defined arm.
Skin and subcutaneous tissue disorders HYPERHIDROSIS	11.1% 1/9 • Number of events 1 • From Baseline Up to Approximately 3 Years Reported: Safety Population. During the Safety Follow-up Period, non-Serious Adverse Events occurred at the 5% frequency threshold. There was no non-SAEs occurred reported in Dose Escalation DLBCL only Cohort 3 Not Defined arm.	0.00% 0/6 • From Baseline Up to Approximately 3 Years Reported: Safety Population. During the Safety Follow-up Period, non-Serious Adverse Events occurred at the 5% frequency threshold. There was no non-SAEs occurred reported in Dose Escalation DLBCL only Cohort 3 Not Defined arm.	0.00% 0/7 • From Baseline Up to Approximately 3 Years Reported: Safety Population. During the Safety Follow-up Period, non-Serious Adverse Events occurred at the 5% frequency threshold. There was no non-SAEs occurred reported in Dose Escalation DLBCL only Cohort 3 Not Defined arm.	0.00% 0/6 • From Baseline Up to Approximately 3 Years Reported: Safety Population. During the Safety Follow-up Period, non-Serious Adverse Events occurred at the 5% frequency threshold. There was no non-SAEs occurred reported in Dose Escalation DLBCL only Cohort 3 Not Defined arm.	0.00% 0/1 • From Baseline Up to Approximately 3 Years Reported: Safety Population. During the Safety Follow-up Period, non-Serious Adverse Events occurred at the 5% frequency threshold. There was no non-SAEs occurred reported in Dose Escalation DLBCL only Cohort 3 Not Defined arm.
Skin and subcutaneous tissue disorders NIGHT SWEATS	11.1% 1/9 • Number of events 2 • From Baseline Up to Approximately 3 Years Reported: Safety Population. During the Safety Follow-up Period, non-Serious Adverse Events occurred at the 5% frequency threshold. There was no non-SAEs occurred reported in Dose Escalation DLBCL only Cohort 3 Not Defined arm.	0.00% 0/6 • From Baseline Up to Approximately 3 Years Reported: Safety Population. During the Safety Follow-up Period, non-Serious Adverse Events occurred at the 5% frequency threshold. There was no non-SAEs occurred reported in Dose Escalation DLBCL only Cohort 3 Not Defined arm.	0.00% 0/7 • From Baseline Up to Approximately 3 Years Reported: Safety Population. During the Safety Follow-up Period, non-Serious Adverse Events occurred at the 5% frequency threshold. There was no non-SAEs occurred reported in Dose Escalation DLBCL only Cohort 3 Not Defined arm.	0.00% 0/6 • From Baseline Up to Approximately 3 Years Reported: Safety Population. During the Safety Follow-up Period, non-Serious Adverse Events occurred at the 5% frequency threshold. There was no non-SAEs occurred reported in Dose Escalation DLBCL only Cohort 3 Not Defined arm.	0.00% 0/1 • From Baseline Up to Approximately 3 Years Reported: Safety Population. During the Safety Follow-up Period, non-Serious Adverse Events occurred at the 5% frequency threshold. There was no non-SAEs occurred reported in Dose Escalation DLBCL only Cohort 3 Not Defined arm.
Skin and subcutaneous tissue disorders PAIN OF SKIN	11.1% 1/9 • Number of events 1 • From Baseline Up to Approximately 3 Years Reported: Safety Population. During the Safety Follow-up Period, non-Serious Adverse Events occurred at the 5% frequency threshold. There was no non-SAEs occurred reported in Dose Escalation DLBCL only Cohort 3 Not Defined arm.	0.00% 0/6 • From Baseline Up to Approximately 3 Years Reported: Safety Population. During the Safety Follow-up Period, non-Serious Adverse Events occurred at the 5% frequency threshold. There was no non-SAEs occurred reported in Dose Escalation DLBCL only Cohort 3 Not Defined arm.	0.00% 0/7 • From Baseline Up to Approximately 3 Years Reported: Safety Population. During the Safety Follow-up Period, non-Serious Adverse Events occurred at the 5% frequency threshold. There was no non-SAEs occurred reported in Dose Escalation DLBCL only Cohort 3 Not Defined arm.	0.00% 0/6 • From Baseline Up to Approximately 3 Years Reported: Safety Population. During the Safety Follow-up Period, non-Serious Adverse Events occurred at the 5% frequency threshold. There was no non-SAEs occurred reported in Dose Escalation DLBCL only Cohort 3 Not Defined arm.	0.00% 0/1 • From Baseline Up to Approximately 3 Years Reported: Safety Population. During the Safety Follow-up Period, non-Serious Adverse Events occurred at the 5% frequency threshold. There was no non-SAEs occurred reported in Dose Escalation DLBCL only Cohort 3 Not Defined arm.
Skin and subcutaneous tissue disorders RASH	0.00% 0/9 • From Baseline Up to Approximately 3 Years Reported: Safety Population. During the Safety Follow-up Period, non-Serious Adverse Events occurred at the 5% frequency threshold. There was no non-SAEs occurred reported in Dose Escalation DLBCL only Cohort 3 Not Defined arm.	0.00% 0/6 • From Baseline Up to Approximately 3 Years Reported: Safety Population. During the Safety Follow-up Period, non-Serious Adverse Events occurred at the 5% frequency threshold. There was no non-SAEs occurred reported in Dose Escalation DLBCL only Cohort 3 Not Defined arm.	0.00% 0/7 • From Baseline Up to Approximately 3 Years Reported: Safety Population. During the Safety Follow-up Period, non-Serious Adverse Events occurred at the 5% frequency threshold. There was no non-SAEs occurred reported in Dose Escalation DLBCL only Cohort 3 Not Defined arm.	16.7% 1/6 • Number of events 2 • From Baseline Up to Approximately 3 Years Reported: Safety Population. During the Safety Follow-up Period, non-Serious Adverse Events occurred at the 5% frequency threshold. There was no non-SAEs occurred reported in Dose Escalation DLBCL only Cohort 3 Not Defined arm.	0.00% 0/1 • From Baseline Up to Approximately 3 Years Reported: Safety Population. During the Safety Follow-up Period, non-Serious Adverse Events occurred at the 5% frequency threshold. There was no non-SAEs occurred reported in Dose Escalation DLBCL only Cohort 3 Not Defined arm.
Skin and subcutaneous tissue disorders RASH MACULO-PAPULAR	11.1% 1/9 • Number of events 1 • From Baseline Up to Approximately 3 Years Reported: Safety Population. During the Safety Follow-up Period, non-Serious Adverse Events occurred at the 5% frequency threshold. There was no non-SAEs occurred reported in Dose Escalation DLBCL only Cohort 3 Not Defined arm.	0.00% 0/6 • From Baseline Up to Approximately 3 Years Reported: Safety Population. During the Safety Follow-up Period, non-Serious Adverse Events occurred at the 5% frequency threshold. There was no non-SAEs occurred reported in Dose Escalation DLBCL only Cohort 3 Not Defined arm.	0.00% 0/7 • From Baseline Up to Approximately 3 Years Reported: Safety Population. During the Safety Follow-up Period, non-Serious Adverse Events occurred at the 5% frequency threshold. There was no non-SAEs occurred reported in Dose Escalation DLBCL only Cohort 3 Not Defined arm.	0.00% 0/6 • From Baseline Up to Approximately 3 Years Reported: Safety Population. During the Safety Follow-up Period, non-Serious Adverse Events occurred at the 5% frequency threshold. There was no non-SAEs occurred reported in Dose Escalation DLBCL only Cohort 3 Not Defined arm.	0.00% 0/1 • From Baseline Up to Approximately 3 Years Reported: Safety Population. During the Safety Follow-up Period, non-Serious Adverse Events occurred at the 5% frequency threshold. There was no non-SAEs occurred reported in Dose Escalation DLBCL only Cohort 3 Not Defined arm.
Vascular disorders DEEP VEIN THROMBOSIS	0.00% 0/9 • From Baseline Up to Approximately 3 Years Reported: Safety Population. During the Safety Follow-up Period, non-Serious Adverse Events occurred at the 5% frequency threshold. There was no non-SAEs occurred reported in Dose Escalation DLBCL only Cohort 3 Not Defined arm.	0.00% 0/6 • From Baseline Up to Approximately 3 Years Reported: Safety Population. During the Safety Follow-up Period, non-Serious Adverse Events occurred at the 5% frequency threshold. There was no non-SAEs occurred reported in Dose Escalation DLBCL only Cohort 3 Not Defined arm.	0.00% 0/7 • From Baseline Up to Approximately 3 Years Reported: Safety Population. During the Safety Follow-up Period, non-Serious Adverse Events occurred at the 5% frequency threshold. There was no non-SAEs occurred reported in Dose Escalation DLBCL only Cohort 3 Not Defined arm.	16.7% 1/6 • Number of events 1 • From Baseline Up to Approximately 3 Years Reported: Safety Population. During the Safety Follow-up Period, non-Serious Adverse Events occurred at the 5% frequency threshold. There was no non-SAEs occurred reported in Dose Escalation DLBCL only Cohort 3 Not Defined arm.	0.00% 0/1 • From Baseline Up to Approximately 3 Years Reported: Safety Population. During the Safety Follow-up Period, non-Serious Adverse Events occurred at the 5% frequency threshold. There was no non-SAEs occurred reported in Dose Escalation DLBCL only Cohort 3 Not Defined arm.
Vascular disorders FLUSHING	11.1% 1/9 • Number of events 1 • From Baseline Up to Approximately 3 Years Reported: Safety Population. During the Safety Follow-up Period, non-Serious Adverse Events occurred at the 5% frequency threshold. There was no non-SAEs occurred reported in Dose Escalation DLBCL only Cohort 3 Not Defined arm.	0.00% 0/6 • From Baseline Up to Approximately 3 Years Reported: Safety Population. During the Safety Follow-up Period, non-Serious Adverse Events occurred at the 5% frequency threshold. There was no non-SAEs occurred reported in Dose Escalation DLBCL only Cohort 3 Not Defined arm.	14.3% 1/7 • Number of events 1 • From Baseline Up to Approximately 3 Years Reported: Safety Population. During the Safety Follow-up Period, non-Serious Adverse Events occurred at the 5% frequency threshold. There was no non-SAEs occurred reported in Dose Escalation DLBCL only Cohort 3 Not Defined arm.	0.00% 0/6 • From Baseline Up to Approximately 3 Years Reported: Safety Population. During the Safety Follow-up Period, non-Serious Adverse Events occurred at the 5% frequency threshold. There was no non-SAEs occurred reported in Dose Escalation DLBCL only Cohort 3 Not Defined arm.	0.00% 0/1 • From Baseline Up to Approximately 3 Years Reported: Safety Population. During the Safety Follow-up Period, non-Serious Adverse Events occurred at the 5% frequency threshold. There was no non-SAEs occurred reported in Dose Escalation DLBCL only Cohort 3 Not Defined arm.
Vascular disorders HYPOTENSION	0.00% 0/9 • From Baseline Up to Approximately 3 Years Reported: Safety Population. During the Safety Follow-up Period, non-Serious Adverse Events occurred at the 5% frequency threshold. There was no non-SAEs occurred reported in Dose Escalation DLBCL only Cohort 3 Not Defined arm.	0.00% 0/6 • From Baseline Up to Approximately 3 Years Reported: Safety Population. During the Safety Follow-up Period, non-Serious Adverse Events occurred at the 5% frequency threshold. There was no non-SAEs occurred reported in Dose Escalation DLBCL only Cohort 3 Not Defined arm.	0.00% 0/7 • From Baseline Up to Approximately 3 Years Reported: Safety Population. During the Safety Follow-up Period, non-Serious Adverse Events occurred at the 5% frequency threshold. There was no non-SAEs occurred reported in Dose Escalation DLBCL only Cohort 3 Not Defined arm.	16.7% 1/6 • Number of events 1 • From Baseline Up to Approximately 3 Years Reported: Safety Population. During the Safety Follow-up Period, non-Serious Adverse Events occurred at the 5% frequency threshold. There was no non-SAEs occurred reported in Dose Escalation DLBCL only Cohort 3 Not Defined arm.	0.00% 0/1 • From Baseline Up to Approximately 3 Years Reported: Safety Population. During the Safety Follow-up Period, non-Serious Adverse Events occurred at the 5% frequency threshold. There was no non-SAEs occurred reported in Dose Escalation DLBCL only Cohort 3 Not Defined arm.
Vascular disorders LYMPHATIC FISTULA	0.00% 0/9 • From Baseline Up to Approximately 3 Years Reported: Safety Population. During the Safety Follow-up Period, non-Serious Adverse Events occurred at the 5% frequency threshold. There was no non-SAEs occurred reported in Dose Escalation DLBCL only Cohort 3 Not Defined arm.	0.00% 0/6 • From Baseline Up to Approximately 3 Years Reported: Safety Population. During the Safety Follow-up Period, non-Serious Adverse Events occurred at the 5% frequency threshold. There was no non-SAEs occurred reported in Dose Escalation DLBCL only Cohort 3 Not Defined arm.	14.3% 1/7 • Number of events 1 • From Baseline Up to Approximately 3 Years Reported: Safety Population. During the Safety Follow-up Period, non-Serious Adverse Events occurred at the 5% frequency threshold. There was no non-SAEs occurred reported in Dose Escalation DLBCL only Cohort 3 Not Defined arm.	0.00% 0/6 • From Baseline Up to Approximately 3 Years Reported: Safety Population. During the Safety Follow-up Period, non-Serious Adverse Events occurred at the 5% frequency threshold. There was no non-SAEs occurred reported in Dose Escalation DLBCL only Cohort 3 Not Defined arm.	0.00% 0/1 • From Baseline Up to Approximately 3 Years Reported: Safety Population. During the Safety Follow-up Period, non-Serious Adverse Events occurred at the 5% frequency threshold. There was no non-SAEs occurred reported in Dose Escalation DLBCL only Cohort 3 Not Defined arm.
Vascular disorders ORTHOSTATIC HYPOTENSION	0.00% 0/9 • From Baseline Up to Approximately 3 Years Reported: Safety Population. During the Safety Follow-up Period, non-Serious Adverse Events occurred at the 5% frequency threshold. There was no non-SAEs occurred reported in Dose Escalation DLBCL only Cohort 3 Not Defined arm.	16.7% 1/6 • Number of events 1 • From Baseline Up to Approximately 3 Years Reported: Safety Population. During the Safety Follow-up Period, non-Serious Adverse Events occurred at the 5% frequency threshold. There was no non-SAEs occurred reported in Dose Escalation DLBCL only Cohort 3 Not Defined arm.	0.00% 0/7 • From Baseline Up to Approximately 3 Years Reported: Safety Population. During the Safety Follow-up Period, non-Serious Adverse Events occurred at the 5% frequency threshold. There was no non-SAEs occurred reported in Dose Escalation DLBCL only Cohort 3 Not Defined arm.	0.00% 0/6 • From Baseline Up to Approximately 3 Years Reported: Safety Population. During the Safety Follow-up Period, non-Serious Adverse Events occurred at the 5% frequency threshold. There was no non-SAEs occurred reported in Dose Escalation DLBCL only Cohort 3 Not Defined arm.	0.00% 0/1 • From Baseline Up to Approximately 3 Years Reported: Safety Population. During the Safety Follow-up Period, non-Serious Adverse Events occurred at the 5% frequency threshold. There was no non-SAEs occurred reported in Dose Escalation DLBCL only Cohort 3 Not Defined arm.
Vascular disorders THROMBOPHLEBITIS SUPERFICIAL	0.00% 0/9 • From Baseline Up to Approximately 3 Years Reported: Safety Population. During the Safety Follow-up Period, non-Serious Adverse Events occurred at the 5% frequency threshold. There was no non-SAEs occurred reported in Dose Escalation DLBCL only Cohort 3 Not Defined arm.	0.00% 0/6 • From Baseline Up to Approximately 3 Years Reported: Safety Population. During the Safety Follow-up Period, non-Serious Adverse Events occurred at the 5% frequency threshold. There was no non-SAEs occurred reported in Dose Escalation DLBCL only Cohort 3 Not Defined arm.	0.00% 0/7 • From Baseline Up to Approximately 3 Years Reported: Safety Population. During the Safety Follow-up Period, non-Serious Adverse Events occurred at the 5% frequency threshold. There was no non-SAEs occurred reported in Dose Escalation DLBCL only Cohort 3 Not Defined arm.	16.7% 1/6 • Number of events 1 • From Baseline Up to Approximately 3 Years Reported: Safety Population. During the Safety Follow-up Period, non-Serious Adverse Events occurred at the 5% frequency threshold. There was no non-SAEs occurred reported in Dose Escalation DLBCL only Cohort 3 Not Defined arm.	0.00% 0/1 • From Baseline Up to Approximately 3 Years Reported: Safety Population. During the Safety Follow-up Period, non-Serious Adverse Events occurred at the 5% frequency threshold. There was no non-SAEs occurred reported in Dose Escalation DLBCL only Cohort 3 Not Defined arm.

Additional Information

Reference Study ID Number: BH39147

www.roche.com/about_roche/roche_worldwide.htm

Phone: 888-662-6728 (U.S. Only)

Email: global-roche-genentech-trials@gene.com

Results disclosure agreements

• Principal investigator is a sponsor employee The Study being conducted under this Agreement is part of the Overall Study. Investigator is free to publish in reputable journals or to present at professional conferences the results of the Study, but only after the first publication or presentation that involves the Overall Study. The Sponsor may request that Confidential Information be deleted and/or the publication be postponed in order to protect the Sponsor's intellectual property rights.
• Publication restrictions are in place

Restriction type: OTHER